﻿Evaluation of the regulatory review system in Turkey and the development of a new model for improving the approval process by Mashaki, Emel
i 
 
 
 
 
 
 
 
 
EVALUATION OF THE REGULATORY REVIEW SYSTEM IN 
TURKEY AND THE DEVELOPMENT OF A NEW MODEL 
FOR IMPROVING THE APPROVAL PROCESS 
 
A thesis submitted in accordance with the conditions governing candidates 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
in 
 
CARDIFF UNIVERSITY 
School of Pharmacy and Pharmaceutical Sciences 
Division of Pharmacy Practice and Clinical Pharmacy 
 
 
Submitted by 
EMEL MASHAKI CEYHAN 
 
SUPERVISOR: 
PROF. STUART WALKER 
 
July 2017 
 
ii      
 
DECLARATION  
This work has not been submitted in substance for any other degree or award at this or any 
other university or place of learning, nor is being submitted concurrently in candidature for 
any degree or other award. 
 
Signed ……………………………………………………………………………Candidate 
Date: 21st of July 2017 
 
STATEMENT 1 
This thesis is being submitted in partial fulfilment of the requirements for the degree of  PhD. 
 
Signed ……………………………………………………………………………Candidate 
Date: 21st of July 2017 
 
STATEMENT 2 
This thesis is the result of my own independent work/investigation, except where otherwise 
stated, and the thesis has not been edited by a third party beyond what is permitted by Cardiff 
University’s Policy on the Use of Third Party Editors by Research Degree Students. Other 
sources are acknowledged by explicit references.  The views expressed are my own. 
 
Signed …………………………………………………………………………….Candidate 
Date: 21st of July 2017 
 
STATEMENT 3 
I hereby give consent for my thesis, if accepted, to be available online in the University’s 
Open Access repository and for inter-library loans after expiry of a bar on access 
previously approved by the Academic Standards and Quality Committee.  
 
Signed ……………………………………………………………………………Candidate 
Date: 21st of July 2017 
  
iii      
 
ACKNOWLEDGMENTS 
Firstly, I would like to express my sincere gratitude to my advisor Professor Stuart Walker for 
his extraordinary supervision, his patience and his endless support during my research. His 
caring guidance and encouragement as well as his immense knowledge and expertise have 
always kept me motivated, focused and faithful that this research was progressing effectively 
and as planned despite all the challenges. Besides my advisor, I am grateful for Professor Sam 
Salek who was the first to kindly guide me in fulfilling my dreams and pursuing my Ph.D. 
degree in Cardiff University. I am also grateful for the support and expert advice I received 
from the Centre for Innovation in Regulatory Science, especially from Dr. Neil McAuslane 
and from my Post Graduate Research Advisors Professor Bob Sewell and Professor Emma 
Kidd. I am truly indebted to the Turkish Medicines and Medical Devices Agency (TITCK) 
senior management who supported this study, especially the President Dr. Hakkı Gürsöz who 
provided me with a unique and invaluable opportunity to conduct the TITCK study. My 
special thanks go to members of the Research Based Pharmaceutical Association (AIFD) in 
Turkey, who generously helped me in data collection and facilitated several important events 
with the industry. My deepest appreciation and thanks goes to great friends and professionals 
for their sincere contribution: Pharmacist Şebnem Uslu Şenoldu and Dr. Banu Kılıç Taşköprü.  
 
For years, I have been working hard to overcome many difficulties in good faith hoping to 
complete my Ph.D. study. It was indeed a long journey and a dream that finally came true. 
Nevertheless, I was extremely fortunate to receive endless encouragement and love from my 
precious family. My inspiring parents, Dr. Mohammed Mashaki and specially my dedicated 
mother Dr. Esin Erk Mashaki who was the real driver behind this achievement, my dearest 
sister Nihal and precious brothers Tarık, Halit and Hamze as well as their beloved families, 
they all deserve my wholehearted thanks and gratitude. This would not have been possible 
without their belief in me. And to my life-coach, my closest friend and loving husband; Dr. 
Murat Ceyhan, You were always there for me to give me the strength, love and determination 
I needed, to lift me up patiently and keep me progressing. Thank you! I owe it all to you!  
 
I dedicate this thesis to two great pharmacists; my grandfather Necati Erk and Professor 
Stephen Hudson from the University of Strathclyde, who both passed away suddenly but have 
always been a role model for the scientific research in pharmaceutical sciences. Finally, to my 
present and future inspiration, to the source of joy and light in my life, who came in the 
middle of my Ph.D. as a real achievement despite all, my beloved sweet daughter Lidya Nur! 
iv      
 
ABSTRACT 
All regulatory authorities share the responsibility for ensuring patients’ timely access to new 
medicines while maintaining quality, safety and efficacy standards. In addition, healthcare 
decision-makers must consider the cost effectiveness of medicines and the impact on the 
national budget. The aim of this study was to evaluate the Turkish regulatory review process 
and approval times from 2012 to 2015 in order to identify the key issues that need to be 
addressed. The study included a comparison between the Turkish review process and its 
quality measures with those of other mid-sized regulatory agencies in Australia, Canada, 
Saudi Arabia and Singapore to determine the strengths and areas for improvement for the 
TITCK. To put these issues into context, the pharmaceutical industry experiences of the 
regulatory environment in Turkey was evaluated as well as patients’ knowledge and 
awareness of the country’s regulatory approach to the approval and reimbursement of 
medicines. Thus, the ultimate aim was to develop an improved review model for the TITCK. 
 
A standardised questionnaire was completed by the TITCK and the four authorities who 
provided details of their review process for new active substances (NASs) and the quality 
measures implemented in their assessment procedures. Metrics for medicines approved 
between 2012 and 2015 were collected from both the TITCK as well as from pharmaceutical 
companies. A further questionnaire was developed and completed by two hundred and ten 
patients and the resulting data were evaluated in a unique study. 
 
The comparative study of the TITCK with four comparable regulatory authorities showed that 
the agency in Turkey conducts a full assessment (Type 3A) for all NAS applications, which is 
in line with the other mid-sized regulatory authorities, although it does not implement a risk 
stratification approach. In general, the regulatory requirements in Turkey are aligned with 
international standards except for certain areas such as the GMP process and pricing. 
Moreover, the results demonstrated that the approval times in Turkey are longer by two to 
three months compared to other countries in this study. The TITCK mean approval time for 
NAS marketing authorisation applications between 2013 and 2015 was three hundred and 
twenty working days, which exceeded the agency’s overall target time of two hundred and ten 
working days. A similar outcome was identified in the pharmaceutical industry study where 
the review time was reported to be four hundred and sixty working days and in contrast to the 
TITCK data this included company response time. Thus, the median time for NASs from first 
v      
 
approval in the world to TITCK approval was identified to be approximately three and a half 
years. This supported the main findings from the patient study that new medicines become 
available in Turkey later than other developed countries. Finally, an evaluation of the TITCK 
decision-making process showed that the essential elements of Good Review Practices 
(GReP) are implemented, although they are not formalised. 
 
The key issues from these four studies were reviewed with the TITCK experts during a 
focused workshop. As a result, a new improved review model for the TITCK was proposed. 
This model utilises the available resources while providing suggested improvements to enable 
the TITCK to achieve its overall target approval time for NAS applications in a consistent, 
transparent and predictable manner. These included optimising the TITCK organisational 
capacity, aligning their requirements with international standards, streamlining the review 
process, implementing GReP and a structured approach to the Benefit-Risk assessment of 
medicines. In this way, patients’ access to medicines would be enhanced and the new model 
would support the goal of the TITCK to become an international centre of regulatory 
excellence in the region.  
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GLOSSARY OF TERMS 
Adverse event: any unfavourable and unintended sign in a patient or clinical investigation of 
a subject administered including a symptom or disease associated with the use of a 
pharmaceutical product and which does not necessarily have a causal relationship with this 
treatment.  
 
Approval: a regulatory authority in one or more markets (a product can be legally marketed 
when the authority grants a licence and subject it to pricing / reimbursement issues) licenses 
the active substance. 
 
Authorisation phase: Includes practices carried out when satisfactory outcomes of the 
evaluation phase have been reached. These are the product pricing process and the final 
decision making procedures. 
 
Benefit-risk framework: a benefit-risk framework is the basis of regulatory decisions in the 
pre-market and post-market review process. It takes into account the extensive evidence of 
safety and effectiveness submitted by a sponsor in a New Drug Application (NDA) or a 
Biologics License Application (BLA), as well as many other factors affecting the benefit-risk 
assessment, including the nature and severity of the condition the drug is intended to treat or 
prevent, the benefits and risks of other available therapies for the condition, and any risk 
management tools that might be necessary to ensure that the benefits of the drug outweigh its 
risks. This assessment involves both quantitative analyses and a subjective qualitative 
weighing of the evidence. 
 
Biological: A substance isolated from animal tissues e.g. vaccines, hormones, antigens. 
 
Biotechnological product: A naturally occurring or modified polypeptide, protein, DNA or 
RNA product (produced by recombinant DNA or hybridoma technology and expressed in cell 
lines, transgenic animals or transgenic plants) for therapeutic, prophylactic or in vivo 
diagnostic use in humans. The only types of vaccines included in the biotech category are 
recombinant vaccines. 
 
Centralised procedure: The centralised procedure is used when marketing Authorisation 
covering the entire EU region is applied for, for example, for new biotechnological medicinal 
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products and new innovative medicinal products. The applications for marketing authorisation 
are then submitted to the European Medicines Agency (EMA). 
 
Clinical trial: Any investigation in human subjects intended to discover or verify the clinical, 
pharmacological and/or other pharmacodynamic effects of an investigational product, and/or 
to identify any adverse reactions to an investigational product, and/or to study the absorption, 
distribution, metabolism and excretion of an investigational product, with the objective of 
ascertaining its safety and/or efficacy. 
 
Drug product: A finished formulation, for example, a tablet or capsule that contains the 
active substance, generally in association with one or more other ingredients. 
 
European Union Member States (EU): Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, 
Slovenia, Spain, Sweden and the United Kingdom. 
 
Evaluation phase: Includes all the stages that involve the scientific assessment and quality 
control analysis carried out to ensure that the medicine is safe, efficacious and of the desired 
quality standard to be given to the patients. This phase consists of three stages, namely, the 
scientific assessment stage, the sponsor’s interaction stage, and the sample analysis stage. 
 
Good Review Practice (GReP): A code about the process and the documentation of review 
procedures that aims to standardise and improve the overall documentation and ensure 
timeliness, predictability, consistency and high quality of reviews and review reports. 
 
ICH Regions: European Union, Japan and the United States of America (USA). 
 
Indication: The specific indication for which the active substance for the project is designed. 
This may represent the cure, alleviation, treatment, prevention or diagnosis of disease in 
humans. 
 
Local study: A study conducted in a single country with the primary aim of providing local 
experience with a compound. 
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Marketing Authorisation (MA): Legal approval granted to a company by a national (or 
regional) authority to market a medicinal product in that particular country (or region). 
 
Marketing Authorisation Application (MAA): An application by a company for a 
marketing authorisation to be submitted to each country (or region) in which marketing 
approval is sought. 
 
Mutual recognition procedure: The Mutual Recognition (MR) procedure utilizes the 
marketing authorisation granted for an active substance by another EU Member State, 
Norway, or Iceland. The Member State whose assessment is recognized as a basis for 
marketing Authorisation is called the Reference Member State (RMS). 
 
National procedure: The national procedure is mainly used in cases where marketing 
authorisation is being applied for in a single member state. 
 
New Active Substance (NAS): A chemical, biological or radiopharmaceutical substance not 
previously authorised as a medicinal product. The term NAS also includes: an isomer, 
mixture of isomers, a complex or derivative or salt of a chemical substance previously 
authorised as a medicinal product but differing in properties with regard to safety and efficacy 
from that substance previously authorised; a biological substance previously authorised as a 
medicinal product, but differing in molecular structure, nature of source material or 
manufacturing process; a radiopharmaceutical substance that is a radionuclide or a ligand not 
previously authorised as a medicinal product. Alternatively, the coupling mechanism linking 
the molecule and the radionuclide that has not been previously authorised. 
 
New Chemical Entity (NCE): An entity produced by chemical synthesis. 
 
New Drug Application (NDA): An application requesting regulatory approval to 
commercially market a new drug for human use. 
 
Patients’ access: The active substance is made available for patients in the private and 
government sectors in any country.  
 
Patients’ access time: This is the time from the submission of the registration dossier to the 
Ministerial price approval of the new medicinal product. 
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Pricing time: The time from the registration of a new medicinal product to the Ministerial 
approval of the product price. 
 
Preclinical: In vivo and in vitro studies to support administration to man. 
 
Pre-submission: The last patient visit for the last pivotal study to be included in the 
regulatory dossier is complete and the dossier is being prepared but has not yet been 
submitted to a regulatory authority. 
 
Review time: The time from the submission of the registration dossier to the registration of 
the new medicinal product. 
 
Shared review: is one where each participating authority takes responsibility for reviewing a 
separate part of the dossier. A joint review is one where the whole dossier is reviewed by each 
authority and the outcome is discussed before a decision is taken. 
 
Strategy: The direction and scope of an organisation over the long-term; which achieves 
advantage for the organisation through its configuration of resources within a challenging 
environment, to meet the needs of the public and to fulfil the stakeholder’s expectations. 
 
Submission phase:  The submission phase involves all the stages and processes carried out 
by the authorities’ administrative staff prior the scientific assessment of the medicine. These 
include the receipt and validation stage and the queuing stage. 
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BACKGROUND 
The history of regulating healthcare services and medicines can be traced back in ancient 
history to Babylon and Mesopotamian times when Hammurabi, who ruled between 1795-
1750 BC, was the first to establish a code of laws in relation to medicines and human 
treatments. This was considered the earliest-known public regulations. (Halwani & Takrouri, 
2006). Similar medical codes and laws can also be found in the ancient Greek Roman times, 
clearly identified within the Hippocratic Oath. History is full of stories, experiences and 
events, which demonstrate the eagerness of humanity to develop pharmaceutical and medical 
sciences and enhance patients’ access to better health services, while healthcare authorities 
focused on how to control and ensure a balance of risks versus benefits for such 
developments.  
 
Recent years have witnessed an increasing interest in patients’ access to medicines by the 
pharmaceutical industry and Health Technology Assessment (HTA) Agencies (Access to 
Medicine Foundation, 2016). A new regulated era began in the 1960s, following McBride’s 
publication of “Thalidomide and Congenital Abnormalities” in the Lancet in 1962 (McBride, 
1962). This was considered a major challenge for the public, national authorities and global 
healthcare organisations such as the World Health Organisation (WHO). Since 1975, the 
WHO has made several efforts and published resolutions to support member countries to 
develop their national regulatory systems and policies to enhance public health and patients’ 
access to medicines in which health authorities play a critical role in assessing the safety of 
pharmaceutical products as well as quality and efficacy prior to marketing authorisations 
(WHO, 2015).  
 
Nevertheless, since the 1960s, throughout the years, the focus of health authorities during the 
marketing authorisation review process has shown a clear shift from quality to efficacy, from 
safety to benefit-risk evaluation, and more recently the added value of approved 
pharmaceuticals (Figure 1.1). This changing and demanding focus for health authorities has 
also been the main driver for the constant change in the regulatory landscape of the 
pharmaceutical industry, which is characterised as a very dynamic, rapidly advancing and the 
most regulated of all industries (Spielberg, 2014). 
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Figure 1.1: Shift of health authorities’ focus during review and approval process 
 
 
Moreover, the need for governments to balance between improving public health and 
controlling healthcare expenditures, especially those related to pharmaceuticals, has increased 
all over the world. This was in parallel with the pharmaceutical companies’ strategy to 
introduce new products and treatments, which in turn has led to a steady increase in the 
research and development costs over decades (Figure 1.2) (Tarmur, 2011).   
 
Figure 1.2: Total R&D expenditure for the global pharmaceutical industry 
Source: Turkey’s Pharmaceutical Sector Vision 2023 Report – AIFD 
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Bringing new innovative products to the market is a complex process and among millions of 
compounds in the research and development phase, only a few eventually reach the marketing 
approval phase. It is estimated that the cost of bringing new drug substance to the market is 
around $2.6 billion and takes an average of ten to fifteen years of research and development. 
(PhRMA, 2015). Thus the main challenge for the pharmaceutical industry, regulatory 
authorities and payers is to balance the need for new, innovative medicines with the 
increasing pressure to control the cost of health care expenditure (TUFTS University, 2015). 
 
Global medicines’ expenditure has dramatically increased in the last decades due to the 
increased growth rates in population and aging as well as a better access to medicines around 
the globe especially in the emerging markets. Accordingly, it is estimated that the global 
pharmaceutical market will reach approximately $1.3 trillion by 2018, which is almost more 
than a 30% increase when compared with 2013 (Aitken, 2014). Furthermore, the total 
spending on medicines will reach $1.4 trillion by 2020 (Constantino, 2015).  
 
The significantly increasing healthcare demands, the cost to ensure patients’ access to 
advanced healthcare services and the need for well-being in modern societies has started even 
to exceed the income in some societies and other developed countries. In Turkey, for 
example, the healthcare expenditure as a share of GDP has increased 49% since 2002 and 
public health expenditure, totalled $18.8 billion in 2005, representing 5.2% of GDP (YASED, 
2012)., whereas it increased to $65.8 billion in 2014 representing 6.4% of GDP (OECD, 
2014). 
 
The Emergence of Regulatory Affairs 
The increasing level of product and technology complexities together with the constantly 
expanding number of regulatory agencies, focusing on approval and marketing authorisations, 
has encouraged several authorities worldwide to issue pharmaceutical laws and regulations to 
control and regulate the pharmaceutical industry. All over the world, there has been a growing 
influence of the health authorities’ regulations on the pharmaceutical industry at different 
levels starting from the development phase through the life cycle of a pharmaceutical product 
to its discontinuation from the market. This level of influence is seen from the change in 
required standards and the increased demand for data during drug development and the 
regulatory review. This has led to the new scientific discipline known as “Regulatory 
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Affairs”; which can be defined as “a comparatively new profession which developed from the 
desire of governments to protect public health by controlling the safety and efficacy of 
products in areas including pharmaceuticals, veterinary medicines, medical devices, 
pesticides, agrochemicals, cosmetics and complementary medicines (TOPRA, 2014)”. 
 
Establishing the rules and standards for marketing authorisation and review processes of 
pharmaceutical products means that companies who are developing, manufacturing and 
eventually applying for a marketing authorisation are equally responsible to ensure that their 
proposed products for licensing are evaluated appropriately. Additionally, they must be 
compliant with all the required quality, safety and efficacy standards of health authorities. 
Currently, with the establishment of health technology assessment agencies with 
responsibility for reimbursement, pharmaceutical products must demonstrate evidence that 
they add value to public health and merit the additional cost they bring to national healthcare 
and social security systems. 
 
Global Perspective for Regulatory Science 
The increasing and different requirements of the regulatory health authorities worldwide 
brought together the pharmaceutical associations from Europe (EU), United States of America 
(USA) and Japan with the health authorities from these three regions to think about 
streamlining this process globally to reduce the cost of development, review and consequently 
the time to market. As a result, the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) was established in 
1990 with the aim to share and discuss all scientific and technical issues related to 
pharmaceutical products’ registrations. 
 
One of the main outcomes from the ICH harmonisation effort was the development and 
implementation of sixty-one regulatory guidelines in the areas of quality, efficacy and safety; 
eighteen in efficacy, eleven in safety, twelve in quality and ten in the multidisciplinary areas 
including the cross-cutting topics which do not fit uniquely into one of the quality, safety and 
efficacy categories (ICH, 2016). These regulations were either adopted or adapted by a large 
number of countries, which contributed to the harmonisation of the regulatory guidelines 
worldwide (Cone, 2016). In addition, the ICH generated a standard format for drug 
applications referred to as the Common Technical Document (CTD), which was proposed by 
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the industry in 1996 and subsequently adopted by the regulatory authorities. The CTD was an 
effective vehicle that enhanced the review process and exchange of information globally as 
well as saving significant resources for the industry. The harmonisation of regulatory 
requirements brought to the attention of the industry and public, the importance and need for 
more transparency and consistency to understand the regulators’ decisions for marketing 
authorisations. It has also paved the way to question the different approval timelines for 
similar products worldwide and the differences of patients’ access to innovative medicines 
and essential treatments.  
 
According to Molzon (2010); ever since the adoption of the CTD requirement, the approval 
timelines of similar new drug products within the major health authorities has become more 
and more harmonised, while it is still fluctuating dramatically in other countries especially in 
emerging and developing markets (Figure 1.3 and 1.4). 
 
Figure 1.3: NASs approval time for major regulatory authorities in 2006-2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
Source: CIRS, R&D Briefing 59 (Copyright obtained) 
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Figure 1.4: Median approval time of NASs in major authorities in 2006 - 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
Source: CIRS, R&D Briefing 59 (Copyright obtained) 
 
Figure 1.3 and 1.4 show the median approval timelines (calendar days) of approved new 
active substances (NASs) from 2006 to 2015 by major health authorities in the EU (EMA), 
US (FDA), Japan (PMDA), Canada (Health Canada), Switzerland (Swissmedic) and Australia 
(TGA). The variability of approval timelines reduced among those authorities since 2011 thus 
presenting an average of ten to fifteen months for approval timelines. 
 
The total approval timelines vary dramatically for the NASs approved between 2011-2015 in 
the major emerging markets such as Argentina, Brazil, Mexico, Russia and Turkey, Egypt, 
Saudi Arabia, South Africa, China, India, Indonesia, Malaysia, Singapore, South Korea and 
Taiwan. Data on the NASs approved in these countries have been analysed based on median 
approval times in each country, but also the variability of approval times by each authority 
(Figure 1.5). However, this variability will depend on a number of factors including the type 
of review whether a verification review such as Argentina or a full review such as in South 
Africa and Turkey. 
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Figure 1.5: Regulatory approval times from date of submission to date of approval for 
NASs in emerging markets in 2011 - 2015 
 
 Source: CIRS Emerging Markets Approval Timelines, 2015 (Copyright obtained) 
 
Moreover, Figure 1.6 provides an analysis and comparison of median interval durations for 
the first regulatory approval for a NAS anywhere in the world, followed by submission and 
approval for the same compound to one of the Emerging Market authorities. This way, the 
differences of local requirements for new drug applications in various countries and the 
variability of the approval timelines and their impact on patients’ access to similar products 
worldwide poses a dilemma of patients’ equal rights to access similar treatments worldwide 
while preserving the national essences and requirements. 
 
Furthermore, unlike most of the emerging markets, NAS applications in Turkey are submitted 
almost in parallel to first world submissions since prior evidences of approvals are not a pre-
requisite for NAS applications. However, the regulatory review process and approvals of 
NASs submitted between 2011 and 2015 are among the longest in comparison with the other 
emerging markets after South Africa and Egypt, which consequently delays the availability of 
NASs in the Turkish market. This is mainly due to the Good Manufacturing Practice (GMP) 
accreditation process introduced in March 2010 and price negotiations, which both have 
significant impact on the review and approval process. 
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Figure 1.6: Median time to roll out to Emerging Market (EM) countries for New Active 
Substance (NASs) approved 2010 – 2015 
 
Source: CIRS Report 2015 (Copyright obtained) 
 
Key Milestones of the Regulatory Review Process 
There are three types of regulatory assessment used worldwide by several authorities. This 
was agreed as an outcome of the CIRS Workshop on “The Emerging Markets: Regulatory 
issues and the impact on patients’ access to medicines”, organised in Geneva, Switzerland in 
March 2006. (Walker, et al., 2006). The workshop was attended by several regulators and 
regulatory agencies worldwide to discuss and evaluate the various types of data assessment 
methods applied to different applications. Accordingly, the three scientific review models of 
new drug applications are described below:  
 
I. Review Assessment Type 1 - Verification model  
This model is used by a number of health authorities that lack sufficient resources and 
capacity to perform a comprehensive scientific review of a new marketing authorisation 
application (MAA). This model helps reduce duplication of efforts by agreeing that the 
approving authority will issue a marketing authorisation for any product once the product is 
officially approved by two or more recognised reference countries. The main responsibility of 
the local authority is to ensure the “verification” of all data submitted as declared in the 
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application dossier. This includes the verification review of the product characteristics 
(formulation, composition and strength) and the proposed labelling information (use, dosage, 
precautions) for local marketing and that it complies with the reference country(s) 
authorisation(s). Approval evidence from recognised reference countries, such as the 
submission of Certificate of a Pharmaceutical Product (CPP), is a pre-requisite for such 
applications in this review model.  
 
II. Review Assessment Type 2 – Abridged model 
This model ensures the optimal use of the available resources by the local authority by not re-
assessing the scientific supporting data included in the application of the MAA as long as 
these data have been evaluated and approved by one or more of the recognised reference 
countries’ authorities. However, the MA application still undergoes an abridged review in 
relation to the product’s use and characteristic in the local market. Therefore, the abridged 
review model usually contains confirmation of the scientific clinical data but also includes a 
local review of quality data (CMC) of the product. The review of the quality data is mainly to 
confirm the product’s stability in relation to climatic conditions and distribution infrastructure 
in the local country.  
 
Moreover, the local review of clinical data might include a benefit-risk assessment in relation 
to its use in the local ethnic population, medical practice/culture and patterns of disease and 
nutrition in the country.  In the abridged review model, approval by a recognised agency 
elsewhere is a pre-requisite before the local authorisation can be granted, but the initial 
application need not necessarily be delayed until formal documentation such as a Certificate 
of a Pharmaceutical Product (CPP) is available, but must be provided before final 
authorisation. 
 
III. Review Assessment Type 3 - Full review model  
In this model the authority has suitable resources and capacity to perform a full independent 
scientific review.  This includes collaborating with both internal and external experts, to carry 
out a ‘full’ review and evaluation of the supporting scientific data (quality, pre-clinical, 
clinical) for a major application. Full review models, do not require a new marketing 
application approval in any other country (s) at the time of the submission and thus can carry 
out an earlier or parallel review to first applications worldwide. However, in some countries, 
11      
 
local regulation requires an evidence of approval in the country of origin or a reference(s) 
prior to local approval being granted.  
 
HEALTHCARE SYSTEM AND THE REGULATORY 
ENVIRONMENT IN TURKEY 
 
 
Source: www.wordtravels.com 
 
Turkey is a transcontinental country that is located at the geostrategic crossroads of Asia and 
Europe. Eight countries; Bulgaria and Greece border the country to northwest, Georgia to its 
northeast, Azerbaijani exclave of Nakhichevan, Iran and Armenia to the eastern side, Syria 
and Iraq to the southeast and the Aegean Sea and Mediterranean Sea to its south border. The 
current population of Turkey is over eighty million and the growth rate is around 1.29% per 
year. (World Population Review, 2016). The Gross Domestic Product (GDP) in 2016 was 
$735 billion and the GDP per capita in Turkey was last recorded at $ 9,317 in 2016 (Turkish 
Statistical Institute, 2016). Moreover, the total public expenditure on health was estimated to 
be 5% of the total GDP (OECD, 2015).  
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The Turkish Healthcare System – A Historical Perspective 
Historically, the Public Healthcare system in Turkey was officially developed based on 
western methodologies during the foundation of the Modern Republic of Turkey in the 1920s.  
The Ministry of Health of the Modern Republic of Turkey was first established in May 1920, 
with the focus to develop the regulatory framework and necessary legislations in the health 
care area in addition to restoring the country from the World War I negative health impacts 
and damages. During that time, the government, with extremely limited resources, provided 
all health services (Akadagi, 2008). 
 
The period from 1923 – 1946 is considered one of the major milestones in the Turkish 
healthcare history when significant developments took place in health care services under the 
leadership of Dr. Refik Saydam who was the Minister of Health. The focus was to establish a 
central execution, planning, programming and provision point of health services. (Tatar, et al., 
2011). Between the years 1946 – 1961 important laws were issued to socialise and further 
facilitate the health services for all citizens in Turkey. These included the law of 
"Socialization of Health Service in Turkey” No. 224, the “Turkish Medical Association” 
(1953/6023) and the Law of “Pharmacists and Pharmacies” (1953/6197). 
 
In the following years, other national plans and programmes to improve healthcare were 
drafted and approved by parliament. However, many of those programmes failed to reach a 
legal framework and consequently were never enforced due to the political instabilities and 
military interventions “coup d’état” in 1960, 1971 and 1980. Nevertheless, the essence of 
those plans and healthcare programmes were the main inspiration behind the latest Health 
Transformation Program (HTP) in Turkey that started in 2002 (Akadagi, 2008). 
 
Following the last military intervention in September 1980, the health policies in Turkey were 
mainly shaped by the 1982 constitution, which ensured the equal rights of all citizens to 
healthcare. For example, article number sixty of the Constitution states; “Everyone has the 
right to social security and the State shall take the necessary actions and establish the 
necessary organization to provide this security” and article number 56 where the regulatory 
role of the states in health care was strengthened; “The State shall regulate central planning 
and functioning of the health services to ensure that everyone leads a healthy life physically 
and mentally. (Constitution of the Republic of Turkey, 1982). 
13      
 
The Health Transformation Program in Turkey 
In 2003 the Turkish government implemented the “Health Transformation Program” (HTP) to 
initiate a new era in the Turkish health care system with the objective to achieve “Health for 
All”. This was identified within an Urgent Action Plan to be initiated by the newly elected 
government in November 2002.  
 
The reforms marked major developments in public access to available health services and 
treatments (Tarmur, 2011). Subsequently, the scope and objectives of the Health 
Transformation Program was made officially public in Turkey by the Ministry of Health 
(Tatar, et al., 2011) and included certain key deliverables such as; 
 
• A fundamental administrative and functional restructuring of the Ministry of Health. 
• The establishment of one central point for all health institutions and social security 
programs to improve the quality of planning and supervising roles of the authorities. 
• An enhancement of patients’ access to several health services and facilities. 
• An increased efficiency and accreditation of healthcare facilities including 
pharmaceutical manufacturing sites and health institutions. 
• The introduction of the “electronic-transformation” in health information systems to 
ensure monitoring and traceability mainly in pharmaceuticals’ use and patients’ data. 
• The introduction of institutional criteria to promote the rational use and management 
of medicine and health supplies. 
• An increase in the transparency of the decision-making process and data accessibility. 
 
With the implementation of the HTP in Turkey, a number of fundamental and important 
changes in healthcare policies took place. The program also enhanced the alignment of the 
Turkish health policies with the European Union (EU) standards that aimed to accelerate 
Turkey’s EU membership. More importantly, it increased the state governance on approved 
and reimbursed pharmaceuticals and aimed to establish a central point for all health services, 
which enabled a better control on the healthcare budget expenditure. Accordingly, the Turkish 
pharmaceutical industry is mainly a centrally reimbursed market where patients’ access to 
medicines is mainly attained by having a pharmaceutical product firstly approved by the 
Turkish Medicines and Medical Devices Agency (TITCK) and afterwards included in the 
national reimbursement list of the National Social Security Institution (SGK) (Tarmur, 2011). 
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The Turkish Pharmaceutical Industry 
The pharmaceutical market in Turkey is ranked 16th among the world’s 35 leading 
pharmaceutical producing countries. (IEIS, 2015). While the provision of healthcare services 
lies largely within the scope of the state and public institutes, the private sector and 
pharmaceutical companies (local and multinational) mainly drive the pharmaceutical industry. 
The market share of originators is approximately 58% and constitutes almost 42% of the total 
market volume when compared to the generic pharmaceuticals. Since 2002, the Turkish 
pharmaceutical market has experienced substantial growth, as pharmaceutical expenditure 
was $8.87 billion in 2007 compared to $2.52 billion in 2002 (IEIS, 2015). 
 
Further, this figure reached $9.82 billion by 2010.  Since then, certain governmental measures 
to control and decrease expenditure volume such as price reductions and health economics 
criteria for reimbursement were introduced. Therefore, the pharmaceutical market expenditure 
decreased and reached to approximately to $8 billion in 2014 (IEIS, 2015). Thus, all those 
cost reduction practices saved nearly $6 billion in three years (Figure 1.7).  
 
After 2012, there has been an upward trend in the pharmaceutical spending that reached an 
average of 2% annual real growth. Furthermore, the pharmaceutical spending in 2009 was 
1.7% of GDP compared to 1.5% in 2002 and then dropped to 1% in 2012 and stayed close to 
1% in 2013 and 2014 (Figure 1.8) (Gürsoy, 2016). 
 
Currently the government’s pharmaceutical vision is to make Turkey one of the world’s top 
ten economies in health services by 2023. This plan is to accomplish this by increasing the 
local R&D expenditure up to 3% of GDP and exports of locally manufactured 
pharmaceuticals to $500 billion. According to the Turkish Ministry of Science, Industry, and 
Technology (AIFD)’s Strategy Report; Turkey should become the Eurasian production base 
for medium- and high-level technology products (Tarmur, 2011).  
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Figure 1.7: Public pharmaceutical spending, real growth and GDP growth in Turkey 
 
Source: Gürsoy, 2016 
 
 
Figure 1.8: Public pharmaceutical spending in Turkey as a percent of GDP, 2002-2014 
 
Source: Gürsoy, 2016 
 
16      
 
Prior to 2012, the Pharmaceutical and Pharmacy General Directorate (IEGM) at the Ministry 
of Health in Turkey was the responsible body for all regulatory activities and control of the 
pharmaceutical industry ranging from market authorisation, pricing, advertising, inspection 
and control of medicines at all different levels in Turkey. This is in accordance with the 
essentials of the “Law on Pharmaceuticals and Medical Preparations” (1928) that mandates 
the regulation of pharmaceuticals and medicinal products in Turkey. Moreover, the Ministry 
of Finance and the Social Security Institute (SGK), as the main purchaser of pharmaceuticals 
in Turkey, both play essential roles in determining the reimbursement processes as the basis 
for the pharmaceutical products. 
 
In 2011 and as part of the HTP, the TITCK was established officially to become the 
regulatory body responsible for regulating the pharmaceutical and medical device industry in 
Turkey. This was a positive improvement and brought an expectation for increasing the 
transparency and scientific developments of the regulatory review and approval processes, 
while enhancing the quality and timelines of the pharmaceutical regulatory procedures in 
Turkey.  
 
One of the main roles of the TITCK is to regulate and control marketing authorisations 
through issuing and enforcing related regulations and requirements for licensing, importing, 
and marketing pharmaceutical products in the Turkish market. In connection with this, the 
TITCK is responsible for enhancing the awareness of the pharmaceutical industry for all 
related regulations accessed from the available official sources, such as the TITCK through 
the official related websites, official gazette, publications and circulars. Market authorisation 
is one of the main responsibilities of the TITCK and this process has a number of stakeholders 
who assist and contribute to the process via several commissions, including academics, 
pharmacologists and clinicians.  The first requirement to apply for a marketing authorisation 
of a pharmaceutical product in Turkey is for it to be a legal entity registered and located in 
Turkey whether this is to represent a local manufacturer or a foreign pharmaceutical 
company. (Ministry of Health Turkey, 1995). The Turkish Patent Law issued in 1995 though 
not fully providing marketing exclusivity, yet, as per the regulations issued in 2005, the 
marketing exclusivity of original pharmaceutical molecules is protected for six years after the 
initial registration of the molecule / product in one of the European Customs Union Zone 
countries.  
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The Regulatory Review Process in Turkey 
According to the local pharmaceutical regulation in Turkey, a registration approval by the 
TITCK is required for any pharmaceutical product prior to marketing in the country. This 
would require an official marketing authorisation application to the TITCK by providing the 
documents listed under the Licensing Regulation, published in the Official Gazette dated 
2005. The regulatory review process in Turkey consists of several milestones and these clarify 
the key assessments through which a product goes from the time of the application to the 
TITCK until the patient’s access to that specific product.  The registration review process, as a 
step is only one of those milestones that need to be completed which include: 
 
• GMP Accreditation 
• Registration review of the submitted application 
• Marketing authorisation 
• Pricing  
• Sales and importation permission 
• Reimbursement 
 
New marketing authorisation applications and the GMP requirements 
A map of the review process in Turkey is illustrated in Figure 1.9; a general simplified flow 
chart represents the main milestones of the review process for a New Active Substance (NAS) 
application from the first step of the preliminary review of the application until the last step 
when the product is registered. The flow chart also demonstrates the pre-submission steps that 
need to be completed within the GMP accreditation process. 
 
In March 2010, the Turkish Ministry of Health issued the GMP regulation, which included a 
pre-requisite step to be fulfilled by all applicants prior to filing for a new drug application or a 
change to manufacturing site, line or suite. Accordingly, under normal circumstances, the 
TITCK requires that all pharmaceutical companies, applying for registration of a 
pharmaceutical product manufactured within or outside Turkey, demonstrate that the 
manufacturing process and site infrastructure are according to the GMP criteria set by the 
regulation.  
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Figure 1.9: Registration review process for a new drug application in Turkey 
 
   Source: TITCK, 2016 
 
The GMP accreditation process usually requires a “Manufacturing Site Inspection” or Turkish 
GMP inspection on a product-by-product basis. The inspection comes after an evaluation 
phase of a submitted GMP application related to an NDA and/or alternative/new 
manufacturing site application. Unlike many countries in the world, except for highly 
prioritised applications (TITCK, 2016), the GMP process in Turkey cannot be filed or 
reviewed in parallel with the new drug registration or site variation process. Therefore, the 
Turkish GMP accreditation step has a direct impact on the review and market access 
timelines. Moreover, once a GMP accreditation is granted from the Turkish authority, it is 
only valid for three years starting from the inspection date and therefore has to be renewed via 
a separate application, which can be submitted six months before the expiration. 
Consequently, the GMP requirement and inspection in Turkey has introduced a pre-
submission step that takes on average two years leading to a delay and bottleneck in the 
regulatory review process, which has an average of two to three years when compared with 
the pre-regulation period prior to March 2010. The GMP process varies in other similar 
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countries for example in Iran the requirements are similar to the Turkish GMP; however, this 
could be running as a separate parallel process to the registration review.  
 
In order to obtain an approval from the TITCK, pharmaceutical companies must fulfil a 
number of regulatory requirements.  Firstly the applicant needs to be a legal entity located in 
Turkey whether a person or a company (Ministry of Health Turkey, 1995). Then an 
application should be submitted to the TITCK by providing the documents listed under the 
Licensing Regulation, published in the Official Gazette dated 2005 and which was updated in 
2013. Currently, all new drug applications are submitted online to TITCK according to local 
licensing requirements. The applicant is required to prepare a regulatory dossier in 
compliance with the common technical document (CTD) with quality, safety and efficacy 
modules covering both the active drug substance and the finished product. The regulatory 
application must be organised according to the TITCK Checklist and format and include all 
the characteristics of the Pharmaceutical Product together with the authorisation status of the 
medicine in other countries as well as proposed and approved claims and labelling (TITCK, 
2005). Following the CTD Pre-Assessment approval, application documents are first assessed 
by the Clinical Assessment Commission for Medicinal Products for Human Use and then by 
the Advisory Commissions for Technology, Bioequivalence/Bioavailability and 
Pharmacology. In addition, laboratory analysis and local risk management plan evaluation 
should proceed in parallel with advisory commissions.  
 
In 2012 with the new restructuring of the TITCK, a Risk Management Department was 
established and the Pharmacovigilance Risk Management Unit started to manage and monitor 
safety risks of all medicinal products. Accordingly, the requirement to submit a local risk 
management plan is dependent on the nature and safety profile of the product. Submission of 
Risk Management Plans (RMPs) is mandatory for all biological and biotechnological 
products during the regulatory review process. 
 
The Registration regulation (2005) Article fifteen states that; “upon completion of the 
preliminary evaluation period which is stated to be a maximum of 90 days (including the time 
period devoted to provide missing documents and answering queries); the regulatory 
submissions will be evaluated by the agency and need to be concluded within 210  days”. In 
general, Turkey evaluates a new drug application based on quality, efficacy and safety similar 
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to other countries worldwide. However, the regulations contain an exceptional review period 
of a maximum of one hundred and eighty calendar days to ensure rapid patients’ and public 
access to certain products. This is applicable when the new drug application is related to an 
innovative pharmaceutical product for treatment or diagnosis, or when a product is considered 
to be lifesaving from a public health perspective or if the new product or technology is 
bringing a cost effectiveness benefit to reduce healthcare expenditure (TITCK, 2005).  
 
Additionally, a prioritised assessment and registration review procedure was introduced by 
the TITCK circular in October 2015 to accelerate the marketing authorisation process for 
critical applications for certain products such as lifesaving medicines. This was then followed 
by a guideline issued in April 2016 in order to define the principles of the priority application 
and review process (TITCK, 2016). According to this guideline, companies are required to 
submit two separate prioritisation applications for both GMP and registration processes. It is 
possible to submit both the GMP inspection prioritisation and the registration prioritisation at 
the same time. Thus, the “Prioritisation Committee” evaluates the innovative medicines’ 
applications based on several criteria including the mode of action, safety, efficacy, additional 
benefits to patient compliance, impact on the national healthcare budget, the unmet 
therapeutic need, technology transfer opportunities to Turkey and price. Depending on the 
assigned registration priority level of the product, the marketing authorisation process could 
be completed within one hundred and fifty working days for highly prioritised products and 
within one hundred and eighty working days for prioritised products apart from clock stops in 
case of notification of deficiency. Also according to the TITCK announcement dated in 
March 2017, all applications that are not within the “High Priority” or “Priority” status will be 
included in the “Post-Pre-Evaluation Process Waiting List.” However, all applications, which 
have been granted high priority or priority status, are immediately moved to the “Active 
Process List,” upon paying the “Scientific Examination and Assessment Fee.”  
 
When the regulatory application is submitted to the TITCK, this is reviewed at different levels 
and goes through several assessment stages before approval. Each step of the review process 
can sometimes contain different sub review processes and can involve external reviewers’ 
assessments as subject matter experts and advisors. Naturally, in cases of questions and 
queries raised by the TITCK concerning an application, a “clock stop” system is introduced to 
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the review process. However, the clock stop system can prolong the progress of the review 
and have an impact on the timeline of the final licensing process.  
 
Pricing process 
The pricing process for pharmaceutical products is separate from the marketing authorisation 
process, yet affects the time of the product to the market. The process is evaluated by a 
separate independent pharmacoeconomic and pricing commission at the TITCK and can be 
conducted either in parallel with the application or after the assessment has been conducted by 
the main technical committee. After assessment by the pricing committee, a sales permit 
application that enables the marketing of the product could be submitted. The Pricing 
Commission holds regular meetings and includes several members from the Turkish Agency, 
Ministries of Health and Finance, Social Security Institute and some other governmental 
representatives. It has the responsibility to provide to the TITCK with various pricing 
assessments such as new prices for products, price increases or reductions.  
 
The pricing system in Turkey depends on a referencing process, which was first introduced in 
2004, and uses the pricing data from a basket of five EU countries (Italy, France, Spain, 
Portugal, and Greece) used as the basis for determining the price of an original product. 
Moreover, a constant exchange rate for Euro into Turkish Lira is determined and applied by 
the Pricing Commission at TITCK throughout the pricing process, which enables a control on 
the governmental healthcare expenditure. The pricing rules and referencing process is 
different for original products compared to generics, as the price of a generic product cannot 
exceed the original reference price or the highest price of the equivalent generic in the market 
(TITCK, 2015).  
 
It is worth stating that the pricing regulation sets the highest limits for pricing of 
pharmaceutical products. Therefore, companies have the option to suggest lower prices to 
enable the inclusion of their products in the reimbursement list of the Social Security Institute 
(SGK). Thus, the price labelled on the outer carton of the packaging material shows the 
official market price based on the pricing process at the TITCK. This means that it reflects the 
actual price charged to the patient during the purchase of the product as out of pocket or over-
the-counter. The discounted price for SGK shows only in the reimbursement price.  
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When pharmaceutical products are approved, priced and licensed in Turkey, they are subject 
to a re-registration process once in the 5th year counting from the first issuance date of the 
Registration Certificate. The re-registration requirement in Turkey has also been updated to 
shift the focus of the TITCK from reviewing the technical aspects to the safety aspects of the 
products and pharmacovigilance (PV). Accordingly, the submission of a periodic safety 
update report (PSUR) or a Periodic Benefit Risk Evaluation Report (PBRER) covering fifty-
five months data is the main requirement for the re-registration step. Then every three years 
after the extension of the marketing authorisation validity period, PBRER should be prepared 
and submitted immediately upon request by TITCK. However, if the drug substance is listed 
in the current “List of European Reference Dates” (EURDs) and frequency of submission of 
PSURs” published at the EMA official website, PBRER could be prepared in accordance with 
this list.  Further, according to the latest local pharmacovigilance regulation in Turkey all 
marketing authorisation applications must include a statement confirming the availability of a 
local Pharmacovigilance System Master File (PSMF).  
 
Reimbursement process 
Turkey is considered one of the efficient centrally reimbursed pharmaceutical markets in the 
world. In order for any pharmaceutical product to be reimbursed in Turkey, it needs to be 
approved for the inclusion in the positive list for reimbursement published periodically by the 
SGK. This requires the submission of a reimbursement application that contains 
pharmacoeconomic data that support the claim that the new treatment is cost-effective in 
comparison with alternative treatments available in the market. While this is a mandatory step 
for original products, the process for generics is relatively easier as the reimbursement 
application does not require including cost-effectiveness analysis. In general, the conventional 
reimbursement method requires original products to provide the SGK with a 41% discount of 
the actual official price approved by the TITCK (Reimbursement Decree 2012). The final 
assessment for each reimbursement application can take three to four months and the 
application for the reimbursement of one product can only be submitted twice in a year. 
Furthermore, an Alternative Reimbursement Model (ARM) with different discount ratios and 
reimbursement conditions can be utilised and proposed by companies based on confidential 
terms for certain products such as orphan or highly expensive medicines (Social Security 
Institution, 2016). The Quality-Adjusted Life-Year (QALY) scores and criteria are not yet 
considered by the health authorities and SGK during the reimbursement decision process. 
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According to local regulations, doctors are allowed to prescribe by brand name and the 
prescribed products can have a higher or lower price than the reimbursed price. In case where 
a higher priced product is prescribed, the patient needs to agree to pay the difference. 
Whereas, if it is lower than the reimbursed price, the full cost is covered by the government. 
In all matters, it is the responsibility of pharmacists to inform the patient of the reimbursement 
status and provide the lower cost choice so pharmacists are allowed to substitute. Certified 
chronic disease patients’ treatments and in-patients’ pharmaceuticals are fully reimbursed. A 
co-payment of 20% of the reimbursed product has to be paid by the patient at the time of 
purchase in the pharmacy and this rate is 10% in the case where the patient is retired.  
 
Finally, according to local regulations in Turkey, early access is granted and reimbursed by 
SGK for life-saving products and orphan drugs on a named patient basis when critical 
products can be imported and used by patients prior to registration approval and the cost is 
reimbursed by SGK as per a specific reimbursement protocol (SGK, 2016). Another 
alternative for early access use of medicines can be provided via compassionate use programs 
sponsored by companies. 
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AIM AND OBJECTIVES OF THIS RESEARCH PROJECT 
Aim 
The aim of the study is to evaluate the pharmaceutical regulatory environment in Turkey in 
terms of requirements, regulatory review process and timelines and how these are perceived 
by the TITCK, the pharmaceutical industry and patients.  
 
Objectives: 
• Identify the key milestones for the TITCK and the main activities and dynamics in 
respect to the review process, timelines and scientific assessment models.  
• Present the trends for the approved new active substances in Turkey from 2012 to 
2015. 
• Assess how the TITCK is incorporating good review practices into the assessment and 
registration processes. 
• Determine the similarities and differences in the Turkish Agency’s review process in 
comparison with Australia, Canada, Saudi Arabia and Singapore. 
• Evaluate the pharmaceutical companies’ attitudes and experiences towards the current 
regulatory review  process and timelines.. 
• Evaluate the impact of the current regulatory process on patients’ access to medicines 
and identify public awareness with regards to medicines’ access. 
• Identify the opportunities for the adoption of best practices from other established 
health authorities leading to a proposed improved model for the regulatory review 
process in Turkey. 
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CHAPTER 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY RATIONALE AND 
METHODOLOGICAL FRAMEWORK 
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STUDY RATIONALE 
The general introduction of this research project gave a historical background of how the 
pharmaceutical regulatory environment evolved in the modern republic of Turkey and reached 
its current status. It also highlighted the outcomes of previous studies, which focused on 
evaluating the regulatory review process, timelines and quality measures in major health 
authorities such as the FDA (United States of America), the EMA (European Union) and the 
PMDA (Japan). However, the literature review identified that there is a lack of comparable 
studies, which provide data on the review models and quality systems of other health 
authorities such as the TITCK. Hence, the regulatory review process and the performance of 
the TITCK as an agency have a significant impact on the pharmaceutical industry and 
patients’ access to medicines. To date these have not been adequately evaluated or 
systematically compared with other authorities. Furthermore, pharmaceutical companies are 
an important stakeholder and key player within the pharmaceutical regulatory environment 
where an open dialogue and relationship between the regulatory authorities and 
pharmaceutical industry can play a key role in fostering innovation and facilitating 
breakthrough therapies. Thus, the experiences of the pharmaceutical industry towards the 
regulatory review process and timelines are crucial to assess the efficiency of an authority’s 
review system. Subsequently this can address the key concerns to ensure timely registration 
approvals in order to meet the increasing demand of patients for high quality, accessible and 
safe medicines. In addition, patients’ awareness of the regulatory environment is believed to 
be an important aspect and a success indicator of the efficiency in the pharmaceutical system 
in a country. Nevertheless, no previous study has been conducted to assess the role of patients 
in the decision-making process of approving and reimbursing medicines in Turkey or the 
impact of the regulatory environment on their access to medicines.  
 
In light of these aspects, the key issues and focus areas of this study were identified through; a 
review of published literature and regulations, a series of discussions with pharmaceutical 
companies’ senior staff and TITCK internal and external experts as well as a critical analysis 
of a fifteen-year personal experience in the pharmaceutical industry. This, as was determined 
earlier, was coupled with a lack of published evidence regarding the regulatory review 
process and the quality measures implemented by the TITCK. Thus, no previous studies 
examined the impact of these processes either on the approval timelines of marketing 
authorisations of new medicines and/or on patients’ access to such medicines.  
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Accordingly, the study design aimed to collect information and data related to the following: 
 
• Evaluation of the regulatory review process and milestones within the TITCK, 
• Assessment of the trends of the TITCK approval times for new medicines, 
• Identification and appraisal of the quality measures implemented by the TITCK during 
the review process, 
• Possible solutions for addressing the delays in the registration processes, 
• Comparison of the Turkish regulatory review process and its quality measures with 
other mid-sized regulatory authorities, 
• Evaluation of the pharmaceutical companies’ experiences towards the regulatory 
review process in Turkey and, 
• Identification of the patients’ awareness towards the Turkish regulatory environment 
and its impact on their access to medicines. 
 
These focus areas led to the conceptualisation and design of four main studies for this Ph.D. 
research project. These were planned to examine the different stakeholders’ views, 
perceptions and experiences about the regulatory review process of new medicines in Turkey. 
Accordingly, the methodological framework, underpinning these studies is described in this 
chapter. 
 
METHODOLOGICAL FRAMEWORK 
Study Design 
The aim of the study design is to ensure the collection of the appropriate evidences and data to 
address the study question adequately, logically and scientifically. Therefore, it is important to 
specify the type of data needed to test a theory, to evaluate a process, or to describe and assess 
an impact of an observed phenomenon or behaviour. Accordingly, this study employs the 
quantitative, qualitative, exploratory, descriptive and constructive research methodologies all 
utilised to evaluate the regulatory review process in Turkey. 
 
Types of Study Designs 
Cross-sectional studies are also known as transversal or prevalence studies. These are a 
simple type of observational studies that aim to analyse data collected from a population, a 
phenomenon or attitude at a specific time with little cost. Moreover, they can be descriptive to 
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assess a population characteristic, a demographic experience or to describe and evaluate a 
specific process, or can be analytical to identify the relationship between two variables and 
investigate the association of a phenomenon with other factors (Trochim, 2006). 
 
Retrospective studies look backwards and examine an event or an exposure that took place 
in the past for which the investigator collects data from past records or databases. However, 
the data analysis in these studies can be limited and some of its aspects may not be possible to 
measure. Therefore, these studies are often criticised for being biased and not representative 
due to the selection of the source for the secondary data (Statsdirect, 2000). Nevertheless, they 
have their place in a researcher’s toolbox when prospective data collection is not possible and 
/ or historical data is needed such as case control studies.  
 
Prospective studies evaluate the probability of a phenomenon, a target outcome or interest 
within a selected group in the future. Thus, the term prospective refers to a selected cohort at 
present from which an outcome is to be examined in the future. Scientific experiments are 
generally designed as prospective studies, which depends on the future outcome and of a 
study conducted as per specific factors to evaluate a certain effect and assess the relationship 
between variables (Farlex, 2017). 
 
Longitudinal studies are observational studies that aim to examine a group of participants for 
a long period of time, which may take several months or even years to be concluded in order 
to identify specific correlations between various factors and variables. These studies require 
continuous follow up and consistent data collection and they do not involve any interventions 
to the variables (Unite for Sight, 2015).  
 
The cross-sectional study approach was mainly adopted in this study to achieve the aim and 
objectives concerning the evaluation of the Turkish regulatory review processes and timelines 
as well as their impact on patients’ access to medicines. However, a systematic retrospective 
approach was also followed for the collection of data from the five regulatory agencies 
involved in the study and to evaluate the approval timelines for the period from 2012 to 2015. 
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Study Participants 
The four main studies considered for this research project recruited different target 
participants in order to generate the required data. The study participants for each study are 
summarised in Table 2.1. 
 
Table 2.1: An overview of the study participants 
Study Study Participants 
Study 1: Evaluation of the TITCK 
review process and timelines. 
• Head of the TITCK, 
• TITCK agency staff and heads of the registration 
departments and units, 
• TITCK vice president, 
• Ex-TITCK external commission members. 
Study 2: Comparison of the TITCK 
review process and timelines with other 
mid-sized regulatory agencies. 
• Australia’s Therapeutic Goods Administration (TGA), 
• Health Canada, 
• Singapore’s Health Science Authority (HSA), 
• Saudi Arabia Food and Drug Administration (SFDA), 
• TITCK. 
Study 3: Evaluation of the 
pharmaceutical companies’ attitude 
towards the Turkish review process. 
Pharmaceutical companies operating in Turkey: 
• Global companies. 
• Local companies. 
 
Study 4: Patients’ awareness of the 
Turkish regulatory environment and its 
impact on their access to medicines. 
• Outpatients under treatment with medicines. 
 
Data collection instruments and procedures 
There are two types of data considered as primary data required for scientific research. These 
can be obtained from various sources using several data collection techniques (The University 
of Minnesota, 2017), which includes: 
• Questionnaires.  
• Interviews. 
• Focus groups. 
• Documents and records available in the public domain or obtained from confidential 
sources. 
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Questionnaires 
They are tools commonly used within a prospective research design as a method to collect 
information from a general or a specific group of population of interest either by consecutive / 
convenient administration or by random sampling. The questionnaire techniques employ the 
use of a predefined series of questions to collect specific data. Subsequently the responses can 
be analysed quantitatively or qualitatively, which makes it easier to carry out the analysis and 
interpret results compared to other techniques. 
 
Strengths and limitations of questionnaire techniques: Questionnaire studies are cost-
effective and efficient data collection techniques, which can provide accurate generalisable 
data based on a representative sample of the target population. Therefore, when the target 
population is very large, diverse in features or geographical located in different areas, such 
data collection techniques could be the best option to use as a reliable tool and in a timely 
manner while securing anonymity. However, postal questionnaire studies, do not allow 
researchers to have a direct contact with the study participants, which may help clarify the 
questions or help to understand the background behind the responses. Moreover, participants 
could be hesitant to share information in a written format and return it back to the researcher. 
This makes achieving a target response rate extremely challenging (NCCP, 2016). In this 
study, the questionnaire technique was selected as the primary data collection tool due to 
logistical challenges coupled with the academic desire to recruit participants from a wider 
field for the four studies. 
 
Interviews 
Interviews are one of the qualitative data collection techniques, which can be used in research 
to explore the different perceptions, views, experiences and attitudes of individual participants 
(Gill, et al., 2008). Interviews can be conducted in a structured (formal), semi-structured or 
informal way, either in person or face-to-face or on the telephone. However, the questions 
asked through interviews should be clear and accurate to enable open-ended responses. 
However, there are some advantages and disadvantages that may need to be considered when 
selecting interviews as a data collection technique (Table 2.2) (Businesscom, 2017).  
 
Semi structured interviews were used in this study as a secondary data collection technique 
which supplemented the collection of factual data and responses from participants related to 
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the regulatory environment in Turkey. This technique was mainly used in the pharmaceutical 
industry and patient studies (study three and four) to identify the main themes and to ensure 
the content validation “often referred to as cognitive debriefing “of the questionnaires during 
the pilot studies. Furthermore, a number of interviews were conducted with some TITCK staff 
and external reviewers to enhance the accuracy of the data collected by the standardised 
agency questionnaire and obtain more information and background to facilitate the analysis. 
 
Table 2.2: Advantages and disadvantages of interviews 
Advantages Disadvantages 
Can achieve high response rate. Time-consuming data technique. 
Possibility to clarify and ensure the 
understanding of questions. 
Costly, in particular if travelling is required. 
Development of a relationship. 
The interviewer can bias data, an element of 
subjectivity. 
Can provide better insight, especially about 
feelings or experiences. 
Lack of accurate record keeping 
Facilitate in depth analysis with background 
information. 
Difficulty to verify and validate the information 
provided. 
 
Focus Group 
A focus group is an effective qualitative research technique often used to provide data about 
how a group of people think, feel, behave or act in relation to a specific topic or area of 
interest. A focus group is conducted by bringing together a group of participants and creating 
a special environment for them to spontaneously discuss and express their perceptions and 
experiences regarding a specific topic. This technique depends on facilitating the interaction 
and active participation of each member; however, the group dynamics can stimulate and 
affect significantly the nature of the interaction (Mach, et al., 2005). In addition, it may be 
used in conjunction with other data collection techniques and/or to obtain further data from 
the interpretations of the participants of initial studies’ outcome or results. This usually allows 
the generation of additional information for a study on a wider scale. There are different 
advantages and disadvantages related to this technique, which need to be considered 
depending on the research question to be answered (Table 2.3) ( Freitas, et al., 1998). 
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The focus group technique was used twice in this study as a tool to evaluate the perception 
and attitude of the participants towards the results of the questionnaire studies conducted with 
the TITCK and pharmaceutical companies. Both focus groups were organised in order to 
further understand and interpret the results and generate the key issues and messages as well 
as the focus areas of each study. 
 
Table 2.3: Advantages and disadvantages of focus group 
Advantages Disadvantages 
Rich source of data to conduct research in a 
relatively short time. 
Requires planning and is difficult to assemble 
the correct group. 
Allows the exploration of more ideas and the 
generation of data. 
Difficult in the data analysis and interpretation. 
Allows data collection on a specific topic from a 
group of participants in a short period of time. 
Data are generated in a controlled atmosphere 
(rather than a natural one). 
Relatively cost effective.  Unpredictable in terms of the group interaction. 
Quick way to supply data and results (in terms of 
evidence of the meeting of the group) 
Requires intensive effort and attention to capture 
the data. 
 
Existing documents and records 
The analysis of available documents and records can be used as a source for data collection 
mainly for qualitative research. Analysis of existing documents is an important tool to collect 
data from a wide variety of sources either available in the public domain or obtained 
confidentially and therefore it is a good methodology for policy and process evaluation as 
well as organisational reforms. Examining existing documents or published records has some 
advantages and limitations where the findings should be confirmed by conducting further 
studies employing other data collection techniques. Nevertheless, this technique is helpful to 
define the main themes of the research study and narrow the study question (Trochim, 2006).  
 
Several publicly available documents and regulations were analysed in this study to obtain 
data regarding the regulatory review process in Turkey. Thus, using this technique facilitated 
both the design of the sub-studies and the development of the related questionnaire, which 
included all the necessary questions to address the key issues identified, based on the 
document analysis. 
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Different Types of Questionnaire Techniques Used in Data Collection  
There are different types of questionnaire techniques that can be used for data collection and 
thus the choice of the most appropriate method often depends on the objectives of the study, 
the nature and the size of the target population, the timing of the study as well as the available 
resources (Mach, et al., 2005). 
 
Paper or Electronic mail-delivered 
Paper based questionnaires can be distributed by post as hard copies to a large number of 
study participants within a specified time. Electronic questionnaires utilise a data collection 
method where the questionnaires are sent electronically via e-mails and are often quicker and 
less costly compared to paper based questionnaires. In general, these are excellent data 
collection tools since participants can respond to them at their convenience and feel more 
comfortable and truthful when responding to questions anonymously even for controversial 
issues. Nevertheless, it is usually difficult to get the completed questionnaire back and 
therefore achieving a high response rate is challenging (Leedy & Ormrod, 2010). 
 
Group-administered or interviewer administered questionnaires 
This type of questionnaires involves bringing together a group of participants and asking them 
to respond to a structured sequence of questions individually. Questionnaires are distributed 
and collected in-group settings at a defined time, which enables a high response rate. This also 
facilitates the clarification of unclear questions to all target participants (Trochim, 2006). An 
example of this type of questionnaire is data collection in an outpatient clinic setting. 
 
Telephone-administered 
This method is a rapid and inexpensive tool used to collect data by calling the study 
participants and recording their responses systematically to generate data for the study. 
Furthermore, responses can be obtained via an automated system where participants can reply 
by selecting from a set of pre-defined answer choices via a touch-tone telephone directly 
linked to a web-based survey system or a voice recognition software (Leedy & Ormrod, 
2010). However, language barriers and different time zones are among the main 
disadvantages of this method, which limits its use for international studies. 
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Web-based 
Web-based questionnaires, also commonly referred to as online surveys, are quick and easy to 
organise where study participants can complete the questionnaires individually at their 
convenience and directly on web sites. Web-based questionnaires are cost effective and 
enable a quick response. Nevertheless, the respondents require a good internet connection to 
access the questionnaire on the website (Wright, 2005). Paper based questionnaires were used 
in this research project to collect data from the participants in the patient study, while these 
were distributed and collected electronically in the regulatory authorities and pharmaceutical 
companies’ studies. 
 
Data Source for the Studies 
To achieve the objectives of this study, data were collected from five regulatory health 
authorities, pharmaceutical companies and patients according to specific criteria. 
 
Inclusion criteria  
For the evaluation of the TITCK regulatory review process and approval timelines, the 
comparison with other regulatory agencies and the pharmaceutical industry studies, the main 
inclusion criteria was related to data on New Active Substances (NASs) obtained from local 
and global companies, which have been approved in Turkey between 2012 and 2015. Detailed 
regulatory information about these products was included in this study such as; first world 
approval, submission date in Turkey, regulatory evaluation time, and approval dates were 
included in the total approval time. Furthermore, the views and perceptions of patients as well 
as the pharmaceutical companies on their experiences with the Turkish regulatory 
environment and in particularly on the registration review process were collected using the 
different types of questionnaires as well as interviews. 
 
Exclusion criteria 
Data related to generic products or those with missing information of submission or approval 
dates as well as patient questionnaires that did not have a signed informed consent were 
excluded from this study.  
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Data Collection Procedure 
Questionnaire techniques were used for all four studies; they were applied electronically to 
regulatory authorities and companies, but as paper copies to patients. Throughout the study 
confidentiality and/or anonymity was strictly adhered to and only aggregated data were 
analysed. For example, data related to product approvals and timelines were collected from 
individual companies “anonymised by using a third party”. Similarly, patient questionnaires 
were completed anonymously where individual responses were not identified and therefore 
this did not allow any follow up during data collection and analysis.  
 
Data Collection Monitoring and Timeline 
Several face-to-face meetings including those with the head of the TITCK and calls with the 
units’ coordinators took place to follow-up on the data to be obtained from the TITCK. 
Participants were asked to provide data related to the regulatory review process, approval 
timelines from 2012 to 2015 and the quality elements implemented by the TITCK. Collected 
data were then standardised into a country report in a word document and returned to the 
TITCK for auditing, correction and comment. In addition, face-to-face meetings with the 
pharmaceutical companies through the industry association were held to ensure their 
participation and emphasise the rationale and objectives of the study.  
 
Questionnaire Development 
 
Three different questionnaires were employed during this research project to be used with the 
different study participants namely;  
 
• The TITCK and other regulatory authorities, 
• The pharmaceutical companies, 
• Patients. 
 
Study One and Two: The first regulatory agency questionnaire was developed based on 
established questionnaires previously used in an Emerging Markets Programme to evaluate 
the regulatory process for new medicines and the impact on their availability to patients 
(McAuslane, et al., 2009). The questionnaire (Appendix I) was reviewed and pre-filled based 
on publicly available data in order to test the validity of the questions. The questionnaire was 
administered electronically and aimed to examine the regulatory review processes, approval 
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timelines as well as the implementation of the quality elements built into the review processes 
in Turkey, Australia, Canada, Saudi Arabia and Singapore. The questionnaire enabled a 
standard mapping of the review process and an understanding of decision-making while 
allowing the comparison among other regulatory agencies. 
 
Study Three: The second questionnaire was developed to assess the views and experiences of 
the pharmaceutical companies with regards to the Turkish review process. The questionnaire 
was designed following a series of consultation with industry experts and a review of previous 
surveys of pharmaceutical companies conducted to evaluate the companies’ experiences about 
the TITCK practices, regulations and their interaction with the industry. Accordingly, the 
main themes of the questionnaire were generated. In addition, a pilot study was conducted 
with some companies to ensure the content validation and usefulness of the questionnaire. 
 
Study Four: The third questionnaire was developed following several discussions with 
patients and physicians regarding the patients’ knowledge and concerns about the 
pharmaceutical regulatory environment in Turkey. This questionnaire was then piloted among 
a group of patients and physicians to determine its acceptability, applicability and ensure its 
content validation.  
 
Consensus generating methods 
Chapters Three, Four, Five, Six and Seven aimed to provide both qualitative and quantitative 
data and evidences to establish a consensus of opinions on the common key issues that 
currently do not have adequate information. Different consensus methods were implemented 
throughout the four studies; in order to establish a certain level of agreement mainly in 
controversial issues where there were insufficient or contradictory data to support certain 
evidences (Fink, et al., 1984). The ultimate aim of these methods was to measure the extent of 
the consensus among the four studies and accordingly resolve the disagreement by 
establishing a consensus development (Holey, et al., 2007). The most commonly used method 
for generating consensus is the Delphi process, a nominal group technique (expert panel) and 
the consensus development conference with each having different features (Table 2.4) (Fink, 
et al., 1984).  
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Table 2.4: Features of consensus generating methods 
Feature Definition/ Use 
Anonymity To avoid dominance; achieved by use of a questionnaire in Delphi and 
private  ranking in nominal group. 
Iteration Processes occur in "rounds", allowing individuals to change their opinions. 
Controlled feedback Showing the distribution of the group's response (indicating to each 
individual their own previous response in Delphi). 
Statistical group 
response 
Expressing judgement using summary measures of the full group response, 
giving more information that just a consensus statement. 
Source: (Jones & Hunter, 1995)  
 
Delphi approach 
Delphi approach is a consensus method in which the opinions and views of an expert panel is 
obtained systematically by sending the questionnaire for individual review for several rounds, 
followed by sharing the aggregated responses anonymously with the group after each round. 
The experts are allowed to express their opinions impersonally and following each collective 
response, they are asked to review their answers in subsequent rounds. Eventually, the Delphi 
method aims to ensure a consensus after several rounds in order to reach the "correct" 
response.  
 
The Delphi technique is considered an inexpensive and quick method, since it does not 
require the physical interaction of experts and the questionnaires round can easily be 
completed via e-mails. Therefore, there are no geographical limitations when selecting the 
experts. Nevertheless, the reliability of this method depends on both the number of experts as 
well as their level of expertise (Fink, et al., 1984). In this study, the Delphi approach was used 
to a certain extent to develop a consensus of views regarding the content of the questionnaires 
both in the patient and industry study. The aim was to determine the main topics and themes 
and accordingly ensure the appropriate data collection to support the scientific evidence 
required for this thesis (Figure 2.1).       
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Figure 2.1: An illustration of the Delphi approach (one round) 
 
 
Nominal Group Technique  
Nominal Group Technique is mostly used in healthcare and clinical disciplines to confirm the 
correctness of a specific treatment or clinical intervention and achieve an agreed single 
objective. It is a structured meeting organisation, which allows a group of experts to 
collectively brainstorm and think about solving a specific problem. This technique requires 
the physical interaction of the expert group where each participant is initially asked to 
individually identify and present their own views regarding the question in a prioritised 
manner. This is then followed by a group discussion and rating of all the views, which is 
repeated to achieve a final list or single solution agreed by all participants. The nominal group 
technique was not used in this research project where several views were to be incorporated. 
 
Consensus Development Conference (CDC) method 
Consensus Development Conference is a formal method developed by the US National 
Institutes of Health (NIH) in 1977, with the aim to evaluate activities and actions regarding a 
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specific topic by bringing together a selected group of people from all relevant stakeholders. 
The selected expert panel examine the presented evidences and accordingly prepares a report 
with a list of recommendations to develop consensus about that topic (Fink, et al., 1984). This 
method, was not used in this research project, however, it was suggested to be used for future 
work based on the findings from the different studies in this thesis.  
 
Development of the Study Plan 
Chapter one presented a comprehensive review and critical analysis of the literature in the 
area of the pharmaceutical regulatory environment in Turkey and in particular the TITCK 
review process. Accordingly, it is believed that there is considerable concern and a systematic 
gap between the actual and the target approval times of the TITCK registration review 
process. This was observed by the delayed access of patients to medicines as well as 
inefficient regulatory performance of the TITCK compared with other developed regulatory 
authorities. Therefore, the aim of this research was to evaluate and critically analyse this area 
of concern from all the industry and patients’ perceptions. Furthermore, the objective was to 
understand the regulatory review practices of the TITCK and address these challenges in 
order to achieve an effective and improved regulatory review. Therefore, the following study 
plan was developed to capture data on the regulatory environment in Turkey. The plan was 
then carefully examined to fulfil the objectives of this research, which consisted of four 
studies each forming a thesis chapter that explores the key characteristics of the Turkish 
regulatory review process. The study flow chart plan is illustrated in Figure 2.2. 
 
The following methods were used to collect the required data for the four studies: 
1. Review of the literature and/publications in relation to the pharmaceutical 
environment, access to medicines and regulatory review process in Turkey. 
2. Identify a list of contacts of key regulatory officials within the TITCK such as the 
head of the TITCK, vice presidents, registration department heads and unit 
coordinators. 
3. Consult with regulatory experts in the industry, ex-commission members, and external 
reviewers of the TITCK.  
4. Develop a questionnaire to be completed by the TITCK to assess the review process 
and timelines and compare the review processes, quality tools, and strategic plans with 
other mid-sized regulatory authorities. 
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Figure 2.2: Study flow chart and key milestones 
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5. Conduct a comparative study of the TITCK with other mid-sized regulatory agencies 
using the same agency developed questionnaire. 
6. Develop a second questionnaire with the aim to evaluate the pharmaceutical 
companies' views and experiences with Turkish review process. 
7. Data collection from the pharmaceutical industry study and produce a study report 
discussed with participating companies. 
8. Develop a third questionnaire to evaluate the patients’ awareness of the 
pharmaceutical regulatory environment in Turkey. 
9. Conduct a comparison and critical analysis of the overall results in order to assess the 
TITCK regulatory review process and compare the relevant experiences of regulatory 
authorities, pharmaceutical companies and patients. 
10. Conduct focus group and workshop meeting with key regulatory experts and heads of 
the TITCK in order to evaluate the results and outcomes from the four studies and 
identify the key areas of improvements. 
11. Produce individual study outcome reports as well as an overall focused report with key 
issues and recommendations following the TITCK workshop. 
12. These reports formed the basis of the relevant chapters in this thesis. 
13. Develop the proposed improved regulatory review model for the TITCK. 
 
Development of the Study Instruments 
The sequence of events to be conducted to achieve the overall aim of this research 
commenced with an evaluation of the regulatory approval timelines in Turkey. This was a 
lengthy and challenging process, as it required a sequence of data collection and exchange of 
information related to the registration review procedures and practices as well as quantitative 
data of submission and registration approval dates of NASs for the years 2012, 2013, 2014 
and 2015. During the course of collecting data on the approval timelines in Turkey, three 
questionnaires to examine the views and experiences of the TITCK, pharmaceutical 
companies and patients, with respect to the Turkish registration review process were 
developed. The first questionnaire was to be completed by the TITCK and distributed among 
four mid-sized regulatory agencies in Australia, Canada, Saudi Arabia and Singapore. The 
second was designed to survey pharmaceutical companies in Turkey, which are marketing 
authorisation holders or applicants of NASs in Turkey. In addition, the third questionnaire 
was developed and distributed to patients in Turkey who were under treatment with medicines 
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in order to evaluate their views of the pharmaceutical regulatory system. Two pilot studies 
were conducted one with three pharmaceutical companies and another one was piloted among 
thirteen patients and four doctors to assess the applicability, content validity and relevance of 
the study instrument planned to be used in the studies. The review and approval times for 
NASs by the TITCK for the years from 2012 to 2015 were obtained directly both from the 
pharmaceutical companies and the TITCK as well as compared accordingly. 
 
Evaluation Process of Questionnaires 
All questionnaires, whether newly developed or created from an existing one, should be 
reviewed and evaluated in terms of appropriateness, effectiveness and reliability in order to 
ensure that the questionnaire measures what it purports to measure. For this purpose, the two 
main methods that are commonly used to develop and evaluate questionnaires are the 
cognitive and psychometric methods. Thus, an evaluation of the psychometric properties of a 
questionnaire is essential before it is used and this includes an evaluation of the applicability 
and acceptability, validity, reliability, consistency, test dimensionality and responsiveness of 
questionnaire (University of Minnesota, 2017). 
 
Evaluation of Psychometric Properties of Questionnaires: 
Applicability and acceptability for use  
Key indicators of the quality of a questionnaire are related to its applicability and 
acceptability to serve the purpose of the study. Applicability defines the appropriateness and 
usefulness of a study instrument in terms of its content, use, wording, clarity and simplicity of 
language, which directly influences the usefulness of the instrument to reach its goals. 
Furthermore, acceptability is measured by the willingness of study participants to complete 
and respond to the questionnaire in a timely manner and therefore accept its features related to 
the clarity, readability and accuracy of questions (Sidani, 2015). 
 
Practicality 
This refers to the level of comfort and convenience of a study participant to respond to a 
questionnaire and engage in the study. Thus, the practicality of a questionnaire depends on its 
mode of administration, format and layout, cost effectiveness and the required resources and 
time to respond to and return the questionnaire. These features if planned and evaluated 
appropriately in advance can directly influence and increase the response rates.  
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Validity 
The validity of the questionnaire is a key feature that needs to be evaluated prior to the 
initiation of a questionnaire study. This requires a sensitive investigation of the instrument as 
it defines the extent to which the questionnaire is capable of measuring for what it is designed. 
There are different types of validity such as; construct validity, content validity and criterion 
related validity (Kimberlin & Winterstein, 2008).  
 
I. Construct validity: This type of validity is the most accurate and sound method to 
confirm validity. Construct validity examines the logical relationship of the measures and 
the variables, that are assessed in the study and therefore includes a comparison between 
the measures where the identified correlations contribute to the evidence of construct 
validity. 
II. Content validity: This type of validity addresses the extent to which the questions in a 
questionnaire are well developed to provide the important features aimed to be measured 
in a balanced way. So far, there is no statistical test or measure to assess whether a tool is 
adequately covering a content area as content validity often relies on the judgment and 
views of experts. Unless there is a “golden standard” available. 
III. Criterion related validity: This type of validity aims to provide evidence of how well a 
new measure correlate with other previously established measures, and produces similar 
standard outcome at a different time, cost, or method. It is important that these criterion 
measures are valid themselves. 
 
Reliability 
This is the measurement and estimate of how much a measuring instrument would be 
producing “correct” outcomes with minimum “errors”. Stability and consistency of an 
instrument are the main parameters that contribute to its reliability. Thus they can always be 
determined using internal consistency and test-retest reliability measures (Kimberlin & 
Winterstein, 2008). 
 
Sensitivity 
The sensitivity of an instrument can be measured by its ability to identify accurately a small 
but important change during the course of the study (Kit, 2008). Psychometric properties were 
considered carefully when the questionnaires of the four studies were designed and developed 
in order to collect data from the participating regulatory authorities, pharmaceutical 
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companies and patients. Two pilot studies were planned within the pharmaceutical companies 
and patients’ study with the aim to ensure the practicality, acceptability, content validation 
and increase the level of confidence about the clarity of the questions. Thus following the 
pilot study, comments and feedbacks of participants were analysed, consolidated and 
incorporate into the final versions of the questionnaire.  
 
DATA PROCESSING AND ANALYSIS  
In this research project, data were collected as either paper based or electronic questionnaires 
using postal mail, electronic mail and semi-structured interviews. The responses from the 
industry and patient studies were first anonymised to ensure confidentiality, then coded and 
analysed accordingly. Data from all four studies were entered into Microsoft Excel for data 
processing and analysis. The results were presented either as means and/or as medians (the 
value halfway through the ordered data set). Depending on the data set, different types of 
graphics ranging from bar charts, frequency tables, pie charts, box and Whisker plots were 
used to illustrate the results and provide a comprehensive visual tool to understand the 
relationships between variables. For open-ended questions and free text responses, a manual 
content analysis was carried out to determine the participants’ insights that were then grouped 
under themes and sub-themes (Wiles, 2008). 
 
Data analysis assumptions 
This research project and the four studies that were carried out to underpin the aim and 
examine the research questions were exploratory in nature and not designed to test a 
hypothesis. Thus, no statistical test was applied for analysis of the generated data. However, 
the outcome of the descriptive and qualitative analysis had the potential of generating 
hypothesis that could be pursued as future studies. Nevertheless, in discussing the outcome of 
each study, it was decided, in order to contextualise the interpretation of findings as such that 
the readers would be better able to relate to them, to assume a number of hypothetical 
hypotheses. It is also hoped that this approach would facilitate the execution of future 
hypothesis testing studies as a continuation of this research project. 
 
Qualitative data analysis 
The processes outlined above resulted in large amounts of qualitative data. Data analysis 
sought to refine the data into a long-list of items to reflect the research project conceptual 
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framework in a manner that is transparent and meaningful. Therefore, data analysis was both 
inductive – discovering new patterns and themes, and deductive - that is, with reference to the 
evolving conceptual framework to permit moving back and forth between hypothetico-
deductive and inductive approaches ensuring that the study aim (s) and prior knowledge were 
not ignored (Mayring, 2000). Several steps were carried out. First, the accuracy of the 
transcribed audio-recordings was checked to ensure preservation of the integrity of the 
generated data. For example, the validity of between 10% of transcribed interviews was 
checked against corresponding interview recordings. 
 
Data analysis sought to use words and phrases generated by participants to interpret the text 
data and craft the evolving concepts, themes and sub-themes of the conceptual framework 
(Hsieh & Shannon, 2005). The data was coded by a trained researcher independently and then 
discussed the developing themes with the research team to identify areas of consistency, 
inconsistency and concept saturation; a process which is repeated throughout data analysis. 
The transparent illustration of developing themes and codes, for example on a thematic map, 
assisted with communicating data pattern conceptualisation. The thematic prevalence of a 
concept – that is, the number of participants expressing a concept also assisted with reporting 
of the results. For example, potential themes were selected for reporting if mentioned by more 
than 5% of interviewees. Good practice guidance that the process of documenting concept 
saturation – that is, the point at which no new relevant or important information emerges and 
collecting additional data will not likely add to the understanding of how study participants 
perceive the concept of interest and the items in the questionnaire, was followed. The concept 
saturation was achieved, first through representativeness of the study population and second 
by continuation of interviews in an additional 10% of the participants before saturation was 
confirmed. 
 
In this study, several methods were adopted in order to conduct appropriate data analyses for 
all the four studies. The results and the outcomes of the analysis from each study were put 
into individual study reports, which were consolidated for further collective analysis and 
reduced to conclude the key areas of concern to be addressed by a set of recommendation for 
an improved regulatory review model for the TITCK. 
46      
 
SUMMARY 
• The chapter describes the rationale for carrying out the study to evaluate the TITCK 
regulatory review process and timelines for the years from 2012 to 2015. 
 
• The various methodologies, techniques and instruments that were used in analysing 
the data obtained from the TITCK, other mid-sized regulatory health authorities, 
pharmaceutical companies and patients have been described. 
 
• A detailed description of the developmental technique of the three questionnaires was 
also provided as well as the methods of data collection and analyses. 
 
• Methodological choices related to database management, data processing and data 
analyses were evaluated. 
 
• The data collected from the TITCK, the other regulatory authorities were categorised 
and examined in three major areas, namely, the regulatory review processes, and 
milestones, the registration and approval timelines and the quality elements 
implemented within the review process. 
 
• The perception and experiences of the pharmaceutical companies and patients about 
the regulatory environment and review process were evaluated using various 
techniques. 
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EVALUATION OF THE REGULATORY 
REVIEW PROCESS AND TIMELINES 
OF THE TURKISH MEDICINES AND 
MEDICAL DEVICES AGENCY (TITCK) 
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INTRODUCTION 
Regulatory health authorities are constantly challenged to improve their capacity to regulate 
the pharmaceutical industry in order to ensure the timely access of patients to safe and 
effective medicines as well as to monitor the quality standards and address the potential issues 
and challenges in the pharmaceutical market (Al-Essa, et al., 2012). Turkey made remarkable 
progress in its healthcare system and regulations through a series of reforms made under the 
“Health Transformation Program” (HTP), which was initiated in 2003. Thus over the past 
decade the HTP has led to the achievement of better health coverage and enhanced patients’ 
access to health services. Furthermore, the HTP introduced significant changes in all aspects 
of health regulations including those related to pharmaceuticals and registration processes 
(Bump, et al., 2014).  
 
However, the pharmaceutical industry perceives the regulatory approval of medicines in 
Turkey to be a long, bureaucratic and complex process that is affected by a number of 
variables. Therefore, the regulatory approval process and timelines are still not comparable to 
other mature health authorities such as the FDA and the EMA since the TITCKis considered 
to have relatively long approval timelines in comparison to those countries that consequently 
delays patients’ access to medicines (Kanzık & Hıncal, 2011). 
 
This study focused on the evaluation of the regulatory review process and timelines at the 
TITCK by assessing the level of adherence to good review practices. In Turkey, all marketing 
authorisation applications of new active substances are reviewed and evaluated by the TITCK. 
Once a marketing authorisation application (MAA) is submitted to the TITCK, the file is 
reviewed at different levels and goes through several assessment stages before approval is 
granted. Each step of the review process can also include different sub review processes and 
can involve external reviewers’ assessments as subject matter experts and advisors. The 
TITCK regulatory review process was closely assessed and evaluated to obtain a deeper 
insight and identify the key issues to be addressed in order to improve the overall system and 
facilitate an objective assessment and comparison with other similar mid-sized health 
agencies in the world. 
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OBJECTIVES 
The objectives of this study were to: 
• Evaluate the regulatory review process in Turkey from the authority perspective. 
• Identify the key milestones of the Turkish review process for new active substance 
applications. 
• Identify the model(s) of the review and capture the review dynamics and processes 
used by the TITCK. 
• Assess the review timelines for each step and the availability of internal procedures 
and quality measures used to ensure consistency, transparency and timeliness. 
• Identify the areas for improvement within the Turkish review process. 
 
The key issues addressed in this chapter were to determine the level of interaction of the 
Turkish Agency with pharmaceutical companies; namely, their openness to scientific advice, 
pre-submission meetings and discussions during question and answer stages throughout the 
scientific review process. Furthermore, an analysis of all the registration requirements in 
Turkey and practices was conducted including the evaluation of fast track review time and 
clock stop for new drug applications. 
 
Hypotheses 
The hypotheses in this study were incorporated for the purpose of clarity and facilitate the 
interpretation of the study outcome, as they are qualitative and exploratory in nature. This 
study examined the following hypotheses 
1. The marketing authorisation application requirements for a New Active Substance 
(NAS) application in Turkey are comparable to international requirements. 
2. The approval times for NASs in Turkey are longer compared to other developed 
countries. 
3. TITCK has not embedded Good Review Practices (GReP) into the assessment and 
registration processes. 
 
METHODS 
The data collection process was conducted using available tools and information to review the 
TITCK Agency’s organisational structure, requirements and relationships with other 
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governmental regulatory bodies. Thus the aim was to map the review process, steps and 
timelines available in the public domain as well as to identify in general where the Turkish 
review system deviates or differs from international requirements.  This was then followed by 
a qualitative and quantitative data collection process which was carried out using a 
questionnaire provided to the TITCK to identify their review practices and key milestones for 
the registration application of new active substances and subsequently there was a face to face 
interview with the head of the TITCK to validate and clarify the responses. 
 
Study Participants 
Initially, to facilitate the conduct of the questionnaire, it was pre-filled based on publicly 
available information and regulations. Subsequently, the pre-filled questionnaire was 
delivered electronically to TITCK to be further completed and to validate the data provided. A 
questionnaire (Figure 3.1) was designed to enable details of the regulatory review process in 
Turkey to be identified and completed by the TITCK (Appendix I).  
 
Additionally, key milestones and quality review measures were addressed in the 
questionnaire. The questionnaire was previously used in the CIRS Emerging Markets 
Programme to identify the regulation of new medicines in the Emerging Markets of 
Argentina, Brazil, China, Egypt, India, Indonesia, Malaysia, Mexico, Saudi Arabia, South 
Africa, South Korea and Taiwan. This enabled an evaluation of the regulatory aspirations, 
barriers, problems and priorities, related to the review of new medicines that could have an 
impact on their availability to patients (McAuslane, et al., 2009).  
 
Data Collection 
This study was facilitated by the head of the TITCK and the vice president responsible for the 
Product Registration and Licensing department. Information on annual application numbers 
and approval dates from January 2012 to December 2015 were obtained directly from the 
TITCK. The data were related to NASs including the number of marketing authorisation 
applications. and the overall TITCK review and approval timelines. Major line extensions 
were not within the scope of this study, since this term is not available within the Turkish 
regulations. 
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Figure 3.1: CIRS agency questionnaire (Full Questionnaire in Appendix I) 
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Structure of the questionnaire 
The questionnaire was divided into three sections: 
• Part 1: Organisation of the agency: this aimed to provide details of the TITCK’s 
organisational structure and resources. It also explored review model(s) for the 
scientific assessment of medicines to determine if the quality, safety and efficacy data 
were assessed in detail by the TITCK or if they used another review model, which 
depends on the results and verifies the review assessments of other authorities.  
• Part II: Key milestones in the registration of medicines; this part aimed to explore 
the review and approval process for new active substances (NASs). As a result, a 
standard process map with milestones was developed to facilitate the collection of data 
and illustration of these data in a common format, which simplify comparisons among 
regulatory agencies. Therefore, the standard process map allowed for the description 
of the TITCK regulatory review process and for the standardisation of the definitions 
used.  
• Part III: Building quality into the assessment and registration process; this part 
examined the key elements of Good Review Practices (GReP) that contribute to the 
quality of the decision-making process and measures adopted by the TITCK to 
improve consistency, transparency, timeliness and competency. 
 
Finally, the questionnaire enabled the interrelations within the agency units and other external 
reviewers to be identified as well as the availability of an assessment framework and 
procedures used by the agency internal staff and/or the external reviewers. Following the 
completion of the questionnaire by the TITCK, data were then transferred into a country 
report in a word format to create a comprehensive overview of the current regulatory review 
process. This was provided to the TITCK to enable auditing, correction, discussion and 
modifications as required. 
 
RESULTS 
The results of this study are presented in three parts: 
Part I: Organisational structure of the TITCK.  
Part II: TITCK regulatory review process map and milestones. 
Part III: Good review practices in the assessment and registration process.  
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Part I: Organisational Structure of the TITCK  
In 2012 and as part of the healthcare reform programme; the TITCK was established officially 
in November 2011 to become the official body responsible to regulate the pharmaceutical and 
medical device industry in Turkey; thus replacing the previously named Pharmaceutical and 
Pharmacy General Directorate (IEGM). The TITCK operates within the administrative 
structure of the Ministry of Health to regulate all activities and requirements related to: 
• Medicinal products for human use. 
• Medical devices and in vitro diagnostics. 
 
The scope of activities of TITCK includes; marketing authorisations/product licences, clinical 
trial authorisations, post-marketing surveillance, regulation of advertising, laboratory analysis 
of samples, price regulation and Good Manufacturing Practice (GMP) accreditation of 
manufacturing sites. At present, the total staff in the TITCK is one thousand and eight where 
more than 25% have a medical background as physicians and pharmacists. In addition, one 
hundred and forty-seven of the TITCK staff members are assigned as reviewers for 
applications for marketing authorisations and product licences. The total annual budget of the 
TITCK for 2015 was calculated to be $42 million where 47% is allocated for marketing 
authorisation applications. Thus the source of funding of the TITCK is 30% from the 
government, whereas the rest is self-funded by fees collected from applicants (TITCK, 2015). 
For example; for a new marketing authorisation application, several fees are charged where 
the amount varies depending on the evaluation steps and activities provided by the agency 
during the review process such as the fees charged for GMP file application, site inspection, 
review application, analysis and different administrative permission fees such as sales and 
importation license fees (Table 3.1). 
 
Table 3.1: Fees charged for review applications – 2016 
2016 – Fees US$ Local Currency ( TL) 
New active substance 1000 USD 3000 TL 
Established ingredient /proprietary product 1000 USD 3000 TL 
Generic (non-proprietary) product 680 USD 2000 TL 
Indication extension 775 USD 2276,22 TL 
Variations 
Type II Variation 
Indication / Label Expansion 
400 USD 1148,88 TL 
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Model of assessment in the TITCK  
There are three types of regulatory assessment used worldwide by regulatory authorities. This 
was agreed as an outcome of the CIRS Workshop on “The Emerging Markets: Regulatory 
issues and the impact on patients’ access to medicines”, organised in Geneva, Switzerland in 
March 2006 (McAuslane, et al., 2009). The workshop was attended by several regulators and 
regulatory agencies to discuss and evaluate the types of data assessment methods applied to 
different applications. Accordingly, the three scientific review models of new drug 
applications were described as below:  
 
I. Review Assessment Type 1 - Verification model  
This model is used by a number of health authorities that lack sufficient resources and 
capacity to perform a comprehensive scientific review of a new marketing authorisation 
application (MAA). This model helps reduce duplication of effort by agreeing that the local 
authority will approve the marketing authorisation of any product once the product is 
officially approved by two or more recognised reference countries. The main responsibility of 
the local authority is to ensure the “verification” of all data submitted as declared in the 
application dossier. This includes the verification review of the product characteristics 
(formulation, composition and strength) and the proposed labelling information (use, dosage, 
precautions) for local marketing complies with the reference country(s) authorisation(s). 
Approval evidence in other countries or recognised reference countries, such as submission of 
Certificate of a Pharmaceutical Product (CPP), are pre-requisites for such applications and 
review models.  
 
II. Review Assessment Type 2 – Bridging model 
This model ensures the optimal use of the available resources by the local authority by not re-
assessing the scientific supporting data included in the application of the MAA as long as 
these data have been evaluated and approved by one of the recognised reference countries. 
However, the MA application still undergoes a bridging review in relation to the product’s 
local use and characteristic in the local market. Therefore, the bridging model reviews the 
scientific clinical data including a local review of quality data (CMC of the product). The 
review of the quality data is to confirm the product’s stability conditions in relation to climatic 
conditions and distribution infrastructure in the local country. Whereas, the clinical review 
could include a benefit-risk assessment in relation to its use in the local ethnic population, the 
medical practice/culture and patterns of disease and nutrition in the country. In the bridging 
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review, approval by at least one recognised agency is a pre-requisite before the local 
authorisation can be granted, but the initial application need not necessarily be delayed as the 
CPP can be submitted in some countries prior to approval. 
 
III. Review Assessment Type 3 - Full review model  
In this model the authority has suitable resources and capacity to perform a full independent 
scientific review.  This includes collaborating with both internal and external experts, to carry 
out a ‘full’ review and evaluation of the supporting scientific data (quality, pre-clinical, and 
clinical) for a major application. Full review models, do not require a new marketing 
application approval in any other country at the time of the submission and thus can carry out 
an earlier or parallel review to first world application (Type 3B). However, in some countries, 
local regulation requires evidence of approval in the country of origin or reference country 
prior to approval (Type 3A). Within this study, the review and assessment model of the 
TITCK was explored and the details of the scientific review process identified. Accordingly, 
the TITCK performs a full review and assessment model for all new active substance 
applications. Therefore, a new marketing authorisation application can be submitted to the 
TITCK but they do need to know the registration status of that product anywhere in the world. 
However, evidence of approval in the country of origin, European Union (EU) or United 
States (US) must be submitted prior to the final approval by the TITCK. Furthermore, 
shared/joint reviews have never been undertaken with other agencies by the TITCK.  
 
Data requirements and assessment 
According to the local pharmaceutical regulation in Turkey, a marketing authorisation 
approval by the TITCK is required for any pharmaceutical product prior to marketing in the 
country. Thus, in order to obtain an approval from TITCK, pharmaceutical companies must 
fulfil a number of regulatory requirements; Firstly the applicant needs to be a legal entity 
located in Turkey whether a person or a company (Ministry of Health Turkey, 1995). Then an 
application should be submitted to the TITCK by providing the documents listed under the 
Licensing Regulation, published in the Official Gazette dated 2005 (Özbal, et al., 2012). 
Currently, all new drug applications are submitted online to TITCK according to local 
licensing requirements as an electronic submission. Furthermore, the applicant is required to 
prepare a regulatory dossier in compliance with the common technical document (CTD) with 
quality, safety and efficacy modules covering both the active drug substance and the finished 
product and therefore fully aligned with the ICH content requirements as well. The marketing 
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authorisation application must be organised according to the TITCK checklist and format and 
includes all the clinical, non-clinical and quality characteristics of the pharmaceutical product 
together with the authorisation status of the product in other countries as well as proposed and 
approved claims and labelling. (TITCK, 2005). The CPP is not required at time of application 
for registration in Turkey. However, a CPP of the assessed product is required prior to final 
approval, yet other evidence such as an electronic CPP or publication on an official regulatory 
website can be accepted as an alternative. 
 
Full clinical and efficacy data are required for the application and thus must be submitted in 
the CTD format with the correct sections (Module 1,2,3,4 and 5) of scientific data. 
Accordingly, the TITCK performs a complete assessment of these data, mainly the quality 
and the clinical parts of the product file.  
 
Additionally, the TITCK along with external reviewers perform structured benefit–risk 
assessments as the first step of the clinical evaluation of the registration review process. Thus, 
this first clinical assessment always takes into account the ethnic factors, the differences in 
medical culture/practice, national disease patterns and unmet medical needs even though 
sufficient data on these criteria are not always supplied in all applications. Similarly, mainly 
for fast track application products; the TITCK always attempts to obtain additional data from 
other agencies’ internal assessment reports and publicly available reports such as the 
European Public Assessment Reports (EPARs) as well as general internet searches and other 
resources such as local epidemiology studies.  Though officially not stated in the regulation; 
the EMA and the US FDA are regarded as reference agencies. Furthermore, the TITCK takes 
into account the evaluations of product information leaflets and summaries of product 
characteristics issued by these reference agencies. 
 
Part II: Key Milestones of the Turkish Review Process 
A process map of the TITCK registration review and its key milestones is shown in Figure 
3.2. It is a general simplified chart flow that represents the main steps performed within the 
TITCK during the review process for NAS applications from the first step of the preliminary 
review of the application until the last step when the product is approved on the first cycle to 
be on the market. Thus, all steps and processes related to the rejection of an application such 
as appeals and hearings are not included in the map. Furthermore, the map does not 
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demonstrate the pre-submission steps that need to be completed within the GMP accreditation 
process prior to marketing authorisation application. 
 
Figure 3.2: Registration review process for a new drug application in Turkey 
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Pre-submission Requirements and the GMP Process 
According to the local regulation, a GMP accreditation by the TITCK for the manufacturing 
sites of the product must be completed prior to the marketing authorisation application (GMP, 
2010). As of September 2014 a principle decision by TITCK (not stated officially in the 
regulation) enabled a marketing authorisation application for prioritised products (orphan and 
life-saving products) to be submitted and reviewed in parallel to an ongoing GMP process.  
Following a decision by the Prioritisation Assessment Committee, these products could also 
be eligible for an accelerated registration review when conducted in parallel to the GMP 
process to save time (TITCK, 2016).  
 
The primary step for registration is to submit a complete GMP dossier, which includes quality 
and manufacturing related data pertaining to the sites, and the product manufactured in the 
site. The GMP application then undergoes a paper based review process and a categorisation 
of the application to determine the priority of each application. Following the GMP dossier 
approval, the applicant is informed about possible dates to conduct the GMP inspection for all 
new sites and manufacturing lines. If the GMP application is related to a manufacturing site 
and line that has been previously inspected and approved before by the TITCK, a paper based 
inspection is carried out instead of a physical one, provided that the tools and equipment are 
similar to the accredited one. Several GMP inspections to the same site can be combined and 
performed together. 
 
The GMP inspection process is not predictable in terms of timelines and so far there is no 
clear official timeline for this procedure. The completion time of the GMP process depends on 
the classification of the product according to its need and importance in four main 
prioritisation categories. Benefit-risk evaluation and pharmaco-economic aspects of the 
product defines the GMP priority category of the product. Products classified as category one 
and recognised as orphan or lifesaving products obtain first priority to complete the GMP 
process in an average of twelve months, whereas products categorised as priority four, such as 
addition of alternative manufacturing sites for the same product, have the least priority from 
the agency and thus process completion might take longer than thirty-six months. After the 
GMP inspection (physical or paper risk based) is completed, the applicant is required to 
follow up and close all the corrective actions on time. The GMP certificate will be issued 
based on the inspection and corrective action report. GMP certificates are valid for three years 
in Turkey and must be renewed prior to expiry following the same accreditation procedure. 
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New Product Application 
Receipt and validation 
The first milestone in the MAA consists of a preliminary evaluation of the submitted dossier. 
The submission of the application is carried out electronically where the complete application 
is downloaded through the TITCK website; this indicates the formal start of the application 
procedure. Within this step, a validation and pre-review check is performed to ensure the 
completeness and correctness of the submitted application according to the Turkish 
regulations. Some items such as the legal status of the applicant, GMP status of the 
manufacturer and payment of fees, are checked as well. The marketing authorisation 
application dossier is also checked for acceptability of the file in terms of CTD format with 
the correct sections (Module 1,2,3,4 and 5) of scientific data. The CPP is not a prior 
requirement in Turkey since TITCK performs a full review and does not require any prior 
approvals of the product in the world at the time of submission.  However, a CPP or other 
evidence of authorisation must be provided before the TITCK authorisation is issued, (e.g., 
copy of authorisation, Internet reference). Legalisation is not required except for certain 
countries if specifically requested by TITCK. The preliminary and validation step is stated in 
the regulation to be thirty working days. Therefore, the date of acceptance and uploading of 
the application is formally recorded. TITCK has to complete the pre-review process within 
thirty working days and in case of incomplete applications, the applicant is requested to 
complete the missing data within another thirty days. Article thirteen states: “The second 
preliminary review of the application to be conducted upon the remedy of the deficiencies and 
submittal to the Ministry shall be finalised within thirty days” (TITCK, 2005). According to 
Article thirteen, if the dossier is evaluated in a second preliminary review and missing 
documents are not submitted again, the dossier will be rejected with a letter indicating missing 
data.  
 
Scientific Registration Review Process 
Queuing / Backlog 
Upon completion of the preliminary review step, the application is held in a queue to be 
presented to the scientific committees for further review. The current queue time is 
approximately two to six months. However, priority products are taken out of the queuing 
system and thus the time for fast track applications is approximately two to eight weeks. 
Queuing timelines are not official or standard but rather based on experiences within the 
TITCK. 
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Scientific Assessment 
The scientific assessment and review of the application is conducted in two separated parts: 
efficacy/safety and quality. The main scientific assessment is done by the Clinical Evaluation 
Commission, which consists of internal and external reviewers officially assigned by the 
TITCK based on therapeutic expertise. Thus the approval of the application by the Clinical 
Evaluation Commission is considered the key critical milestone in the assessment procedure. 
After the completion of this stage, the review process commences by other committees.  
 
Expert Committees 
Six types of committees (total number nineteen) within the TITCK carry out the different 
scientific assessments (Table 3.2). Additionally, a list of one hundred and twenty external 
experts are used for the assessment of scientific data and are invited to attend weekly 
committee meetings held within the TITCK for assessment and review of applications. 
External experts are mainly responsible for providing a detailed assessment report and 
recommendation, a clinical opinion on the product and advice to the agency staff on specific 
technical issues. Accordingly, the TITCK is mandated to follow the committees’ 
recommendations. Moreover, there is no contractual agreement for external reviewers to work 
within deadlines set by the agency as they are only mandated to sign confidentiality and 
conflict of interest agreements with the TITCK. Therefore, the review timelines for the 
committees are not standardised. 
 
Table 3.2: Scientific assessment committees at TITCK 
Committee name Number Roles & Responsibilities Members 
Priority Evaluation 
Committee 
1 
Evaluation of priority and accelerated 
registration review applications before the 
registration review process starts. 
13 
Clinical Evaluation 
Commission 
1 Review of safety and efficacy aspects. 30 
Technological Evaluation 
Committee 
12 
Review of chemistry, manufacturing and 
control (CMC) and quality aspects. 
8-9 per 
committee 
Bioavailability and 
Bioequivalence Committee 
2 Review of non-clinical aspects. 
12 per 
committee 
Pharmacological Evaluation 
Committee 
2 
Review of product clinical claims and 
labelling. 
24 per 
committee 
Risk Management and 
Pharmacovigilance 
Committee 
1 
Review of product safety profile and risk 
management plans. 
12 
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Scientific Assessment Sequence 
The sequence of the scientific review of the application among the different committees can 
vary according to the status of the application, where several committee reviews can run in 
parallel or sequentially depending on the global submission status of the product. Thus, in the 
case of a parallel MAA submission with the EMA or the FDA; the registration review process 
starts from the Technological and Bioavailability/Bioequivalence Committees’ assessments 
and then proceeds with the Clinical Evaluation Commission as final stage since this 
commission requests information mainly from the EMA/FDA and/or other authority's 
decision and clinical assessment.  Quality control analysis, pharmacovigilance review and 
pricing process can be conducted in parallel and independently to the review process 
immediately after the Clinical Evaluation Commission’s approval. Sample analysis as part of 
the review and approval procedure must be completed before the finalisation of the regulatory 
review process. Thus as of March 2015, applicants will have to wait to be informed by 
TITCK when they can start the sample analysis process and pay the related fees. So far there 
is no clarity on the timelines. 
 
Questions to Applicant 
During the review process, several questions or queries can be raised either by internal or 
external reviewers regarding the application. Accordingly, questions are sent to the applicant 
when they arise in each review process by the committees as there is no official time limit for 
the sponsor to respond. The responding deadline can sometimes be stated in the official 
question letter. The review ‘clock’ stops while questions are being answered, but the overall 
‘sponsor time’ is not calculated. 
 
Interaction of TITCK with the applicants 
Meetings with the TITCK can be arranged by the applicant to discuss questions and queries 
that arise during the assessment. Agency meetings with the TITCK do not have an official 
framework, yet can be held with the TITCK staff at specific times and appointments as 
announced by different departments of the agency.  However, for urgent issues, meetings can 
also be arranged by the applicant to discuss various issues related to the MAA. Thus the level 
of contact that companies can have with TITCK staff and experts during development and 
during the agency’s assessment process are limited to some formal contact (possibility of face 
to face meetings) and some informal contact (possibility of telephone or email contact). In 
Turkey, pre-application scientific advice meetings similar to those conducted with the EMA 
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and the FDA are not available to applicants. However, during the review process and 
interaction with the applicant, general details related to the progress of the MAA file is given 
and details of technical internal staff that can be contacted to discuss the application during 
the review may be provided upon request from the applicant. Finally, there are no restrictions 
or fees required from applicants to conduct meetings with the TITCK. 
 
Priority Review and Fast track applications 
A shorter marketing authorisation application (MAA) for generic and biosimilar products is 
stated in the official registration regulation. Besides this, there is an official procedure for 
priority/fast track products stated in the registration regulation based on a decision dated in 
August 2015 and thus a list of applications/products are subject to accelerated review. The 
accelerated registration review process was introduced by the TITCK via a circular in October 
2015 to accelerate the marketing authorisation process for critical applications for certain 
products such as lifesaving medicines. A list of priority criteria was defined which included 
life-saving and critical products needed urgently. Moreover a guideline was issued in April 
2016 in order to define the principles of the priority application and review process. (TITCK, 
2016) . Accordingly, products subject for fast track and accelerated review are first evaluated 
by the TITCK Prioritisation Committee, which then enables an accelerated review process. 
Industry experience identified this period to be six months for life saving and critical 
products. 
 
Pricing  
Price negotiation starts during the registration review and licensing process. The pricing 
process can be conducted in parallel and independently to the review process immediately 
after the main commission approval. Furthermore, registration approval can be completed 
prior to pricing approval and this must be granted prior to the sales permission application, 
which enables the product to be commercially available. The pricing procedure in Turkey is 
based on reference countries, thus a list of reference countries is assigned every year in 
January by the TITCK. Currently there are five reference countries for pricing; Portugal, 
Spain, France, Italy and Greece. Furthermore, the pricing of a new product is calculated based 
on the lowest ex-factory price in the Euro currency of the reference countries and then 
converted to the local currency in Turkish Lira (TL) using a constant exchange rate of 
Euro/TL announced officially every year in January by the TITCK. The exchange rate for 
TITCK in 2017 was declared to be 1 Euro = 2.3 TL (Ministry of Health, 2015) . 
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Decision on the Application and Authorisation Procedure 
Upon the completion of all the scientific commissions’ review and the assessment by all 
relevant committees, as well as the finalisation of the quality control analysis and labelling 
assessment, the marketing authorisation is approved and signed by the Head of the Agency. 
Once the Marketing Authorisation is issued, the MAA holder can apply for sales permission 
to enable marketing in the territory and importation permission if required. 
 
Product Labelling  
There is a separate negotiation of the product labelling which includes the Summary of 
Product Characteristics (SmPC) and Patient Information Leaflet (PIL) after the scientific 
review is completed and before the approval is issued by the TITCK head. Thus the 
Pharmacological Committee reviews the proposed SmPC and PIL before MA approval is 
granted. Furthermore, during the sales permission application the final sample of the product, 
packaging material and labelling are also reviewed and approved accordingly. 
 
TITCK Review Timelines 
The overall approval timeline is set to be two hundred and ten working days in the regulation 
(Article 15) (TITCK, 2005). “Article 15- The Ministry shall analyse the registration 
application which has undergone a preliminary analysis and results to be complete, for 
checking whether the registration conditions have been fulfilled and shall finalise the process 
within two hundred and ten days (working days) after the acceptance of the application. 
However, the aforesaid period shall not include extraordinary circumstances and the period 
of time throughout which the applicant procures the documents that the Ministry required of 
it”. Target timelines for the TITCK review process can be seen in Table 3.3. 
 
Table 3.3: Timelines in the review procedure 
Process Target 
Validation 30 working days (42 calendar days) 
Queuing / Backlog 
2-6 months 
2-8 weeks (prioritised review) 
Clinical Evaluation Commission No limit 
Sponsor response time No limit 
Expert Committee(s) No limit 
Authorisation procedure No limit 
Overall review time  
Prioritised accelerated review 
Highly prioritised products 
210 working days (294 calendar days) 
180 working days (252 calendar days) 
150 working days (210 calendar days) 
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Regulatory authorities are constantly challenged to improve their regulatory performance and 
accordingly its outcome that is usually evaluated by the number of applications reviewed and 
approved as well as the approval timelines. However, the regulatory performance of each 
authority can be affected by several factors including number of reviewers, number and type 
of applications submitted each year and the quality of the review process (Cone & 
McAuslane, 2006). Thus, the number of approved products by the TITCK varies each year 
due to similar factors.  
 
Examining the data obtained from the TITCK for the four-year period (2012-2015), the 
results showed an overall trend of an increase in the number of NAS applications submitted 
by the pharmaceutical companies from 2012 to 2015. Thus, the number of NAS applications 
increased almost four times in 2015 (eighty-two applications) compared to 2012 (twenty 
applications) (Figure 3.3). Furthermore, the number of NAS marketing authorisations 
applications that have been approved and rejected by TITCK in 2011, 2012, 2013 and 2014 
are shown in Figure 3.4.  
 
Figure 3.3: Distribution of NAS applications received by TITCK between 2012 and 2015 
 
 
0
10
20
30
40
50
60
70
80
90
2012 2013 2014 2015
20 
46 44 
82 
N
um
be
r 
of
  N
A
S 
A
pp
lic
at
io
ns
 
Years 
65 
Figure 3.4: NASs applications approved and rejected by TITCK between 2012 and 2015 
 
The number of applications that were approved by the TITCK was eighteen, forty-four, thirty-
six and eighty applications in 2012, 2013, 2014 and 2015 respectively. In addition, the 
approval timelines (mean/working days) for NASs from 2013 through 2015 are shown in 
Figure 3.5 although data for the year 2012 were not provided by TITCK for internal reasons 
and therefore not included in the analysis. 
 
Figure 3.5: Distribution of approval times (mean) for NASs between 2013 and 2015 
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The highest number of NASs approved in 2015 was eighty with an average approval time of 
two hundred and seventy working days and only two NAS applications were rejected by 
TITCK. In 2013, forty-four NASs were approved, with an average approval time of three 
hundred and fifty working days. In 2014 the average approval time for thirty-six NAS 
applications was almost comparable to the previous year and was stated by the TITCK to be 
three hundred and forty working days. However, the highest number of NAS applications that 
were rejected by TITCK in the last four years was in 2014 with eight NAS applications. The 
fastest average approval time in the years between 2012 and 2015 was achieved in 2015 with 
an approval average time of two hundred and seventy working days and the highest number of 
applications was received in the same year. Thus in 2015, the scientific review and 
assessment time was reduced by eighty working days from three hundred fifty working days 
in 2013 to two hundred and seventy working days in 2015, while the number of applications 
received by TITCK increased by thirty-six applications in 2015 compared to forty-six NAS 
applications received in 2013. These data demonstrated that the TITCK’s performance and 
efficiency in the review time has dramatically improved in 2015 probably due to the increase 
in the number of reviewers and committees. However, the efficiency of the review could be 
further improved if the GMP requirement was conducted in parallel for all NAS applications. 
 
Part III: Good Review Practices in the Assessment and Registration Process  
Quality in the assessment and registration process is important to regulatory authorities as it 
ensures consistency, transparency, timeliness and competency in the review process. 
Regulatory authorities are continuously developing and implementing a variety of measures to 
improve and achieve higher quality standards and to meet the expectations of industry and the 
general public (McAuslane, et al., 2009). Thus usually the quality level of a pharmaceutical 
product is determined by the product characteristics and the chemical and manufacturing 
control (CMC) processes that constitute module three “Quality module” in the CTD file. 
However, recently apart from the timeliness, the quality of the regulatory review and the 
decision-making process have become important aspects that must be closely monitored and 
evaluated to determine the regulatory performance and efficiency of an agency (Cone & 
McAuslane, 2006). The purpose of the third section of the questionnaire was to obtain an 
insight into the strategies, measures and resources that the TITCK have in place to develop 
and maintain the quality of their review processes. Accordingly, the results indicated that 
currently the TITCK seems to have a comprehensive and official internal quality policy 
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defined as ‘Overall intentions and direction of the organisation related to quality. 
Nevertheless, the results also identified that Good Review Practice (GReP)1 is still not 
implemented by the TITCK but there are plans to establish this within the next two years. 
However, a number of Standard Operating Procedures (SOPs) are used by the TITCK mainly 
for the labelling review process, pharmacovigilance assessments and for guidance for 
scientific assessors. Furthermore, assessment templates that set out the content and format of 
written reports on scientific reviews are also commonly used. Internal reviewers are provided 
with a checklist to facilitate the assessment process of applications. Peer review and an 
additional evaluation of the original assessment by an independent person or committee are 
not practiced by the TITCK. Furthermore, shared or joint reviews2 with other regulatory 
authorities are not conducted within the TITCK and it is anticipated that the agency will not 
be undertaking such reviews within the next two years.  
 
Quality management 
The TITCK has identified the following as the most important measures for the introduction 
of quality measures within the agency; to be more efficient; to reduce errors as well as to 
improve communication. Currently, the TITCK have a dedicated department of two staff for 
assessing and/or assuring the quality of the regulatory process. Thus to monitor and improve 
quality measures in the TITCK, several activities are undertaken to bring continuous 
improvement into the assessment and authorisation process. For example, reviewing 
assessors’ and stakeholders’ feedback through reported complaints, conducting meetings and 
workshops and ensuring that the necessary action is taken; carrying out internal quality audits 
(e.g. self-assessments) and using findings to improve the system. Moreover, it was also noted 
that the TITCK is using an internal tracking system to monitor the progress of application, 
however, this is not accessible by companies. While external quality audits by an accredited 
certification body are not conducted either, although the agency might implement this in the 
near future to contribute to the improvement of the system. 
 
                                                 
1 Good Review Practice (GReP): A code about the process and the documentation of review procedures that 
aims to standardise and improve the overall documentation and ensure timeliness, predictability, consistency and 
high quality of reviews and review reports. 
 
2 A shared review is one where each participating authority takes responsibility for reviewing a separate part of 
the dossier. A joint review is one where the whole dossier is reviewed by each authority and the outcome is 
discussed before a decision is taken. 
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Quality in the review and assessment process 
To help improve the quality of applications and the scientific review at the TITCK, several 
measures and guidelines have been implemented and made through published guidelines 
accessible through the TITCK’s website, industry associations and timely publication of any 
updates or changes to the regulations in the official gazette. 
 
Training and continuing education as an element of quality 
Training and continuing education is an important element of quality to ensure that agency 
staff are aware of all available quality policies and procedures which will ensure consistency 
in performance. Within the TITCK, all agency staff receive formal training through various 
training methods which are mainly carried out through; on the job training, in-house courses, 
support for post-graduate degrees in the related area, participation in international 
workshops/conferences as well as placements and secondments in other regulatory authorities. 
Additionally, there is some degree of collaboration between the TITCK with other agencies in 
the training area of assessors. For some tasks, the TITCK supports the placements and 
attendance of agency staff in other international regulatory agencies’ inspections, reviews or 
technical related training to gain real experience. Accordingly, TITCK staff are partly tested 
on the training given, but completion of the training is not required for professional 
advancement. 
 
Transparency of the review procedure 
Transparency is one of the main areas on which the TITCK focuses to improve and this is 
derived from the incentive to meet the public need and provide assurances on safety and to 
increase confidence in the regulatory review system. This study examined ‘transparency’ in 
terms of the ability and willingness of the agency to assign time and resources to providing 
information on its activities to both the informed public (which includes health professionals) 
and industry. Currently the agency assigns medium priority to transparency. Accordingly, a 
number of activities to enhance the openness of the regulatory system have been identified. 
This includes, information provided to the general public on the performance of the agency in 
terms of the approved products and approved product labelling. This public information can 
be accessed through the TITCK website.  
 
Furthermore, all MA holders are required to publish a small advertisement in the newspaper 
about the approval of a new active substance in Turkey. The advertisement has to follow the 
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TITCK format, to be in black and white, mentioning only the new active substance name. The 
TITCK uses several facilities to provide information both for the public as well as for the 
marketing authorisation applicants. For example, transparency to companies is provided 
through several physical interactions related to the follow up of their application progress, 
which can be tracked easily by the company representatives in Ankara. However, although an 
electronic submission system is available, currently applicants cannot access the status of their 
application under review within the agency as this information is kept internally although 
companies can, through their company representatives, follow the process by verbal 
communication with the agency staff on an informal daily basis if required.  
 
The TITCK has an internal electronic system used to track applications that are under review 
and identify the stage in the process. However, the system does not provide information 
relevant to the excess of target review time or record the terms of authorisations once granted. 
Additionally, the TITCK has an archiving system that easily provides information on 
applications in a way that can be searched within the agency. 
 
Finally, the study identified the TITCK’s own perception of its unique positive qualities that it 
implements in the review of new medicines to make them available for patients.  Accordingly, 
the TITCK identified the following main factors that make a major contribution to the 
effectiveness and efficiency of the TITCK’s review procedures and decision-making 
processes for NAS applications namely to: 
• Follow up all international regulatory authorities’ decision-making processes and 
practices. 
• Make available a pool of numerous and various specialties to conduct the scientific 
evaluation. 
• Ensure the availability of well-educated agency personnel with appropriate 
administrative assessment competencies. 
 
Nevertheless, there are still a number of challenges facing the TITCK that act as barriers to 
making new medicines available in a timely manner through the regulatory process. These 
include the limited human resources, insufficiency of physical and technological 
infrastructure as well as the patent related rights regulations are not aligned with international 
standards.  
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DISCUSSION 
The TITCK is a recently established agency within the Ministry of Health, yet it has a long 
history since 1923 in regulating the pharmaceutical industry when it previously used to be 
structured as a Medicines Directorate under the administrative structure of MoH. Therefore, it 
is well recognised that Turkey has an efficient regulatory review system that has enabled for 
many years the timely registration and patients’ access to medicines shortly after their launch 
in ‘major’ developed countries like the EU and the USA.  However, recent changes in the 
pharmaceutical regulatory environment including the introduction of local GMP accreditation 
process in March 2010 has resulted in the approval process and timelines being significantly 
impacted. This study has evaluated the regulatory review process with its different milestones 
within the TITCK and identified the key steps, activities and measures of the review process 
that may have a critical impact on the quality and regulatory performance of the TITCK. 
 
Hypothesis 1: The marketing authorisation application requirements for New Active 
Substances (NAS) application in Turkey are comparable to international requirements. 
The Marketing authorisation application requirements in Turkey follow global guidelines and 
thus all NAS applications must be submitted to TITCK in compliance with the common 
technical document (CTD) with quality, safety and efficacy modules covering both the active 
drug substance and the finished product. These are therefore fully aligned with the ICH 
content requirements. Moreover, though officially not stated in the regulation the European 
Medicines Agency (EMA) and United States Food and Drug Administration (US FDA) are 
regarded as reference agencies. Therefore, this hypothesis is accepted. 
 
Hypothesis 2: The approval times for NASs in Turkey are longer compared to other 
developed countries.  
This study examined the pattern of total regulatory approval times in Turkey between 2012 
and 2015 for NAS applications as well as the number of applications received for the same 
period. Interestingly, the fastest mean approval time was achieved in 2015 when it was three 
hundred and seventy-eight calendar days (two hundred and seventy working days) despite the 
highest number of applications received (eighty-two applications) in 2015 compared to 2012 
(twenty applications). Whereas in 2013 and 2014 the approval times provided by the TITCK 
were four hundred and ninety (three hundred and fifty working days) and four hundred and 
seventy-six calendar days (three hundred and forty working days) respectively. Similarly, the 
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TITCK granted eighty approvals in 2015 compared to eighteen, forty-four and thirty-six in 
2012, 2013 and 2014 respectively. However, approval times do not include the companies’ 
response time to the questions. These findings demonstrated that the TITCK’s performance 
and efficiency has dramatically improved over the last few years. However, the target time of 
two hundred and ten working days (two hundred and ninety-four calendar days) was still not 
achieved. Data provided by the TITCK were presented as mean rather than median, which is 
the way it is presented in other countries.  
 
The approval timeline for the EMA (submission to final approval) including company 
response time was four hundred and seventeen calendar days in 2015, for the FDA it was 
three hundred and fifty-one calendar days, for the PMDA it was two hundred and eighty-four, 
for Health Canada three hundred and fifty-five, for TGA three hundred and seventy three and 
for Swissmedic four hundred and sixty-four calendar days (Figure 1.4). Therefore, the TITCK 
should evaluate the resources required and the expected number of applications reviewed in 
order to meet the target times. This can be achieved by introducing a more collaborative 
systematic approach between the TITCK and the industry. Thus, pharmaceutical companies 
should notify the TITCK in advance of the expected number of major regulatory submissions 
including NAS applications at the time of their annual budget/resource planning. This could 
facilitate both the planning for the review process as well as enhance the transparency and 
communication between the TITCK and pharmaceutical companies prior to applications.  
 
Additionally, the TITCK should batch the questions raised during the review process and set 
reasonable deadlines for companies to respond. Similarly, this would enable companies to 
better plan their resources and maximise their efforts to reduce the clock stop period during 
the review of their applications. The findings from the study also suggest that the TITCK 
could consider collaborating with other regulatory health authorities as well as increasing the 
amount of available resources to meet the target timelines. On the basis of these findings this 
hypothesis is accepted. 
 
Hypothesis 3: TITCK has not embedded Good Review Practices into the assessment and 
registration processes. 
This study identified that the TITCK has a relatively sound and robust quality management 
system and builds good quality measures into its review and assessment system. This includes 
the use of SOPs and assessment templates as well as incorporating a structured training 
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system for the TITCK staff. Thus by adapting the EU standards and the international practices 
and guidelines in the pharmaceutical regulatory area, the TITCK is perceived as a developed 
regulatory authority that has the ability and scientific qualifications to carry out their own 
assessments and review processes comparable to other developed regulatory health authorities 
such as the EMA and the FDA. In addition, the TITCK has developed an electronic 
submission system that enables companies to upload all regulatory submissions online. 
Similarly, the electronic system enables the TITCK to perform its activities effectively, while 
maintaining an internal tracking system of the progress of applications and a good archiving 
platform for all submissions, reviews and assessments.  
 
The TITCK currently has a number of elements of Good Review Practices (GReP) in place. 
However, the TITCK may not fully recognise the functions of GReP in their system and that 
is probably why they have not as yet developed a guidance document on GReP. 
Consequently, GReP are neither formally embedded in their system nor followed consistently. 
However, it is recommended that the TITCK should develop formal guidelines for 
implementing GReP to ensure the consistency and standardisation in their review process. 
This could be achieved by collaborating with other international regulatory agencies and 
organisations to identify the best practices in this area as well as establishing a standard 
training system to ensure GReP are fully implemented by staff at all levels. In the light of the 
above findings and recommendations this hypothesis is rejected. 
 
In conclusion, a number of exploratory hypotheses were raised in this study to evaluate the 
TITCK review process, timelines and implementation of Good Review Practices for the 
period from 2012 to 2015.The findings supported two of the hypotheses with regards to the 
alignment of the TITCK NAS application requirements with the international standards and 
the long approval timelines compared to other major regulatory agencies’ timelines while 
rejecting the third one about the full implementation of the GReP. In addition, the results 
identified that the TITCK review performance was improving over the past four years. They 
also indicated that while the number of approved applications by TITCK was increasing, there 
was a decreasing trend in the approval timelines, which is a positive development even though 
the target timeline of two hundred and ten working days is still not achieved. This study 
provided for the first time a comprehensive overview of the registration review with all the 
milestones based on accurate data directly collected from the TITCK. Thus, this facilitates the 
in depth analysis and understanding of the Turkish review system’s strengths and areas of 
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improvements and therefore enables the establishment of the required action plans by all 
stakeholders be it the agency or the industry in order to enhance the ultimate target of 
enhancing patients’ access to medicines. 
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SUMMARY 
 
 This study has evaluated the regulatory review process and timelines by the TITCK for the 
first time since it was established as an agency and took over the responsibility for 
pharmaceutical regulations from the Ministry of Health in 2011. It has identified the key 
milestones, timelines and evaluated the measures used for GReP and suggested 
opportunities for an enhanced regulatory review.  
 
 TITCK performs a full review as its assessment model for all new active substance 
applications. Therefore, a new marketing authorisation application for an NAS can be 
submitted in Turkey prior to any approval in the world. However, evidence for approval in 
the country of origin, EU or USA must be submitted prior to the final approval by the 
TITCK.  
 
 Marketing authorisation applications must be submitted to TITCK in compliance with the 
common technical document (CTD) with quality, safety and efficacy modules covering 
both the active drug substance and the finished product and it is therefore fully aligned 
with the ICH content requirements. 
 
 A local GMP accreditation of all manufacturing sites of the product is a pre-requisite to the 
marketing authorisation application. 
 
 There is an official procedure for priority/fast track products to accelerate the marketing 
authorisation process for critical applications products such as orphan drugs and life-saving 
medicines and products meeting medical needs, which are given priority in the queuing 
line and assessment process. 
 
 This study identified that the TITCK has a number of quality measures and policies in 
place to ensure consistency and standard performance including SOPs, review templates 
and an electronic submission tracking system; however, Good Review Practice (GReP) 
guidelines have still to be fully developed and implemented.  
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INTRODUCTION 
History is full of examples of unfortunate cases and catastrophes that have triggered the rapid 
development of modern pharmaceutical regulations that started to evolve in the 19th century 
and progressed mainly after the Second World War (Rägo & Santoso, 2013). The 
sulphanilamide elixir disaster in 1937, which caused hundreds of deaths mainly children in 
the USA, was an eye opener for the public towards medicines’ adverse events and potential 
risks. Consequently, this unfortunate event facilitated the establishment of the Federal Food, 
Drug and Cosmetic Act (FDA – Food and Drug Administration) in the USA and significantly 
changed pharmaceutical regulations in terms of the approval requirements and process (Jarell, 
2012). Another example which further accelerated the development of pharmaceutical 
regulations was the Thalidomide tragedy in Europe and in almost more than forty-six 
countries in the world between 1958 and 1960 which led to the birth of approximately ten 
thousand babies with phocomelia and other birth defects (Fintel, et al., 2009).  
 
As a result, along with the support of the World Health Organisation (WHO) and the 
involvement of other regulatory authorities; the entire pharmaceutical regulatory and 
authorisation approval systems were reshaped after the 1960s. Thus, the main goal was to 
define the minimum standards for drug development and marketing authorisations as well as 
to promote harmonisation of pharmaceutical regulations across countries to ensure the timely 
access of patients to safe and effective medicines. For example, the European Commission 
(EC) introduced several directives after 1975 to regulate pharmaceutical development and set 
the clinical and non-clinical standards to perform trials with new medicinal products to 
generate the required data.  
 
Furthermore, the harmonisation of the registration review process and marketing authorisation 
requirements was established in the EU through the mutual recognition and centralized 
procedure (Rägo & Santoso, 2013). In parallel, a joint collaboration of regulatory authorities 
and industry associations from the EU, Japan and the USA led to the establishment of the 
International Conference on Harmonisation (ICH) in the 1990s. Accordingly, the ICH defined 
Technical Requirements for the Registration of Pharmaceuticals for Human Use, which 
focuses primarily on the requirements for new, innovative medicines and facilitated 
pharmaceutical regulatory harmonisation (ICH, 2016).  
77 
The WHO on national, regional, inter-regional and international levels also supported similar 
harmonisation efforts in both pharmaceutical regulatory requirements as well as review 
procedures in order to ensure the availability of safe, effective and good quality 
pharmaceuticals to patients worldwide. Nevertheless, the impact of harmonisation and the 
level of alignment of each country to the minimum international standards in the regulatory 
review process remain the key challenge to be measured and identified. However, there is still 
no consensus or standard definition of the registration review process in terms of 
methodology, review conduct, stages, timelines and criteria to be employed in the decision 
making process or even whether countries are actually fulfilling a review process at all or 
have similar review processes for the same medicines.  
 
On the other hand, individual countries and authorities may have different experiences, 
competencies and knowledge regarding the regulatory review process, which can add value to 
other countries if recognised and identified properly. Therefore, through the comparison of 
various systems and review processes, the best practices can be shared for the benefit of all 
countries. With this in mind, this study was conducted to compare the current TITCK 
regulatory review processes and timelines in comparison with other international, mid-sized 
regulatory health authorities. Thus, the study aimed to identify areas of strength and those 
requiring further improvement within the TITCK in relation to the review process as well as 
to assess the level of adherence to good review practices in order to facilitate the TITCK 
progress toward this goal.  
 
OBJECTIVES 
The main objectives of this study were to: 
 
• Identify the regulatory review process model used in the TITCK in terms of process 
flow, key milestones and timelines. 
• Evaluate the key stages in each review process of other regulatory health authorities in 
Australia, Canada, Saudi Arabia and Singapore to determine the commonly shared 
milestones and different practices. 
• Compare the review process and practices of the TITCK with the regulatory health 
authorities in Australia, Canada, Saudi Arabia and Singapore. 
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• Determine the strengths and areas for improvement for the TITCK review process. 
• Identify the Good Review Practices (GReP) implemented by the TITCK to ensure 
consistency, transparency, timeliness, and predictability of the review process. 
 
Hypotheses 
Pharmaceutical regulations and medicines’ approval timelines have always captured the 
attention of both the public as well as local, regional and global stakeholders of the 
pharmaceutical industry due to the significant impact of these regulations on patients’ access 
to medicines. In Turkey, most of the pharmaceutical regulations are aligned with those of the 
International Conference of Harmonisation (ICH) Guidelines and the EU Directive 
2001/83/EC on medicinal products for human use. The regulations mandate the 
implementation of the CTD guidelines for preparing the marketing authorization application 
file and the approval target is set to be two hundred and ten working days (TITCK, 2005).  
 
However, experience from the past fifteen years by the pharmaceutical industry and outcomes 
of previous studies show that the registration review process and approval timelines in Turkey 
are still not at the desired level required. Thus from an industry perspective, the TITCK is 
generally perceived to have relatively long approval timelines in comparison with other 
mature health authorities such as the FDA and the EMA which consequently delay patients’ 
access to medicines (Kanzık & Hıncal, 2011).  
 
While each country has its own national requirements, it is well recognised that individual 
health authorities have different expertise, competencies and knowledge that could be of value 
to other countries by comparing the various review models and sharing best practices. 
Nevertheless, such comparisons can be of more value and facilitate improvements if 
conducted among countries with common challenges and similar health agencies’ 
characteristics. Accordingly, a comparison of an emerging market regulatory agency with 
mature sophisticated health agencies such as the FDA and the EMA may often lead to an 
unreasonable comparison due to the different characteristics and competencies these agencies 
possess. For example, in terms of organisational structure, it is known that the FDA has the 
largest number of reviewers compared to other health agencies and the scope of the FDA’s 
regulatory authority is broad and includes many areas other than pharmaceutical products 
(FDA, 2016). The EMA is a central networking organisation agency based on twenty-eight 
member countries representing a population of almost five hundred million. Thus, the review 
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and decision-making process within the EMA involve many experts from across Europe and 
the use of a model that depends on a rapporteur and co-rapporteur (EMA, 2016). Therefore, 
many emerging markets have an interest in comparing themselves with other mature 
regulatory authorities such as; Health Canada and Australia (Hashan, et al., 2016).  
 
To date, comparative data to demonstrate the performance of the TITCK registration review 
model with other developed and emerging countries of similar sizes and characteristics have 
not yet been identified.  Therefore, this was the first study to compare the registration review 
model in Turkey with Australia (TGA), Canada (Health Canada), Saudi Arabia (SFDA) and 
Singapore (HSA).  
 
The comparative countries were selected to ensure an adequate representation of health 
agencies of similar characteristics and review models, maturity of the agency as well as 
agencies of countries from different regions in the world other than those leading agencies in 
Japan, EU and the USA. Furthermore, the size of population of the selected countries such as 
Australia and Canada was considered as well. The SFDA is considered one of the most 
established agencies in the Middle East region and has a leading role in the pharmaceutical 
regulatory field where it is listed as a reference agency for many countries. Similarly, the 
HSA in Singapore is a well-developed reference agency to many other agencies in the Asia 
Pacific region and uses a specific risk stratification model. Within this model, the agency 
maximises their resources and therefore can be a good model to follow for other emerging 
markets with limited resources (Hashan, et al., 2016). 
 
In the light of the above, this study examined the following hypotheses: 
 
1. The TITCK review model for NAS applications is similar to that of other mid-sized 
regulatory authorities.  
2. The marketing authorisation application requirements in Turkey are similar to those of 
other international agencies. 
3. The approval times for NASs in Turkey are longer than other countries such as 
Australia, Canada, Saudi Arabia and Singapore. 
4. Good Review Practice (GReP) requirements implemented by the TITCK are 
comparable to other similar countries, which ensure consistency, transparency, 
timeliness, and predictability of the review process. 
80 
METHODS 
Study Participants 
The regulatory health authorities who are responsible for the regulation and review process of 
pharmaceutical products in five countries were included in this study namely; Australia’s 
Therapeutic Goods Administration (TGA), Health Canada, Singapore’s Health Science 
Authority (HSA), and the Saudi Arabia Food and Drug Administration (SFDA) as well as the 
TITCK. 
 
Data Collection Process 
The questionnaire designed and used in this study was completed by the TITCK to collect 
data related to the regulatory review process of New Active Substances (NASs) including the 
marketing authorisation applications submission dates, the registration dates and the overall 
review and approval timelines. The questionnaire had been previously used in an Emerging 
Markets Programme to evaluate the regulatory process for new medicines in a number of 
countries and identified the regulatory aspirations, barriers, problems and priorities, related to 
the review of new medicines that can have an impact on their availability to patients 
(McAuslane, et al., 2009). The questionnaire was designed to enable the mapping of the 
process flow and the internal parameters that influence the progress of the review and 
understand the decision-making process as well as the implementation of GReP and review 
outcomes in countries like Saudi Arabia (Hashan, et al., 2016).  
 
Moreover, this standard mapping facilitated the collection of important information and 
allowed the data to be illustrated in a common format to simplify comparisons among other 
regulatory agencies. The questionnaire was divided into three parts where the introduction 
aimed to provide details of the TITCK’s organisational structure and resources and to explore 
the review model(s) used for the scientific assessment of medicines. The second part aimed to 
explore the review and approval process for new active substances (NASs) within the agency 
through a standard process map which was developed through a previous study of procedures 
of mature regulatory agencies as well as those of the emerging pharmaceutical markets 
(McAuslane, et al., 2009).  
 
The standard process map allowed for the description of the review and included common 
definitions. The last part of the questionnaire documented the activities that contribute to the 
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quality of the decision-making process and measures adopted by the TITCK as a regulatory 
agency to build quality into the assessment and registration process in order to improve 
consistency, transparency and timeliness. Following the completion of the questionnaire by 
the TITCK, data were then transferred into a country report in a word format to create a 
comprehensive overview of the current regulatory review process at the Turkish Agency, thus 
enabling auditing, correction, discussion and modifications if required by the TITCK. 
 
Similar questionnaires had also been completed and validated within the same time frame by 
Australia’s Therapeutic Goods Administration (TGA), Health Canada, Singapore’s Health 
Science Authority (HSA), and the Saudi Arabia Food and Drug Administration (SFDA) 
(Hashan, et al., 2016). Data were then transferred into a word document with a consistent 
format and standardised terminology of the questionnaire for the purpose of comparison and 
to enable the compilation of important information about the structure, processes, and 
practices of international regulatory agencies. The resulting reports were sent to the 
authorities for auditing, correction and further comments. 
 
RESULTS 
This study identified that each of the five mid-sized regulatory health authority have similar 
goals for regulating the pharmaceutical industry and establishing the marketing authorisation 
standards and requirements to ensure the timely access of patients to medicines while 
safeguarding their safety, quality and efficacy. Process maps of the five countries are 
presented in a standardised format, which enables appropriate comparisons to be made 
(Figure 4.1-4.5) Nevertheless; regulatory authorities demonstrate a number of differences 
within their review systems in terms of processes, timelines and review practices.  
 
Accordingly, the results of this study as well as the comparative analysis of the review 
systems are presented in two parts;  
 
• Part I: Comparative assessment of the regulatory review processes and milestones, 
• Part II: Good review practices. 
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Figure 4.1: Registration process map for Turkey 
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Figure 4.2 Registration process map for Australia 
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Figure 4.3: Registration process map for Canada 
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Figure 4.4: Registration process map for Saudi Arabia 
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Figure 4.5: Registration process map for Singapore 
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Part I: Comparative Assessment of the Regulatory Review Processes and 
Milestones  
Review model 
Many regulatory health authorities apply a different level of data assessment, according to the 
type of product and/or its worldwide regulatory status. Accordingly, there are three basic 
types of scientific review, which have been identified by McAuslane and colleagues for the 
scientific regulatory review of a product (McAuslane, et al., 2009) and in summary are: 
 
Type 1 verification model: this is generally used to reduce duplication of review effort since 
it requires that the product is authorised by two or more recognised reference agencies, 
elsewhere. Thus, the responsibility of the agency is only to verify and validate the application 
for local marketing to ensure that it conforms to that agreed in the reference authorisation(s).  
 
Type 2 the abridged assessment model: this conserves resources by not re-assessing 
scientific supporting data that has been reviewed and approved by at least one reference or 
competent regulatory agency and includes an ‘abridged’ independent review of the product in 
terms of its use under local conditions.  
 
Type 3A and 3B full assessment models: here the agency carries out a complete scientific 
review and evaluation of the supporting scientific data (quality, pre-clinical, clinical) for a 
major application. While for Type 3A assessment, a pre-registration by a reference agency is 
required, for type 3B; pre-approval by a reference regulatory agency is not required.  
 
Within this study, the review and assessment model of the TITCK was explored and 
accordingly it was identified that the TITCK performs a full review for all new active 
substance applications. Therefore, a marketing authorisation application for a new active 
substance can be submitted in Turkey prior to any approval in the world. However, evidence 
of approval in the country of origin, EU or US must still be submitted prior to the final 
approval by the TITCK (Type 3A). In comparison with the other agencies; the SFDA, TGA, 
HSA and Health Canada utilise a full assessment model (Table 4.1). However, the SFDA 
requires that a certificate of pharmaceutical product (CPP) is submitted with the application 
for final marketing authorisation (Type 3A) whilst a CPP submission for some applications is 
not required for the TGA, Health Canada and HSA (Type 3B). On the other hand, in order to 
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optimise the use of resources, TGA can conduct an abridged review if requested by the 
sponsor and if the product has been approved by two or more reference agencies and HSA 
conducts an abridged review if the product has been approved by one or more reference 
agencies, or a type 1 (verification model) if the product has been approved by two or more 
reference agencies. 
 
Table 4.1: Models of assessment of the five agencies and extent of the scientific review 
Type of review model Turkey Australia Canada Saudi 
Arabia 
Singapore 
Verification review (Type I)    a b 
Abridged review (Type II)  c   d 
Full review (Type III)      
Extent of scientific review 
1. Chemistry, Manufacturing and Control (CMC) data 
Extensive assessment       
2. Nonclinical data 
Extensive assessment     e 
3. Clinical data 
Extensive assessment      
Additional information obtained (where appropriate) 
Other agencies’ internal review reports      
Reports on the internet      
General Internet search      
a The SFDA recently announced that it will conduct a verification review if the product has been approved by the EMA and  
  the FDA 
b Only if the product has been approved by two or more reference agencies. 
c Only if requested by the sponsor and if the product has been approved by two or more reference agencies. 
d Only if the product has been approved by one or more reference agencies 
e Only for Biological and Biosimilar products 
 
Data requirements 
The TITCK requires full clinical and efficacy data for the application and this must be 
submitted in the CTD format with the correct sections (Module 1,2,3,4 and 5) of scientific 
data. Accordingly, the TITCK performs a complete assessment of these data, mainly the 
quality and the clinical parts of the product file. Additionally, the TITCK performs a 
structured benefit–risk assessment, examines the influence of the ethnic factors, the 
differences in medical culture/practice, national disease patterns and unmet medical needs 
even though sufficient data on these criteria are not always supplied in all applications.  
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Furthermore, most of the quality elements of the application are assessed by the TITCK 
through the Good Manufacturing Practices (GMP) accreditation process, where a complete 
GMP application is submitted for evaluation and a physical inspection of all involved sites is 
included. The GMP accreditation process is a pre-requisite for all new marketing 
authorisation and type 2B site related CMC applications. As a result, the start of the review 
process can be delayed by twelve to eighteen months. An exception is made only for life 
saving and critical products categorised as priority one where the GMP accreditation process 
can be conducted in parallel to the review process to save time and accelerate patients’ access 
to these products (TITCK, 2016).  However, the GMP process in some countries like Saudi 
Arabia and Australia may be completed by the submission of a copy of a GMP certificate 
issued from a reference agency (TGA, 2016). Furthermore, some agencies like Singapore, 
may conduct an inspection in parallel to the review process according to the ICH GMP and/or 
PIC/S guidelines (HSA, 2016).  
 
All the comparative authorities in this study require full datasets for the pharmaceutical CMC, 
non-clinical and clinical sections and conduct a detailed assessment of all three sections for 
full review. On the other hand, the assessments conducted by the HSA depend on the type of 
review it conducts, allowing the conservation of resources for use in the review of medicines 
associated with a high risk for their population. At the TITCK, the sequence of the scientific 
review of the application can vary according to the status of the application, where several 
committee reviews can run in parallel or sequentially depending on the global submission 
status of the product (EMA/FDA). Thus, in the case of a parallel MAA submission with EU 
or FDA; the registration review process starts with the technical assessment and then proceeds 
with the clinical evaluation in order to consider any other regulatory agency’s clinical opinion 
or decision mainly from EMA/FDA. Except for the TITCK, the review of quality, safety and 
efficacy data are conducted in parallel at all four regulatory agencies in this study.  
Furthermore, the external experts are used on an ad hoc basis by the TGA, HSA and SFDA, 
whereas Health Canada does not use external experts for dossier review. The external experts 
are mainly responsible for providing a detailed assessment report and recommendations as 
well as a clinical opinion on the product.  
 
Pricing data is not required by the TITCK at the time of submission; however, negotiation 
starts during the registration review and licensing process. The pricing process can be 
conducted in parallel and independently to the registration review process after the main 
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clinical assessment is completed. Nevertheless, registration approval can be obtained prior to 
pricing approval since this is required in later steps prior to the sales and importation 
permission applications which enable the product to be commercially available. Of the five 
agencies, only the SFDA requires information related to pricing as part of the marketing 
authorisation dossier. Thus, pricing evaluations are not part of the technical review at the 
other comparative agencies.  
 
Target and approval times 
The TITCK overall approval target timeline is two hundred and ten working days (two 
hundred and ninety four calendar days) in the regulation, with one hundred and eighty 
working days for a prioritised accelerated review and one hundred and fifty working days for 
highly prioritised products. However, prioritised accelerated review and highly prioritised 
products are not defined in the regulation. In practice, the actual approval timelines are much 
longer than that stated in the regulation. 
 
The TITCK review process consists of the following common steps: validation of the 
submitted dossier, scientific assessment, company response and final authorisation. The 
TITCK target time for the validation is thirty working days. The TITCK mean approval times 
for New Active Substances (NASs) marketing authorisations applications approved in 2013, 
2014 and 2015 were three hundred and fifty, three hundred and forty and two hundred and 
seventy working days respectively (Figure 3.5).  
 
In comparison, for the SFDA, which conducts a type 3A review, the overall target approval 
time is four hundred and twenty calendar days (two hundred and ninety working days). 
Whereas TGA, Health Canada and HSA, which all conduct type 3B reviews have overall 
target approval times of three hundred and five calendar days; TGA, three hundred and fifty-
five calendar days; Health Canada and three hundred and ninety-five calendar days for HAS 
although these are mainly abridged reviews. While the review times for SFDA were lower 
than the target time, the review times from 2012-2015 for TGA exceeded the specified target, 
but for Health Canada approval times were approximately on target during the same time 
(Figure 4.6). 
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Figure 4.6 Regulatory approval times from date of submission to date of approval for 
New Active Substances (NASs) approved 2013-2015 (Calendar days) 
 
 
Part II: Good Review Practices (GReP) 
Building quality measures and the implementation of Good Review Practices (GReP)3 in the 
registration review process is important for regulatory health authorities since it ensures 
consistency, transparency, timeliness and competency in the review processes (McAuslane, et 
al., 2009) and enables regulatory authorities to achieve timely approvals for new medicines 
while safeguarding the high quality which may have a significant impact on accelerating 
patients’ access to medicines; thus reducing the costs to both governments and marketing 
authorisation applicants. Furthermore, the implementation of GReP enhances the global 
harmonisation and regulatory convergence by facilitating the exchange of best practices, 
                                                 
3 Good Review Practice (GReP): A code about the process and the documentation of review procedures that 
aims to standardise and improve the overall documentation and ensure timeliness, predictability, consistency and 
high quality of reviews and review reports. 
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assessment reports and outcomes among regulatory authorities that significantly contributes to 
the better management of resources of regulatory authorities and the timely approvals of 
medicines (WHO, 2015). Therefore, regulatory health authorities are focusing on improving 
the quality standards of the review process and implementing the required quality measures to 
enhance their efficiency and meet the expectations of industry and the general public. This 
study identified the different quality metrics that have been implemented by the five agencies 
with the aim of comparing the practices in place to ensure quality, transparency and 
predictability of the regulatory review process. All five agencies have good review practices 
(GReP) in place, but implement them informally, except for Health Canada, which has a 
programme for formal use. 
 
Quality measures 
The quality measures evaluated in this comparative study included the availability and use of: 
an internal quality policy, GReP, standard operating procedures (SOPs) for assessors, 
assessment templates, the existence of a quality assurance department, the use of scientific 
committees and the use of shared and joint reviews with other agencies.  The TITCK have six 
of the seven measures in place, namely an internal quality policy, GReP system, SOPs for 
assessors, assessment templates, a dedicated quality assurance department and a scientific 
committee (Table 4.2).  
 
 
Table 4.2: The quality measures implemented by the five agencies 
Measure 
Regulatory Authority 
Turkey 
(6/7) 
Australia 
 (6/7) 
Canada 
(5/7) 
Saudi 
Arabia 
(6/7) 
Singapore 
(5/7) 
Internal quality policy      
Good Review Practice 
System 
 
(Informally) 
 
(Informally) 
 
(Formally) 
 
(Informally) 
 
(Informally) 
SOPs for guidance of 
assessors      
Assessment templates      
Dedicated quality 
department      
Scientific committee      
Shared and joint reviews   
(Occasionally) 
 
(Occasionally) 
a  
(Occasionally) 
 
a Shared and joint review with the GCC countries. 
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In comparison, SFDA and TGA also each have six of the seven measures in place, whereas 
Health Canada and HSA employ five. Additionally, Health Canada, TGA and HSA 
occasionally conduct shared or joint reviews with other regulatory authorities. 
  
Transparency and communication  
The transparency of any regulatory health authority can be defined in terms of the ability and 
willingness of the agency to assign time and resources to providing information on its 
activities to both the informed public (which includes health professionals) and industry. Thus 
each regulatory authority may prioritise differently the level of being open and transparent in 
its relationship with the public, professions and industry depending on the main drivers and 
incentives of the agency to allocate time and resources to certain activities and practices that 
facilitate the openness of the regulatory system. For example, the political will in the country, 
public pressure as well as the press and media attention on the regulatory review system can 
be among the main drivers of the agency to focus on transparency.  
 
Additionally, agencies may aim to increase the level of confidence in their review system, in 
order to provide assurances on safety safeguards and to ensure better staff morale and 
performance (McAuslane, et al., 2009). Information communicated by regulatory health 
authorities to the public and relevant stakeholders could include: feedback on submitted 
dossiers, technical staff contact information, pre-submission scientific advice, official 
guidelines, ability to track the progress of applications, summary of the grounds of approval, 
approval times, advisory committee meeting dates and the approval of products. The TITCK 
has only three of these nine parameters in place. This includes, information provided to the 
general public in terms of information of the approved products and approved product 
labelling, feedback to industry on submitted dossiers only at the validation step as well as 
through providing official guidelines to assist the industry.  
 
Furthermore, the TITCK has an internal electronic system to track applications under review 
identifying the stage in the process, however the system cannot be accessed by applicants, nor 
does it provide information regarding review timelines. Official pre-submission advisory 
meetings are also not provided by the TITCK; nevertheless, such meetings can be conducted 
on request and on an ad hoc basis informally and depending on the case under review. The 
SFDA has five of these parameters in place, HSA six, Health Canada eight and TGA all nine 
(Table 4.3). 
94 
Table 4.3: Transparency and communication parameters in the five agencies 
Measure 
Regulatory Authority 
Turkey 
 
(3/9) 
Australia  
 
(9/9) 
Canada  
 
(8/9) 
Saudi 
Arabia 
(5/9) 
Singapore  
 
(6/9) 
Feedback to industry on submitted dossiers      
Details of technical staff to contact      
Pre-submission scientific advice to industry      
Official guidelines to assist industry      
Industry can track progress of applications      
Summary of grounds on which approval was 
granted      
Approval times      
Advisory committee meeting dates      
Approval of products      
 
Of the five agencies, TITCK, SFDA and HSA do not publish a summary basis of approval, 
while SFDA, Health Canada, and HSA do not supply advisory meeting dates, or give 
feedback to the industry on the submitted dossier. Neither the TITCK nor the SFDA share 
information that is needed to contact their technical staff during the review. The reason behind 
this approach is possibly the concern of the agencies that stakeholders may influence or apply 
pressure on the reviewers. 
 
Continuous improvement initiatives 
During the past few years, building quality measures into the regulatory review process has 
become one of the important focus areas for major regulatory authorities and pharmaceutical 
companies. Thus, regulatory health authorities are devoting more time and resources to build 
the necessary quality indicators and improve the processes accordingly. Previously, approval 
times and the speed of the regulators’ review were the only indicators of quality used to 
measure the authority’s review performance and process efficiency (Cone & McAuslane, 
2006). However, studies have shown that the quality of the regulatory review and decision-
making process from receipt of the applications to final approval must also be considered and 
equally monitored to be improved (Salek, et al., 2012). Reasons for introducing quality 
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measures within the authority include, enhancing the review process efficiency, minimising 
the errors, ensuring consistency, reducing costs, achieving stakeholder satisfaction and 
increasing transparency through improving communication within the authority and with all 
stakeholders. Accordingly, the continuous improvement initiatives assessed in this study 
included external and internal quality audits, tracking systems and the review of assessors and 
stakeholders’ feedback. This study identified that the TITCK does not have an internal 
tracking system to track the different milestones of applications through the various review 
stages. Moreover, although the TITCK conduct internal quality audits through its dedicated 
internal quality department, yet the agency does not go through any external quality audits. 
Accordingly, Turkey has three of these five continuous improvement processes in place while 
Australia and Singapore have four of these and Saudi Arabia engages in all five continuous 
improvement processes and Health Canada has three (Table 4.4). 
 
 
Table 4.4: Quality improvement initiatives in the five agencies 
Measure 
Regulatory Authority 
Turkey 
(3/5) 
Australia  
(4/5) 
Canada  
(3/5) 
Saudi Arabia 
 (5/5) 
Singapore  
(4/5) 
External quality audits      
Internal quality audits      
Internal tracking systems      
Reviews of assessors’ feedback      
Reviews of stakeholders’ 
feedback      
 
Training and education 
One of the important elements of a quality process is the training and continuing education of 
staff at the regulatory health authorities as well as of assessors working within the authority, 
including those employed on a full-time basis as well as those contracted for specific 
assessments. The type of training and continuing education that can enhance the review 
process includes international workshops, external and in-house courses, on-the-job training, 
lectures by external speakers, induction training, sponsorship of postgraduate degrees and 
placements and secondments.  
 
The TITCK apply all of the training and education elements except for the provision of 
induction training for new employees and assessors, which is described as being handled 
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through on-the-job training. In comparison, the SFDA has seven, lacking only the availability 
of in-house training, whereas Australia, Canada and Singapore employ all eight (Table 4.5). 
 
Table 4.5: Training and education in the five agencies 
Measure 
Regulatory Authority 
Turkey 
(7/8) 
Australia  
(8/8) 
Canada  
(8/8) 
Saudi Arabia 
 (7/8) 
Singapore  
(8/8) 
International workshops/ conferences      
External courses      
In-house courses      
On-the-job training      
External speakers invited to the 
authority      
Induction training      
Sponsorship of post-graduate degrees      
Placements and secondments in other 
regulatory authorities      
 
Enablers and barriers to good quality decision-making  
This study identified the TITCK’s own perception of its unique positive qualities and the 
major impediments it faces in carrying out the review of new medicines and making them 
available to ensure patients’ timely access to medicines. Therefore, the TITCK indicated that 
the availability of a pool of high calibre employees and good scientific committee experts as 
well as building close relationships with other international regulatory authorities’ to share 
good decision-making processes and practices, are factors that make a major contribution to 
the effectiveness and efficiency of the review. Whilst other agencies provided a diverse set of 
enablers as part of their questionnaire responses, there was some consistency among all five 
countries. Moreover, the study revealed the main challenges encountered by the TITCK that 
act as barriers to a good quality review system and to making new medicines available in a 
timely manner with limited human resources include physical and technological infrastructure 
as well as the patent related rights regulations are not aligned with international standards. 
Questionnaire responses from the comparative agencies indicated that incomplete submissions 
and lack of experienced staff were considered barriers to an effective and efficient authority. 
In summary, the key features of the TITCK review process compared with TGA, Health 
Canada, SFDA, and HSA are presented in Table 4.6. 
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Table 4.6: Key features of the five agencies’ review process 
Marketing Authorisation Turkey Australia Canada Saudi 
Arabia 
Singapore 
Certificate of a Pharmaceutical Product 
(CPP) is required at time of submission      
Medical staff: More than 20% of the 
review staff are medically qualified      
Review times: The authority sets targets 
for the time it spends on the scientific 
assessment of NAS application. 
     
Approval times: The authority has a 
target for the overall time for the review 
and approval of an application. 
     
Questions to sponsors are batched at 
fixed points in the review procedure.      
Company response time: Recording 
procedures allow the company response 
time to be measured and differentiated 
in the overall processing time 
     
Priority Reviews: The agency 
recognises medical urgency as a 
criterion for accelerating the review and 
approval process for qualifying 
products. 
     
Parallel processing: The different 
sections of technical data (Quality, 
Safety, and Efficacy) are reviewed in 
parallel rather than sequentially. 
     
Price negotiation: Pricing discussion is 
separate from the technical review and 
does not hold up the approval. 
     
Sample analysis: The focus is on 
checking quality in the market place and 
requirements for analytical work do not 
hold up the marketing authorisation. 
     
 
DISCUSSION 
In today’s world, enhancing patients’ access to new medicines is of critical importance for all 
health authorities and stakeholders. However, the expected improvement in patients’ access to 
medicines cannot be realised in many countries around the world due to several reasons 
including stricter pharmaceutical regulations, long approval timelines, increased payer 
pressures and complicated legal practices.  
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In Turkey, the registration review process of pharmaceutical products is conducted in 
accordance with the “Registration Regulation of Human Medicinal Products” which was 
amended in 2009 and thus sets forth the principles, procedures, and policies regarding the 
registration of medicines, with the aim of achieving the desired efficacy and safety as well as 
the required quality (Ministry of Health, 2005). One of the main goals and focus areas of the 
Turkish health authority in the past decades was to ensure alignment with international 
standards and build a robust high quality regulatory health agency comparable to other mature 
developed health agencies, in order to ensure the timely access of patients to medicines. 
 
Hypothesis 1: The TITCK review model for NAS applications is similar to that of other 
mid-sized regulatory authorities. 
The TITCK currently performs a full review (Type 3A) for all new active substances and a 
marketing authorisation application for a NAS can be submitted in Turkey prior to any 
approval in the world although, a pre-approval by a reference regulatory agency is a 
prerequisite for marketing authorisation final approval. During the review process, the TITCK 
conducts a full assessment of the data, but mainly for the clinical and quality parts where a 
complete GMP application and inspection process is included as a pre-requisite for the 
application. This may also run in parallel to save time for life saving and critical products. 
Taking into consideration the limited resources within the TITCK and the relatively large 
number of applications received by the agency, the TITCK might need to utilise and conserve 
constrained resources more efficiently. One method for the conservation of regulatory 
resources is the use of a risk stratification approach for the review (Alsager, et al., 2015). 
With this approach, agencies such as HSA, TGA and Health Canada may conduct an abridged 
review in certain circumstances where products have been approved by one or more reference 
agencies. Therefore, they are able to conserve resources for a full review for products that 
have not been previously reviewed or medicines associated with a high risk for patients.  
 
Additionally, the TITCK could benefit more from joint reviews or assessment outcomes of 
other regulatory health authorities mainly for the clinical part thus reducing the pressure and 
review load of the assessors. This option could be explored with agencies of similar size and 
resources such as Health Canada, SFDA or TGA. Moreover, the TITCK can equally benefit 
from the GMP assessment and accreditation process of other regulatory health authorities. 
One method for this collaboration is by becoming a full member of the Pharmaceutical 
Inspection Co-operation Scheme (PIC/S) which was established with the aim to harmonise 
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GMP accreditation procedures in the world by setting common standards for the GMP 
process, the provision of related training to inspectors and the development of required 
competencies for the assessment among regulatory authorities to increase mutual confidence 
(PICS, 2016). In May 2013, the TITCK applied for a full membership to PIC/S. Such a 
membership will enable the TITCK to benefit from the co-operation and networking between 
regional and international organisations in this area and rely on other inspectors’ assessment. 
This could save the time and resources of their own agency by relying and using other 
reference agencies’ GMP approvals similar to the SFDA. Another suggestion would be for the 
TITCK to conduct the GMP process in parallel to the registration review procedure similar to 
Health Canada, HSA and TGA in order not to further delay the application and therefore the 
authorisation process.  
 
Finally, it appears from this analysis that the full review of the TITCK is in line with the other 
mid-sized regulatory agencies. However, the TITCK does not have a risk stratification 
approach as some other agencies. In addition, the GMP accreditation procedure is not fully 
aligned with the globally implemented process. In the light of these findings, it would appear 
that this hypothesis is rejected. 
 
Hypothesis 2: The marketing authorisation application requirements in Turkey are 
similar to those of other international agencies. 
In Turkey, the submission of a CPP at the time of application is not required; however, a CPP 
or evidence of approval in the EU, the USA or another country is required for final 
authorisation. This is similar to countries like Mexico, and China that also require proof of 
prior marketing authorisation before final approval (McAuslane, et al., 2009). Other agencies 
employ the use of alternate evidence of market authorisation such as information from other 
agency websites. However, other mid-sized agencies in countries like Australia, Canada and 
Singapore do not require a CPP when they perform a full assessment of the application while 
SFDA requires a legalised CPP for regulatory submissions although this is not mandated by 
the World Health Organisation (WHO, 2017). 
 
In cases of a NAS submission to TITCK in parallel with other developed agencies like the 
EMA and the FDA, the agency proceeds with the review process but relies on the approval of 
those agencies to grant its final approval. Therefore, it is suggested that a regulatory agency 
like the TITCK who conduct a full assessment may also consider abolishing the need for a 
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CPP or any evidence of prior marketing authorisation approval. This could be implemented 
initially for critical and lifesaving products in order to ensure patients’ access to these 
medicines as soon as possible regardless of its registration status in the world. However, most 
of these medicines become available to patients in Turkey based on the assessment of the 
clinical data only and even prior to any licensing, as part of the early access programs 
(TITCK, 2009). Similarly, the TITCK requires that the data submitted with the NAS 
application are in accordance with the ICH guidelines and the CTD (common technical 
document) format including all its five modules of quality, non-clinical and clinical. 
Therefore, marketing authorisation application dossiers provided by global companies do 
meet the TITCK requirements since the content of the dossier with the exception of module 
one data is aligned with those of other developed agencies.  
 
Like the SFDA, the TITCK requires information relating to pricing as part of the review 
process and this includes the reference price lists for the drug product in five countries 
namely; Portugal, Spain, France, Italy and Greece. Nevertheless, the final marketing 
authorisation approval does not depend on the pricing negotiation. In contrast, other pre-
marketing administrative steps such as final packaging and labelling approval, sales and 
importation permission do rely on prior price approval. Comparatively, price evaluation is not 
part of the review process at TGA, Health Canada or Singapore. Currently, price negotiation 
is a complex process in Turkey where a number of other government departments get 
involved in the decision-making process such as; the Social Security Institute (SGK), Ministry 
of Finance, and Under-secretariat of Treasury as well as the Ministry of Development 
(TITCK Price Decision, 2015). Thus, the price approval of a medicine is subject to the 
evaluation and consensus agreement of stakeholders other than the TITCK and thus does not 
include any scientific regulatory assessment. In the established agencies such as; the EMA, 
the FDA and Health Canada, pricing is conducted as an independent separate process after the 
marketing authorisation approval. Therefore, the agency is only responsible for the scientific 
regulatory assessment of the application and does not get involved with pricing or 
reimbursement discussions. In this way the regulatory review and assessment is conducted 
only on the basis of the scientific judgement of data. Accordingly, it is suggested that the 
TITCK should not perform pricing assessment as part of the review process, but rather initiate 
the process separately and preferable in parallel or following licensing. In the light of the 
above, apart from the pricing process, the marketing authorisation application requirements in 
Turkey are similar to those of other international agencies although an evidence of approval 
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elsewhere is still required prior to authorisation. Accordingly, with an exception that an 
authorisation is required elsewhere prior to final approval, this hypothesis is accepted.  
 
Hypothesis 3: The approval times of NASs in Turkey are longer than other countries 
such as Australia, Canada, Saudi Arabia and Singapore. 
The TITCK mean approval times for NAS marketing authorisation application were identified 
to be four hundred and seventy-six, four hundred and ninety, three hundred and seventy-eight 
calendar days for the years 2013, 2014 and 2015 respectively. These exceeded the agency’s 
overall target time of two hundred and ten working days (two hundred and ninety-four 
calendar days). This suggests there is room for improved timeliness, consistency and process 
predictability in the system. Part of the delay in approval could be attributed to the time taken 
by the sponsoring company to respond to agency questions. Therefore, setting target timelines 
for question and answer phases and enhancing the dialogue and transparency between the 
TITCK and the industry could improve the quality of dossier submissions and reduce the 
number of agency questions raised during the review process.  
 
The mean approval time of the TITCK for NAS applications in 2015 is two hundred and 
seventy working days (thirteen months) excluding companies’ response time instead of two 
hundred and ten (ten months), which indicates that the TITCK did not meet its target approval 
time. Further, industry experience also shows that question and answer phases can take fifteen 
months with an average of ten to fifteen questions received for each NAS application thus an 
average of two to four months to close each question. Therefore, it is suggested that the 
TITCK batch their questions and set target response timelines for companies. Moreover, 
companies should keep a systematic record of the number of questions received and response 
times. Additionally, delays in approval may also be related to the structure and working 
procedures of the committees where most of the review and assessment decisions are taken 
‘leaving only administrative and technical parts of the application to be reviewed by internal 
assessors’. Therefore, the TITCK may consider delegating the review and assessment of some 
variations or extensions to internal assessors in order to reduce the number of dossiers 
assessed by committees and enhance the committees’ review thus allowing them to focus on 
new product applications and major clinical or quality variations.  
 
The approval times at the TGA in 2015 is three hundred and seventy-three calendar days and 
therefore exceeded agency target times. Whereas, Health Canada approval time is three 
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hundred and fifty-five, which is approximately the same as target times for this period.  The 
reason for this is because the agency makes vigorous efforts to keep to target times to avoid 
the penalties of up to 50% of user fees as mandated by the User Fees Act if target times are 
not met (Hashan, et al., 2016).  
 
The TITCK has established target times for the authorisation procedure and overall approval, 
whereas the SFDA, the TGA, Health Canada and the HSA set separate target times for 
validation, scientific assessment, and authorisation as well as overall approval times. Defining 
target timing for individual milestones within the review facilitates planning for both agencies 
and sponsoring companies, and this permits the identification of the most appropriate areas 
for improvement. Although currently the TITCK has a manual system, they are planning to 
convert this into an electronic internal tracking system to monitor the various milestone 
timelines’. However, so far the timelines and different milestones are not available to 
stakeholders in a systematic formal way. Establishing an electronic tracking system with 
target timelines would enhance the efficiency and continuity of the review process while 
enabling the TITCK to monitor the timelines between milestones as well as to observe the 
time between first-in-world approval and approval in Turkey. 
 
In conclusion, it would appear that the approval timelines in Turkey are not only presented as 
mean rather than median as the other countries in this study, but do not include question and 
answer times and therefore they are not comparable with the approval times of other agencies 
such as the FDA, the EMA (Figure 1.4). Furthermore, it might appear that the TITCK has 
longer approval timelines compared to other countries; this was also confirmed by the 
industry study data on approval times, which will be discussed in details in chapter five. 
Therefore, the results are inconclusive due to the fundamental difference of not being able to 
compare median and mean approval times.  
 
Hypothesis 4: Good Review Practice (GReP) requirements implemented by the TITCK 
are comparable to other similar countries, which ensure consistency, transparency, 
timeliness, and predictability of the review process. 
Good review practices (GReP) facilitate a timely and high-quality regulatory review and 
enable regulatory convergence, which can have a significant impact on resource conservation 
as well as patients’ access to medicines. Thus previous studies demonstrated that building 
quality and GReP into the regulatory review process is as significant regulatory performance 
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indicator as the approval the timelines (Cone & McAuslane, 2006). In relation to this, the 
World Health Organization has set the standards of GReP with the aim to guide national and 
regional regulatory authorities (WHO, 2015). Similar to other comparator agencies, the 
TITCK in this study employ many of the essential elements of GReP. However, the good 
review practices implemented by the TITCK are currently still not formalised and require an 
enhancement in some areas such as; transparency to stakeholders, training tools such as 
induction courses for new assessors and building an electronic tracking system available to 
stakeholders. By adapting the standards of the global guideline of good review practices and 
monitoring its implementation within the TITCK, it could be formalised to become a 
mandatory system to improve and ensure consistency, timeliness and review process 
predictability.  
 
Furthermore, the TITCK may consider providing other elements which can contribute to 
enhance transparency in the review process as well as the quality of applications, such as, the 
provision of a summary basis of approval; thus communicating to the companies, patients and 
healthcare providers the agency decision making process. In providing a rationale for the 
publication of summary basis of approval, Health Canada describes, in its website what the 
Summary Basis of Decision (SBD) documents are for. Therefore, they inform the public in a 
general way why Health Canada authorized certain drugs and medical devices in the country 
based on regulatory, safety, effectiveness and quality considerations. Accordingly, it states 
that this: “. . . improves the transparency of the drug and medical device regulatory review 
processes. They also give Canadians improved access to information about decisions to 
authorize products for sale in Canada” (Health Canada, 2016).  
 
Finally, the TITCK is not currently implementing a structured framework for the evaluation 
of the benefit-risk (BR) assessment of medicines, which is the key step in the review process 
for NASs. Thus, the assessment process depends largely on the reviewers’ performance and 
experiences, which may vary significantly as some reviewers, could be more experienced and 
keen to improve the quality of the review performance compared to others. Therefore, to 
enhance the quality and standardisation of the review process, the TITCK can consider the 
implementation of a structured peer review process that is practiced by many mature agencies. 
For example, in Australia the TGA uses a multi-layered peer review process during which 
applications are reviewed for a second time by senior reviewers to ensure that an optimal 
decision is made (Al-Essa, 2011). It is also recognised that establishing such a BR framework 
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would require a high level of expertise and time. Therefore, it is suggested that the TITCK 
should consider adopting and implementing the Universal Methodology for Benefit-Risk 
Assessment (UMBRA) framework as this has been positively assessed by several mature 
agencies and currently under evaluation by agencies in the emerging markets (Walker, et al., 
2013). In addition, the TITCK could also gain benefit by reviewing the assessment templates 
of other regulatory authorities worldwide, which may demonstrate to the TITCK as to how the 
benefits and risks are assessed in their review processes. In relation to the good review 
practice elements, Turkey is comparable to other countries and therefore, this hypothesis is 
accepted. However, with regards to transparency and communication, these are areas that 
could be improved.  
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SUMMARY 
 This study has evaluated the regulatory review process and timelines by the TITCK for the 
first time since it was established as an agency when it took over the responsibility for 
pharmaceutical regulation from the Ministry of Health in 2011. It has identified the key 
milestones, timelines and evaluated the measures used for GReP and provides 
opportunities for an enhanced regulatory review process.  
 
 A comparison of the current TITCK processes and practices with those of similar medium-
size regulatory agencies such as the SFDA, the TGA, Health Canada and the HSA has 
enabled the development of several proposals to assist the agency in its efforts to become 
an internationally recognised reference agency.   
 
 In general, the TITCK review model and the marketing authorisation requirements of 
applications are similar to other regulatory agencies’ review model and requirements. 
Therefore, this model enables the review of NAS applications in parallel to other 
developed regulatory agencies such as the FDA and the EMA. However, the requirement 
of a prior approval or a CPP at the time of final authorisation may still delay patients’ 
access to medicines. 
 
 The TITCK could conserve resources and reduce the time in the review process, by 
exploring the possibility of introducing shared or joint reviews with other similar 
regulatory authorities. The resulting delay caused by the current GMP process, could be 
avoided by the TITCK collaborating with other agencies or becoming a member of an 
international organisation such as PIC/S, which they have already applied for, and 
following the standard schemes in the GMP accreditation process. Accordingly, the 
TITCK could benefit from the inspection outcomes and GMP certificates issued by other 
regulatory health authorities in relation to the same manufacturing sites and quality data.  
 
 The TITCK could reduce approval times by redefining the pricing process and separating it 
from marketing authorisation. This will enable the TITCK to better present its review 
performance both locally to the public and other stakeholders as well as to reduce the 
timescales between Turkey and first approvals in the world.  
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 Good Review Practices are implemented informally to a certain extent within the TITCK. 
However, GRePs need to be established as a formal system and become mandatory and 
carefully monitored during implementation. Furthermore, it is recommended that the 
TITCK define target times for each review milestone in addition to the predefined overall 
authorisation procedure approval timing. Moreover, it should improve internal tracking 
systems to monitor these milestones and thus enable this information to be available to all 
stakeholders.  
 
 The TITCK is currently lacking a number of elements that contribute to transparency and 
communication. These would include publicly available summaries of the basis for 
approval, developing standards for scientific and advisory meetings for applicants prior to 
submission as well as developing relationships with other reference agencies to encourage 
training through secondments and job shadowing. 
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CHAPTER 5 
 
 
 
 
 
 
 
 
EVALUATION OF THE ATTITUDES 
AND EXPERIENCES OF 
PHARMACEUTICAL COMPANIES 
TOWARDS THE TURKISH 
REGULATORY REVIEW PROCESS  
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INTRODUCTION 
An ideal healthcare system consists of three fundamental characteristics, which are cost, 
quality and access. All three aspects are equally crucial to establishing an efficient healthcare 
system where individuals can easily access high-quality healthcare services at an affordable 
cost while the system provides the expected return on investments for all involved companies 
within the industry (Figure 5.1). Access and cost are usually determined by health authorities’ 
policies and regulations and therefore have direct impact on the quality of the healthcare 
(YASED, 2012). 
 
Figure 5.1: Fundamental aspects of an ideal healthcare and pharmaceutical system  
 
 
Similarly, the key to an ideal healthcare system is its relationship to a good pharmaceutical 
system, where it relies on the availability of assured quality, safe and affordable medicines to 
patients (SPS, 2011). This barrier to an adequate and timely access to medicines often results 
from the lack of the availability of medicines mainly due to price policies and poor 
governance in the pharmaceutical system which significantly affects the affordability of 
medicines and ultimately the efficiency of the healthcare system as well as the pharmaceutical 
investments within the system (Mhlanga & Suleman, 2014). Since 2002 the healthcare system 
in Turkey has undergone significant developments with respect to their services and patients’ 
access to medicines. This was due mainly to the introduction of the Health Transformation 
Program (HTP), which resulted in an improved access to higher quality healthcare services 
including medicines. This has been accompanied by several developments in the 
pharmaceutical industry, which significantly increased in the last decade and witnessed many 
major changes in policies and regulations (ISPAT, 2014). Along with these developments 
such as an increase in R&D investment, manufacturing sites and the establishment of 
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international subsidiaries in Turkey, the government, in parallel, has initiated a number of 
measures to control the increasing healthcare budget mainly for pharmaceuticals and to enable 
a sustainable financing source for wider coverage. This is because the increasing higher 
consumption of pharmaceuticals has created pressure on the national budget due to the wider 
scope of social security and increased patients’ access (YASED, 2012).   
 
However, restricting costs and healthcare expenditure can have a negative impact on patients’ 
timely access to innovative and high cost medicines as well as on the pharmaceutical 
industry’s profitability and investments. These changes in the pharmaceutical regulatory 
environment can act as a barrier to new medicines reaching the market in a timely manner. 
For instance, the regulatory environment in Turkey imposes major challenges to 
pharmaceutical companies in many areas such as the local GMP process and the pricing 
procedure. This is despite the alignment of the Turkish regulations with the European 
directives and the standards of the International Conference of Harmonisation (ICH). Yet, the 
registration review process is perceived to be a complex one and thus suffers from a 
significant backlog and delay in approvals. In theory, the approval timeline for a new 
medicine in Turkey is stated to be two hundred and ten working days, nevertheless, recent 
examples from the industry identified that major delays occur during the approval process due 
to the increasing requests mainly for clinical data and the recently introduced GMP inspection 
requirements. Consequently, six years ago it took eighteen months to three years for a new 
medicine to be approved in Turkey (Kretschmer, 2011). Therefore, it is important for the 
pharmaceutical industry to have a clear understanding of the registration review process with 
all its quality aspects and practices implemented by the regulatory authority. This is essential 
if the key issues are to be addressed effectively in order to enhance approval timelines and 
patients’ access to medicines. Similarly, it is important to identify pharmaceutical companies’ 
experiences of the review process and take into consideration industry experts’ opinion about 
the issues and challenges.  
 
The aim of this chapter is to assess the experiences and attitudes of the pharmaceutical 
companies in Turkey towards the regulatory registration process, the requirements of the 
TITCK and their timelines. This also includes an evaluation of the level of interaction with 
the TITCK and the process review in terms of predictability, transparency and consistency. 
For this purpose, a questionnaire was designed to evaluate the current attitudes and 
experiences of pharmaceutical companies. This study aimed to identify the major issues and 
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challenges faced by pharmaceutical companies during the regulatory review process and in 
obtaining marketing authorisation approvals for innovative medicines. This research was 
designed to be complementary to the other two studies that evaluated patients’ perception of 
the regulatory environment and the review system of the TITCK. 
 
OBJECTIVES 
The main objectives of this study were to: 
• Determine the attitudes and experiences of pharmaceutical companies towards the 
Turkish regulatory review process. 
• Identify the key issues companies are facing in the Turkish regulatory environment.  
• Evaluate the changes in the regulatory approval timelines and processes between 2012 
and 2015. 
• Identify the improvements that the pharmaceutical industry would like to see to ensure 
that the medicines’ approval process is both efficient and effective. 
• Assess the impact of the current regulatory process on patients’ access to innovative 
medicines. 
 
METHODS 
The experimental method used in this research was similar to the other studies that examined 
both the patients’ perspective as well as that of the TITCK in relation to the pharmaceutical 
regulatory environment in Turkey. This was to ensure consistency in the data collection for all 
three studies from the different perspectives and facilitate the comparison, which would 
contribute to the identification of areas of improvement within the system. Therefore, a 
descriptive research method was utilised to describe the experiences of pharmaceutical 
companies towards the regulatory review process and timelines. Accordingly, the 
questionnaire was designed as a cross-sectional study aimed at collecting data during a 
specific time period to evaluate the current industry perspective.   
 
Questionnaire Development 
In this study the main objective and emphasis was to develop a tool to collect data in line with 
the objectives. For this purpose, the questionnaire was designed to be utilised as a qualitative 
research method and was carried out in three phases: 
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• Phase 1: Identification of the main themes and development of the first version of the  
                      questionnaire. 
• Phase 2: Pilot study and content validation. 
• Phase 3: Development of final version of the questionnaire. 
 
Phase 1: Identification of the main themes and development of the first version of the 
questionnaire. The main themes of the questionnaire were generated firstly by reviewing 
previous surveys of pharmaceutical companies by the pharmaceutical industry association on 
an annual basis with the aim of obtaining the general status of the companies’ experiences 
about the TITCK practices, regulations and their interaction with the industry. The main 
topics, not covered by the association’s annual survey, were also identified. Thereafter, a face-
to-face meeting with the regulatory affairs and market access committees of the Research 
Based Pharmaceutical Companies’ Association (AIFD) was organised in order to identify the 
main areas of need for the industry and generate the themes required for the questionnaire. 
Accordingly, a total of four main themes were identified and the first version of the 
questionnaire was designed in four parts with the following headings: 
- Theme 1: General questions and company details. 
- Theme 2: Local requirements in Turkey and regulatory metrics.  
- Theme 3: Regulatory review process.  
- Theme 4: The way forward for TITCK. 
 
The questionnaire included twenty-two questions mainly as multiple choice and five open-
ended questions with the aim of collecting detailed information and opinions from the 
companies during the pilot study. 
 
Phase 2: Pilot study and content validation. 
A pilot phase for this study was designed to identify areas of improvement in terms of 
structure, terminology, deletion and/or addition of questions to ensure that these were 
comprehensive and easy to understand. Thus, the initial questionnaire was completed by three 
pharmaceutical companies, who were representative of the core team of the Regulatory 
Affairs Committee within AIFD. Upon completion of the questionnaire by each company 
representative, participants were asked to provide their input to specific questions (Table 5.1). 
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Table 5.1: Pilot phase questions for content validation 
 In general how did you find the questionnaire? 
 How do you evaluate the language of the questionnaire? 
 Are there any questions which you found difficult to answer, and if so, which ones? Please state 
briefly why you think they were difficult? 
 Are there any repetitive questions in the questionnaire? 
 Are there any questions you think are not relevant in this questionnaire? 
 Are there any other questions you would like to add to the questionnaire? 
 Do you think that this questionnaire is relevant to pharmaceutical companies? 
 How long did it take you to complete this questionnaire? Please state in minutes. 
 
Following the pilot phase, a face-to-face meeting with an experienced regulatory affairs 
industry representative was organised to evaluate the responses and inputs from the 
participants. The analysis identified areas for improvement in terms of structure, wording, 
terminology used, deletion and/or addition of questions. These were then reviewed to see if 
they could be merged with other questions or need to be modified. For instance, two 
companies stated that they had difficulty in answering the question related to the agency’s 
transparency and suggested to address this topic in several questions. 
 
Furthermore, companies suggested including some questions related to the TITCK 
communication strategy in terms of consultation, scientific advice and question and answer 
processes. One company was hesitant to answer the question related to areas of improvement 
and therefore this question was clarified and limited to a specific period of time. As a result, 
the questionnaire was modified and further twenty-one questions were added to obtain the 
views of the companies about the TITCK transparency, communication, decision-making 
process and the applicability of a structured benefit-risk framework (Table 5.2). 
 
Table 5.2: Added questions as a result of the pilot study 
Topic Questions added to main study 
Communication with TITCK Questions: 7, 8, 9, 28, 29, 30, 31, 32, 40, 41 & 42. 
TITCK additional requirements Questions: 20, 21, 22, 35 & 39. 
Implementation of Good Review Practices Questions: 23, 37 & 38. 
Availability of benefit-risk framework Questions: 33 & 34. 
 
Phase 3: Development of final version of the questionnaire. 
The review of the questionnaire and analysis of the companies’ feedback during the pilot 
study was critical to the design of a more effective questionnaire as an assessment tool for the 
main study. Thus, the final version of the questionnaire comprised forty-six questions, mainly 
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as closed or multiple choices to ensure a statistical standardisation and facilitate the objective 
analysis for comparison and the time to complete the questionnaire was recorded to be thirty 
minute. Furthermore, the questionnaire included ten open-ended questions to identify 
potential views from the industry regarding developments in the regulatory environment, 
requirements and review process (Figure 5.2).  
 
Figure 5.2 Pharmaceutical industry questionnaire 
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Study Participants 
The questionnaire was distributed to all pharmaceutical companies operating in Turkey who 
have experience with the regulatory process for New Active Substance (NASs) as a marketing 
authorisation holder or applicant, which were the study inclusion criteria. Therefore, all other 
pharmaceutical companies were excluded from this study. Hence, the questionnaire was 
distributed to: 
 
• International pharmaceutical companies: this included thirty-eight innovative 
pharmaceutical companies officially registered as full members of the AIFD. 
• Local pharmaceutical companies: the questionnaire was sent to the three local 
companies who are involved in the registration of NAS through the Pharmaceutical 
Manufacturers Association of Turkey (IEIS). 
 
Questionnaire Administration and Data Collection 
The questionnaire was sent via e-mail to companies by the industry associations. The deadline 
for returning the questionnaires was stated in the e-mail to be two weeks, nevertheless, 
follow-up e-mails were sent out again after a further two weeks. The communication pack  
was accompanied by: 
 
- The study questionnaire (Figure 5.2). 
- A cover letter providing brief information about the study, expected outcome and 
instructions on how to complete the questionnaire and the required timeline. 
- A confidentiality agreement (Appendix II). 
- List of abbreviations and definitions used in the questionnaire study. 
 
Following a request from pharmaceutical companies a “Question and Answer” document was 
prepared to encourage their participation (Appendix III). The data from the participating 
companies were collected and anonymied by a third party to ensure confidentiality and avoid 
any potential conflict of interest. All completed questionnaires were returned directly to the 
third party where they were blinded and subsequently analysed appropriately to generate a 
study outcome report that was provided to the companies. Important aspects of this study 
were communicated to the TITCK as planned and agreed by the companies. 
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RESULTS 
The results of this study are presented in four parts: 
 
• Part I: General questions and company details. 
• Part II: Local requirements in Turkey and regulatory metrics. 
• Part III: Regulatory review process. 
• Part IV: The way forward for TITCK. 
 
Part I: General Questions and Company Details 
The questionnaire was distributed to thirty-eight global pharmaceutical companies and three 
local companies. Accordingly, a total number of twenty-one completed questionnaires were 
received with a response rate of 51% (Table 5.3). 
 
Table 5.3: List of companies that participated in the study 
International companies 
1) Abbvie 11) Glaxo Smith Kline 
2) Alexion 12) Janssen (Johnson &Johnson) 
3) Allergan 13) Merck Sharp & Dohme 
4) Astra Zeneca 14) Novo Nordisk 
5) Astellas 15) Pfizer 
6) Bayer 16) Roche 
7) Boerhinger Ingelheim 17) Sanofi 
8) Bristol-Myers Squibb 
9) Celgene 
18) Shire 
19) Takeda 
10) Eczacıbaşı-Baxalta 20) UCB 
Local companies 
21) IDE İlaç Danışmanlık ve Eğitim   
 
Throughout the study, several meetings were conducted with the industry associations and 
pharmaceutical companies in order to encourage their participation and clarify all aspects 
regarding the study. Nevertheless, some companies were hesitant and did not participate for 
several reasons. This was despite, the mitigation actions that were taken to address these 
concerns (Table 5.4). 
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Table 5.4: Companies’ participation objections and mitigated action plans 
Companies concerns Mitigation actions 
Legal concerns   Confidentiality agreement was attached to the questionnaire. 
 Third party directly collected and blinded the data for the analysis. 
Sensitivity of the requested 
data 
 Written confirmations within the confidentiality agreement and 
cover letter which ensured that; 
 Commitment to all terms of confidentiality and that no outcome 
reports or data would be shared with the authorities before 
discussion and agreement with the participating member 
companies. 
 No outcome or individual company data would be disclosed in the 
public domain or be available to a third party.  
 External reports or presentations of the data would include only 
anonymised figures. 
Unwilling to participate  Seven face-to-face/online meetings were organised with industry 
associations to encourage participation and obtain their support. 
 One online meeting between the European Federation of 
Pharmaceutical Industries and Associations (EFPIA) and AIFD 
was organised to emphasise the importance of the study and 
encourage participation. 
 Headquarters of international companies were informed about the 
study to obtain their endorsement and support at their affiliate 
level in Turkey. 
Lack of awareness of the 
study objectives 
 Three face-to-face meetings were organised with the companies to 
present the study elements and clarify all questions and concerns. 
 Preparation of a “Question and Answer” document for companies. 
Lack of time  Questionnaire pack was sent out to companies in two rounds. 
 Deadline to collect responses was extended three times. 
 
Details about the responding companies were analysed in order to obtain a clear 
understanding of their main characteristics as well as their views of the pharmaceutical 
regulatory environment in Turkey (Table 5.5). The majority of respondents were international 
companies who had been operating in Turkey for more than fifteen years and therefore had 
extensive experience of the authority’s review process. Moreover, the analysis identified that 
half the companies were marketing authorisation holders of between one and ten NASs and 
fourteen (67%) had no manufacturing site in Turkey. 
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Table 5.5 Background of the responding companies 
Company characteristics /Percentage (n = 21) 
Company Presence in Turkey 
0-5 years 
6-10 years 
11-15 years 
16-20 years 
 
Registered NASs by Company 
0-10 NASs 
11-50 NASs 
51 - 99 NASs 
>100 NASs 
 
Owning local production facility  
Yes 
No 
Other (Contact manufacturing  facility) 
 
2   (9%) 
6   (29%) 
0   (0%) 
13 (62%) 
 
 
10 (48%) 
4   (19%) 
5   (24%) 
2   (9%) 
 
 
3   (14%) 
14 (67%) 
4   (19%) 
Number of employees   
  1-50 employees 
  51 - 99 employees 
  100 - 499 employees 
  500 – 999 employees 
  >1000 employees 
 
Number of regulatory staff 
  1-4 employees 
  5-9 employees 
  10 – 14 employees 
  ≥ 15 employees 
 
Nature of the regulatory unit 
In-house  
Out-source  
Both  
 
3   (14%) 
2   (9%) 
11 (52%) 
3   (14%) 
2   (9%) 
 
 
8   (38%) 
9   (43%) 
2   (9.5%) 
2   (9.5%) 
 
 
18 (86%) 
0   (0%) 
3   (14%) 
 
Ten companies evaluated the general consultative process of the TITCK mainly prior to 
issuance a new regulation or announcement of a major change to be satisfactory; while seven 
stated that it was poor and only four companies indicated that it was good (Figure 5.3). 
 
Figure 5.3: Industry evaluation of the TITCK consultative process 
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Furthermore, the majority of companies (n=15) stated that it would be very valuable to have a 
structured framework for regular consultation with TITCK. Thirteen companies (62%) 
indicated that the efficiency of the TITCK has moderate impact on their company’s 
willingness to increase its investment in Turkey in areas such as research and development 
and manufacturing while six (29%) evaluated this impact as a major impact and only one as 
minor. 
 
Part II: Local Requirements in Turkey and Regulatory Metrics 
The second part of the questionnaire included the companies’ understanding of the local 
requirements in terms of clarity and enforcement of regulations for a New Drug Application 
(NDA) in Turkey. Thus, the majority (n=17) stated that in general the local requirements for 
NDA applications are clearly listed; however they are not fully enforced and subject to 
various interpretations. Only four companies reported that the related local requirements are 
clear, strictly listed and enforced (Figure 5.4).  
 
Figure 5.4: Clarity and enforcement of the local NDA requirements 
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as; Turkish GMP process, product quality control and laboratory analysis; post marketing 
variation requirements, orphan drug requirements and pricing (Table 5.6).  
 
Table 5.6: Companies’ description of how local regulations are not aligned with EU 
Deviation area Examples of companies’ quotes why not aligned 
1.GMP requirement o GMP inspection requirement for sites renewals is not 
aligned. 
o Parallel GMP process to the registration review is 
allowed only for prioritised products in Turkey; 
however this is applicable for all applications in EU. 
2.Product quality control and analysis o Analysis of the product in registration review is not 
aligned. This is carried out after approval as a market 
control in EU, however in Turkey; it is required during 
the registration process. 
3.Variation regulation o The post marketing variation guideline is not aligned. 
o Variation guideline is not updated and aligned with EU. 
4.Biosimilar regulation 
 
o Biosimilar regulation lacks the related guideline that 
defines the requirements for each therapeutic group. 
o Biosimilar guidelines are not in line with EU. 
5.Orphan drug regulation o There is no orphan regulation in Turkey. 
o Orphan drug regulation is not yet published. 
6.Line extension o Line extension regulation is not applicable in Turkey. 
o Line extension guideline is not published yet in Turkey. 
7.Pricing 
 
o Pricing procedure is based on fixed exchange rate that 
does not reflect the real current exchange rate. 
8.Administrative requirement o Sales permission requirement is not aligned with EU.  
o Additional CTD Module 1 documentation is required 
only for Turkey. 
9.Others 
 
o Lack of Supplementary Protection Certificate.  
o Duplicate submission cannot be made on behalf of the 
same company. 
 
Sixteen companies (76%) indicated that in general, the TITCK request more information 
today than three years ago for regulatory submissions of NASs. However, nine of these stated 
that additional requests are not aligned with international regulatory requirements, while four 
companies stated they are aligned and three being unsure (Figure 5.5).  
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Figure 5.5: TITCK requests that are outside international requirements 
 
The majority of the companies indicated that quality, Chemistry, Manufacturing and Control 
(CMC) and administrative data were the most frequent sections of the dossier for which 
TITCK requested additional information outside expected requirements and that the TITCK 
has never requested additional data relating to the non-clinical section (Figure 5.6). 
 
Figure 5.6: Sections of dossier where questions were outside standard requirements 
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Companies evaluated the current TITCK Good Manufacturing Practice (GMP) requirement 
introduced in 2010 that mandated the local accreditation of all manufacturing sites for 
pharmaceutical products. The GMP accreditation step is still a pre-requisite for all new drug 
applications except for those evaluated as prioritised products such as orphan and lifesaving 
medicines.  Accordingly, most of the companies (n=17) stated that they agree with the GMP 
requirements as long as they are conducted in parallel to the registration as subsequently this 
would not delay the review (Figure 5.7).  
 
Figure 5.7: Perception of the local GMP process by the Industry 
 
 
However, companies reported the average delay for NDA submissions to be twenty-two 
months since the GMP requirements were introduced and the range was identified to be 
between two and seventy-two months.  
 
While twelve pharmaceutical companies responded that they had no information on how the 
nomination process of departmental heads and reviewers at TITCK is determined, only two 
believed that this process is carried out based on scientific abilities and merits. Moreover, the 
majority of companies evaluated the TITCK reviewers’ scientific competencies and agency’s 
abilities to review biological and biotechnological applications as satisfactory. However, no 
evidence was provided by companies to support their perception (Figure 5.8).  
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Figure 5.8: Companies’ assessment of the TITCK scientific competencies 
 
 
Regulatory Metrics: 
This study identified that almost all companies have NAS applications currently pending 
approval at TITCK (Figure 5.9). Additionally, the median time to roll out to Turkey for New 
Active Substance (NASs) approved between 2012 and 2015 was determined (Figure 5.10). 
 
Figure 5.9: Number of NASs currently pending approval at TITCK 
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Figure 5.10: Approval timelines of NASs by TITCK (industry data) 
 
 
This analysis shows a composite of median interval duration for a NAS submission to TITCK 
after first approval anywhere in the world, followed by the median time of final TITCK 
approval for the same compound in Turkey. The methodology used in this analysis was based 
on data provided on the first approval date in the world, application submission and approval 
date by TITCK for NAS applications. These dates were used to calculate the duration of the 
gap between first market approval and TITCK submission, which was identified to be five 
hundred and seventy-three calendar days (nineteen months) for the period between 2012 to 
2015 and approval time for NASs by the TITCK identified to be six hundred forty-four 
calendar days (twenty-one months). Data are shown for approval dates for three different 
periods: this study period from 2012 to 2015 for seventy-three NASs provided by twenty-one 
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companies from the industry study. Data for the first and second periods, obtained from 
previous studies, are the period between 2010 to 2014 and 2011 to 2015 respectively. These 
data identified that the duration of the gap between first market approval and TITCK 
submission for the second period was two hundred and forty-eight calendar days (eight 
months) compared with only eight calendar days for NAS approved in the first period from 
2010 to 2014. This indicated an increasing delay and gap in the NAS applications to the 
TITCK after first approval anywhere in the world since 2010. The delay could be attributed to 
the introduction of the Turkish GMP regulation in 2010 where many companies were either 
hesitant or not able to submit their NAS applications due to the unclear GMP requirements, 
which was later on amended in 2012.  
 
Additionally, the approval time for NASs by the TITCK was identified to be six hundred 
forty-four calendar days (twenty-one months) for this study, five hundred and seventy-seven 
calendar days (nineteen months) for the second period and seven hundred calendar days 
(twenty-three months) for the first period. Thus, the mean TITCK approval time remained 
approximately the same for the three periods ranging from nineteen to twenty-three months. 
The number of NASs approved by the TITCK showed an increasing trend from 2012 to 2015, 
where it increased to twenty-five NASs approved in 2014 compared to seventeen NASs 
approved in 2012 (Figure 5.11).  
 
Figure 5.11: Number of NASs approved by TITCK (industry data 2012-2015) 
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The therapeutic classification of approved NASs was identified for the same period of time, 
where the highest number of approvals was granted mostly to oncology and antineoplastic 
agents, followed by endocrinology and antidiabetic products (Figure 5.12). 
 
Figure 5.12: Therapeutic areas of NASs approved by the TITCK (2012 – 2015) 
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have access to new medicines as they become available in the Turkish market approximately 
three and a half years later compared to first approval of the product in the world. Thirteen 
companies (62%) agreed that the maximum time for the TITCK to complete the review 
process for a NAS application should be twelve months (Figure 5.13). This is approximately 
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target approval stated in the regulation.  
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Figure 5.13: Companies’ view on the maximum time for the regulatory review of NASs 
 
 
However, in practice the mean approval time in 2015 for NASs in Turkey is two hundred and 
seventy working days which is around twelve months based on the TITCK data which, does 
not include the clock stop for question and answer that on average is around ten months for 
each NAS application according to the data of the regulatory metrics of companies. 
 
Part III: Regulatory Review Process 
Only five companies indicated that TITCK’s practices were aligned with global Good 
Regulatory Practices (GReP), while nine stated that they were not aligned and seven were 
unsure. None of the companies indicated that the review process is transparent in that files 
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However, the decision-making process within each milestone is not transparent. Eight 
companies stated that the review process is relatively transparent as files can be tracked from 
TITCK's letters or through the question and answer phases (Figure 5.14).  
 
Figure 5.14: Industry perception of the TITCK transparency 
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Figure 5.15: TITCK’s major sources of delay in approving new medicines 
 
 
The main sources of delay with the highest impact, as rated by the companies, were the lack 
of statutory timelines, performance criteria for reviewers and a consultation with the applicant 
company as well as insufficient agency meetings. This was followed by concerns about the 
efficiency of the review process, the types of questions raised during the review and the 
unavailability of staff resources and reviewers. Since the companies’ perception of the TITCK 
review expertise was found to be either satisfactory or good, consequently the impact on the 
review and approval timelines was considered low. 
 
A good review by an authority includes a comprehensive analysis of all clinical, non-clinical 
and quality aspects of new medicines to ensure the approval of their safety and efficacy. This 
also requires timely communication and consultation with applicants and reviewers as well as 
with other subject matter experts (Mussen, et al., 2007). In addition, the ability of a company 
to communicate easily with the regulatory authority during the review process is also 
important to track their application and enhance transparency. However, this study identified 
that fourteen companies (67%) described the ease of communication with TITCK on issues 
relating their files during the review process as poor (Figure 5.16). 
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Figure 5.16: Companies’ experiences with regard to TITCK communication 
 
 
All companies indicated that they have never been provided with scientific advice by the 
TITCK prior to filing an NAS application and the only stage they have the most 
communication with TITCK was during the review mainly when questions arise. Most of the 
pharmaceutical companies have liaison offices in the capital city Ankara to facilitate the 
timely communication with the authorities such as the TITCK, MoH and SGK. Thus, thirteen 
out of the nineteen companies stated that they set meeting times and agendas with the TITCK 
through their official liaisons, while nine companies declared that they also book their 
meetings with the TITCK online.  
 
One of the most important and challenging tasks of regulatory health authorities during the 
review of a new medicine is the timely conclusion of the assessment while safeguarding an 
appropriate evaluation of the benefits and harms. Therefore, recent studies have shown that 
regulatory health authorities are becoming interested in the implementation of different 
decision-making methods as well as a benefit-risk framework (Bujar, et al., 2016).  
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a structured benefit-risk framework (B-R) would be beneficial when the TITCK is reviewing 
the dossier (Figure 5.17).  
 
Figure 5.17: Companies’ view of the availability of a structured decision-making and 
benefit-risk framework at the TITCK 
 
 
Furthermore, companies evaluated the impact of the recent requirement by TITCK for a risk 
management plan for NASs with the majority of companies (n=19) stating that they found this 
requirement reasonable, whereas, two companies had no experience. Only three companies, 
who had previous experience with risk management plan submissions, indicated that this 
requirement had a negative impact on their review timelines. 
 
Part IV. The Way Forward for TITCK 
One of the main objectives of this study was to enable pharmaceutical companies to identify 
the main areas of improvement at the TITCK and the Turkish review process and accordingly 
provide a number of possible solutions and recommendations, which could help, address these 
issues (Table 5.7). 
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Table 5.7: Areas of improvements in the review process as suggested by the industry 
Improvement areas Examples of companies’ quotes 
 
Scientific 
commissions 
and committees: 
• Commissions’ regulatory review should be more structured and transparent.  
• Applicants should be allowed to discuss issues directly with commissions. 
• Commissions meeting must be regularly set. 
• Increase the number of commission members and frequency of meetings. 
• Assign a dedicated person from each commission for each application. 
• Create review SOPs for commission members to standardise the evaluation. 
Requirements 
 
• Regulations should be adapted as per global harmonised legislations. 
• Harmonisation and update of regulations in line with the EU legislations. 
 
 
Communication 
• Use of electronic correspondences (e-mails) to improve the review timelines. 
• Show the status of each review step online on: www.ebs.titck.gov.tr. 
• Enable companies to see and respond to questions online as they arise.  
• Allow companies to communicate with TITCK on phone and record the call. 
• Provide presentation opportunity for companies during registration review. 
• Build an online tracking system to enable the follow up of applications. 
Pre-submission 
meetings 
• TITCK should provide scientific advice and opinion before submission. 
• Enable pre-submission meetings with companies as in EU countries. 
GMP • Simplify the Turkish GMP requirement and inspection criteria. 
• Allow parallel GMP submission and review for all submissions. 
Transparency • TITCK could improve transparency and be open for discussion.  
• Review process and milestones should be communicated to companies. 
Timelines • TITCK should accelerate the review process.  
• Define target timelines during review processes for each milestone. 
Fast track • Prioritisation (fast track) criteria must be defined and clarified. 
Good review 
practices 
• TITCK should implement a more standardised review approach. 
• TITCK should be consistent in the decision-making process. 
• Implement a structured review and use of SOPs for the review process. 
 
Nine of the responding companies were satisfied with the level of industry-TITCK 
communication/dialogue on regulatory issues affecting the sector, while more than half 
indicated that they were not satisfied. In addition, fourteen companies believed that the 
TITCK has a long-term strategy with respect to the regulatory environment, however; eight 
companies evaluated the TITCK’s communication policy of its long-term strategy to be poor 
(Figure 5.18).  
137 
Figure 5.18: TITCK’s communication policy of its long-term strategy 
 
 
These findings suggest that there is room for improvement for TITCK regarding its 
communication policies with companies at all levels be it related to requirements, the review 
of applications or regulatory strategy and vision.  
 
The last part of the questionnaire included open-ended questions regarding both positive and 
negative regulatory developments in the last few years. Accordingly, companies identified the 
introduction of the prioritisation guideline as one of the important positive developments 
(Figure 5.19). Furthermore, the implementation of the electronic signature for applications, 
the regulation on the rational use of medicines was indicated as the most significant positive 
developments at the TITCK since 2011. Companies also indicated the following to be among 
the positive developments at the TITC: the introduction of the electronic submission system 
for all applications via the TITCK web portal, the enforcement of the pharmaceutical tracking 
and tracing system (ITS) with the barcoding and serialisation process as well as the utilisation 
of e-mails as a communication and appointment setting vehicle and the accreditation of the 
analysis laboratories of the TITCK. 
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Figure 5.19: The three most important positive developments at the TITCK since 2011 
 
 
 
Companies provided the three most important negative developments at the TITCK since 
2011, which had a major impact on the review process. Thus, the local GMP requirement 
enforced in March 2010 was the most cited development by companies. The majority of 
companies indicated that they understand the benefit of conducting local GMP inspections by 
TITCK, which is perceived to be of high quality. However, the requirement to complete this 
process prior to an NAS application as a pre-requisite to submission rather than to have it 
conducted in parallel to the review process is a major challenge and source of delay to 
approval. The frequent organisational changes at the TITCK, which affected all functions and 
levels including the scientific committees within the agency, were identified as the next most 
important negative factor. Fourteen companies (67%) indicated that the fragile structure of the 
TITCK and the constant change of roles, department heads and committee members mainly in 
2015 caused a significant backlog and delay in the review process and consequently in the 
approvals of critical NAS applications. 
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 In addition, some companies stated that the eagerness to quickly implement changes within 
the TITCK infrastructure resulted in frequent database changes and transitions, which caused 
data loss on several occasions. The third most cited negative development was the poor 
TITCK communication policies, which, according to half of the companies, had deteriorated 
since 2011 and had become more challenging and restrictive. This led to a significant 
regression in the transparency of the TITCK review and decision-making processes as 
perceived by the industry (Figure 5.20). 
 
Figure 5.20: The three most important negative developments at the TITCK since 2011 
 
 
Companies identified three major factors that could contribute towards an effective agency. 
These included the TITCK’s improvements in the areas of communication, transparency, 
building structured decision-making into the review process and utilising a benefit-risk 
framework. The majority of companies (n=16) suggested that the communication policies of 
the TITCK with the industry should be improved in order to facilitate mutual collaboration. 
Several companies commented that the TITCK should be more open to discussions with 
companies in matters related to requirements, applications and review process. Therefore, the 
general recommendation from the companies was for the TITCK to have a more structured 
framework for effective communication and consultation (Figure 5.21).  
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Figure 5.21: Companies’ suggestions of three major factors that could contribute 
towards an effective agency 
 
 
 
The second most highlighted improvement recommendation from the industry was related to 
transparency. Twelve companies (57%) suggested that the TITCK should be more transparent 
with regard to the review process, submissions and approvals. One of the suggestions was for 
the TITCK to publish the submission and approval dates of new products when they are 
granted marketing authorisations and to publish the names and addresses of the manufacturing 
sites inspected by the TITCK. This would facilitate the sharing of experiences and enable 
companies to make the most accurate prediction about their own approvals. Furthermore, 
companies indicated the implementation of a structured decision-making process and a 
benefit-risk framework as the third most recommended improvement area for the TITCK. If 
this was implemented it would enhance the transparency, predictability and timeliness of the 
review process.  
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Finally, companies cited the three factors that they saw as barriers to making a new medicine 
available in a timely manner. Seventeen companies emphasized that the GMP accreditation 
process is a significant barrier for the timely access to new medicines. This is because the 
local GMP certificate process is a pre-requisite for a MAA except for highly prioritised 
products. With an insufficient number of inspectors and the large number of applications 
pertaining to accreditation of new sites as well as manufacturing site changes, the process is 
taking on average twenty-two months. A second barrier, the long TITCK evaluation and 
review process which mainly depends on external reviewers. Therefore, the workload of the 
external reviewers is constantly increasing and consequently companies have to wait a 
considerable time for the commission’s decision.  
 
Finally, the third factor was related again to the poor communication policy of the TITCK 
with the applicants. Thus having structured consultative meetings, mainly in the pre-
submission phase, would reduce the number of questions during the review and therefore 
accelerate the approval. Other factors were those related to the pricing policy, additional 
requests from the TITCK which are outside the global requirements as well as indication 
restrictions. These occur due to the TITCK’s assessment of indication based on economic and 
public finance criteria, which is supposed to take place during the reimbursement process with 
the SGK rather than the review process at the TITCK. 
 
DISCUSSION 
Implementation of a good regulatory review process by health authorities has a major impact 
not only on the timely access of patients to their medicines but also on the growth and 
development of the pharmaceutical industry. Hence, a good regulatory environment often 
supports a sustainable investment environment where companies can receive authorisation 
approvals for their product and market these in a timely manner. Such an environment is 
characterised by three main principles which are: transparency, in the sense of sharing public 
policies and assessments with all stakeholders, predictability, which enables companies to 
anticipate outcomes and regulatory changes to manage their activities and investments in the 
most productive manner as well as establishing an open dialogue which reinforces 
communication between stakeholders and policymakers in the pharmaceutical sector 
(YASED, 2012). Therefore, evaluating the pharmaceutical industry’s views about the 
regulatory review process and timelines of the TITCK in terms of transparency, predictability 
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and ease of communication and how these impact the marketing authorisation timelines of 
their products in Turkey was essential.  
 
Within this study, the pharmaceutical companies in Turkey provided critical information on 
many aspects of the TITCK review practices, requirements together with positive and 
negative developments. These were evaluated in four main themes namely; communication 
and transparency, requirements, decision-making process as well as the agency structure and 
resources, which indicates the major challenges identified by the Turkish pharmaceutical 
industry.  
 
Communication and Transparency 
Consultative process and scientific advice meetings: this was evaluated by the industry 
where half of the companies stated that the TITCK consultative approach prior the issuance or 
major change of a regulatory requirement was satisfactory. However, most of the companies 
described the ease of communication with TITCK as poor before a regulatory submission or 
during the review process. The lack of a continuous consultation and constructive dialogue 
with the agency is perceived by the industry to be one of the major sources of delay for 
regulatory approval and thus creates a non-transparent and unpredictable environment, which 
ultimately cannot support a long-term investment strategy. Therefore, improving 
communication and implementing a structured framework for consultation by the TITCK with 
companies at all stages before the issuance of a regulation or during the review process is the 
most significant factor that could contribute towards an effective and high standard regulatory 
agency. Moreover, a continuous open dialogue can enhance the trust and reduce the number 
of questions raised during review. This will save the agency as well as the companies 
significant time and resources that will eventually be reflected in faster approvals and patients 
timely access to medicines.  
 
In this context, the TITCK can take certain measures to improve its communication and 
consultative processes by building a structured communication policy that should include a 
number of key elements (Figure 5.22). These can enhance the interaction of the agency with 
companies and fulfil significant improvements in the system such as; the introduction of a 
flexible scheduling system for meetings with companies for critical and urgent cases, enabling 
applicants to present their arguments to internal and external reviewers during the review and 
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the question and answer stages to clarify concerns and create a scientific platform for 
negotiation and finally, setting standards for pre-submission and scientific advice meetings 
with companies.  
 
It is well recognised by the industry that the TITCK currently has a good consultation process 
on regulations as they ensure that comments from all related parties are well received prior to 
issuing a major change or new regulation. However, a similar systematic approach is not 
implemented for pre-submission advice meetings.  
 
Figure 5.22: Aspects of good communication practices of a regulatory agency 
 
 
Since, the TITCK often provides administrative advice about the application dossier and on 
some occasions, they do provide scientific advice. These meetings are conducted officially by 
other regulatory agencies to maintain an open communication with the industry and ensure 
that resources are optimal and timely (EMA, 2014). Therefore, it is recommended that the 
TITCK structure the pre-submission meetings and describe these practices clearly in 
Good regulatory 
agency 
communication 
elements 
Consultation on 
regulation 
Pre-submission 
meetings 
Scientific 
advice 
Question and 
answer 
Long-term 
strategy 
communication 
Structured 
meetings and 
appointments 
Summary basis 
of approvals/ 
assessment 
reports 
Online / 
electronic 
tracking system 
Scientific 
presentations 
and negotiation 
platforms 
144 
guidelines in terms of scope, procedure, timelines and required fees. In addition, the TITCK 
could consider the use of scorecards as a vehicle to provide feedback and evaluations 
regarding application dossiers, which could provide a good assessment, and learning tool both 
for applicants and for agencies. Using a developed scorecard system can provide a standard 
and effective indicator of the regulatory performance in terms of the quality of the application 
and review process. This could equally facilitate the feedback at the end of each review both 
for regulatory authorities and companies (Salek, et al., 2012). 
 
Use of electronic communication vehicles: During the last decade, the TITCK has 
significantly developed its electronic infrastructure and online systems. The implementation 
of a national electronic tracking and tracing system (serialisation and barcodes) for 
pharmaceuticals in 2010 is a good example. Accordingly, the TITCK mandated the 
implementation of a barcoding and serialisation system for each product in the market to 
optimise the rational use of medicines and minimise counterfeit products. Furthermore, since 
2008 the introduction of an electronic submission via the TITCK web portal is well 
acknowledged as companies also receive a tracking number, which enables the follow-up of 
the file when questions are raised. However, there is room for improvement in tracking 
applications during the review process by companies, as the TITCK should establish an 
electronic tracking system to identify the stages of the file and enhance transparency as well 
as prompt more predictable standard timelines in the review process. In addition, the use of 
electronic online services and e-mail communications as web-based notifications can facilitate 
the timely communication between companies and the TITCK and therefore ensure the 
monitoring of the progress of applications, which can enable better understanding and 
planning when target times are exceeded. 
 
Question and answer: the question and answer stages vary in practice among regulatory 
agencies as different countries may ask different types of questions related to the same 
application. This depends on their interest, expertise area and country need. It is also known 
that the CMC area is the area where most agencies like the TITCK have expertise whereas the 
clinical and non-clinical areas are not frequently challenged except when an outstanding 
safety concern is raised. In addition, while some regulatory agencies batch questions and send 
them at different points of the review to the applicant, other agencies send questions as soon 
as they are raised and therefore the review clock is stopped each time. Batching questions 
during the review process can contribute to the predictability of the process and often help 
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companies better plan their resources. The TITCK could optimise the question and answer 
process by batching questions at each milestone and setting clear deadlines for companies to 
respond. This way, approval timelines would suffer less from delayed questions and answers. 
Moreover, the TITCK could provide companies with an online notification of the questions 
raised and allow companies to respond initially online or electronically in order to accelerate 
the process and clarify certain issues immediately.  
 
Long-term strategy communication: the TITCK publish on an annual basis a strategic plan 
that contains information about the plans and projects related to the previous year. However, 
for planning and forecast purposes, these reports could include future plans as well as long-
term strategies to be implemented by the agency in Turkey. The TITCK may also consider 
including budget and resource data and thus request companies to provide them with an 
estimate of major NAS applications that they are likely to submit in advance. Sharing the 
regulatory vision and strategic future plans of the agency with its stakeholders and vice versa 
would ensure that they are well prepared and would enhance predictability.  
 
Requirements  
In general, the Turkish pharmaceutical requirements for NDA applications are detailed and 
aligned with global ICH standards and hence as highlighted in this study, these requirements 
are partially aligned with those of the EU and are clearly listed. However, they are not fully 
enforced and subject to various interpretations. Furthermore, companies expressed their 
satisfaction with the improvements in the regulations area especially in relation to the 
issuance of the prioritisation guideline in 2016 and the introduction of the accelerated 
registration review process. However, it is important to emphasize that the TITCK will still 
need to make additional efforts to harmonise the marketing authorisation requirements with 
global requirements while updating the current ones in line with the EU directives. It is well 
recognised that the harmonisation of requirements facilitates the sharing of best practices and 
decision-making outcomes between regulatory authorities (nationally, regionally and 
internationally) and enables the optimum use of resources and efforts during the review 
process. It also contributes to building effective regulatory systems and leveraging solid 
collaborative networks based on trust and scientific expertise between authorities (Al-Rubai, 
et al., 2015). For instance, the Turkish GMP accreditation process, the scientific evaluation 
and approval of indications, the recognition of orphan drug designations and regulatory 
framework as well as the pricing procedure are the main aspects of the review process, which 
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were highlighted by the industry to be areas that urgently need to be aligned with international 
regulations and standards.  
 
Decision-Making Process 
More regulatory agencies are aware of the need to improve transparency by providing more 
information to stakeholders about the review and decision-making processes and outcomes. 
However, only a few agencies implement the main elements of transparency such as the 
provision of scientific advice and information related to the technical staff to be contacted 
during review and publishing the summary basis for their approvals. The summary basis of 
approval is a report where regulatory authorities detail the assessment outcome and 
mechanism of the decision-making process that was considered in approving a new medicine 
(Habibi & Lexchin, 2014). Currently only four countries; Australia, Canada, the EU and the 
USA are publishing these summary basis of approvals and providing assessment reports to 
companies. However, several other countries are in the process of reviewing their methods, 
criteria and the timelines and considering making available summary basis of approval to 
stakeholders. With this in mind, the TITCK may wish to consider publishing approval 
summaries to the public similar to the public assessment report (PAR) in order to verify the 
decision on the application. This would enhance the TITCK transparency since the PAR in the 
EU for example was developed to communicate a usable, transparent and detailed body of 
information regarding the approval of a new medicine (Papathanasiou, et al., 2016). 
Furthermore, the TITCK could have access to the assessment reports of other countries to 
obtain more insight of other authorities’ assessment and experience. This could be directly 
requested from companies and may contribute to accelerate the TITCK review process by 
putting some reliance on products reviewed or approved by other major authorities as 
recommended for consideration by the WHO (WHO, 2016). 
 
Standardisation of the review system helps to improve and facilitate the registration process as 
well as maintaining the supply of safe and effective medicines within a reasonable period (Al-
Rubai, et al., 2015). In addition, this would entail an assessment and approval procedure based 
on scientific evidence and use of structured decision-making and benefit-risk frameworks. 
One of the most important uses of Benefit-Risk assessment pertains to the approval of new 
medicines or new safety or clinical data by regulatory authorities in a more scientific and less 
complicated method, which would save time and effort and promote transparency (Mussen, et 
al., 2007). This will also contribute to a better coordination of the regulatory activities and 
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tasks across departments and reviewers and prevent delays in approvals (Li-Ling, et al., 
2013). In relation to this, the TITCK should consider devoting more effort to improving the 
quality of their decision-making process and ensure its consistency by implementing and 
enforcing detailed guidelines, internal standard procedures (SOPs), requirements and target 
timelines for each milestone of the review process. For this purpose, the TITCK may wish to 
implement some of the available methodologies for benefit-risk assessment frameworks that 
can be either descriptive or quantitative to increase transparency as these consist of a clear 
guide for good decision-making practices (PROTECT, 2017). 
 
Agency Structure and Resources 
One of the key concerns, highlighted by the companies was the constant change in the 
organisational structure of the TITCK as well as the change of staff, roles and responsibilities 
within the agency. Since these frequent changes often create a chaotic, fragile and 
unpredictable environment within the agency (mainly in 2015 and 2016) and cause significant 
backlogs and delays in the approval of new drug applications. Moreover, the reorganisation 
and introduction of systematic changes engendered the loss of several databases and critical 
reviewers’ outcomes and information related to applications, which affected the consistency 
of assessments during the different transitions.  
 
Additionally, as the majority of companies indicated, the nomination process of departmental 
heads and reviewers at TITCK as well as the assignment of the regulatory tasks for internal 
and external reviewers are unknown. This often creates the perception that agency 
nominations and assignments are not based on scientific abilities and merits and therefore 
may trigger the questioning of the assessment decisions and outcomes. Furthermore, the 
TITCK usually refers to external reviewers in order to ensure the involvement of scientific 
expertise in the review process. However, it was also identified that the pharmaceutical 
companies are unaware of how external reviewers and commission meetings take place or 
who the reviewers and contacts for their applications are and the scientific commission 
meetings to evaluate applications are clearly insufficient to meet the increasing demands for 
new product registration and approval. Therefore, it is suggested that the TITCK firstly 
maintain, if possible, a more stable structure of the agency, which is made known to the 
industry, and improve the communication and transparency between its different departments 
as well as between the agency and external stakeholders. It is also recommended to increase 
the frequency of commission meetings and establish specific committees with more frequent 
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meetings to handle urgent cases and specialized matters such the registration of life-saving 
products and evaluation of orphan drugs. Furthermore, the TITCK could reduce the 
registration review process inconsistencies across departments and the different commissions 
by implementing good review and decision-making practices with SOPs and assessment 
templates as well as minimising system complexities such as enabling the parallel review of 
GMP and separating the pricing process from the registration review to maintain the scientific 
evaluation.  
 
Finally, it is recommended that the agency improve resource management by investing in 
staff training to ensure they are well organised and equipped with the required competencies, 
as well as trained and empowered in sufficient numbers within the agency to achieve the 
ultimate target of patients’ access to medicines. This can be achieved by leveraging training, 
seminars and workshops to improve the experience of TITCK staff and collaborating more 
with industry associations, academia and international institutes to benefit from the overall 
available local knowledge as well as from the global experience of the pharmaceutical 
sciences and decision-making processes. In this way, the registration review process would be 
expedited resulting in faster approvals and enhanced patients’ timely access to medicines. 
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SUMMARY 
• The pharmaceutical companies who participated in this study provided critical 
information on the regulatory review process and timelines of the TITCK.   
 
• In general, companies were satisfied with the introduction of the electronic submission 
as well as with the tracking and tracing system. However, they emphasised that there 
are still opportunities for improvement at the TITCK in using more electronic and 
online services to expedite and facilitate communication with companies and enable 
follow-up of the application review. 
 
• The majority of companies emphasised the communication challenge they face with 
the TITCK and therefore they indicated that poor communication with the agency at 
the different stages of the NDA application have major negative impacts on the review 
process and timelines as well as on transparency. Accordingly, they have suggested a 
number of improvements in this area and further collaboration with the industry. 
 
• The participant companies were satisfied with the level of competencies and review 
abilities of the TITCK staff. However, they reported that the number of commissions 
and staff, mainly for those involved in the GMP and review process, should increase. 
 
• The study confirmed that most of the pharmaceutical companies suffer from 
significant delays in obtaining marketing authorisation approval for their products and 
therefore access of patients to their products is prolonged compared with other 
developed countries. This is mainly due to several factors such as long GMP 
processes; increased number of questions asked by the TITCK outside of global 
requirements, constant changes in the TITCK organisational structure and commission 
members, pricing procedure and long laboratory analysis steps.  
 
• Companies agreed that the implementation of a structured systematic decision-making 
approach and the use of a benefit-risk framework would be a possible way forward for 
the TITCK as it will result in an increased transparency, predictability and consistency 
within the registration process. In addition, it could enhance the scientific 
communication between the TITCK and the companies and promote improved 
communication with the stakeholders.  
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CHAPTER 6 
 
 
 
 
 
 
 
 
 
PATIENTS’ AWARENESS OF THE 
REGULATORY ENVIRONMENT AND 
ITS IMPACT ON THEIR ACCESS TO 
MEDICINES 
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INTRODUCTION 
Patients’ access to medicines is a major concern both for regulators as well as for the 
pharmaceutical industry. Currently it is estimated that two billion people worldwide still 
cannot access the medicines they need for their treatment mainly due to the increasing cost of 
healthcare expenditures (Access to Medicine Foundation, 2015). However, allocating the 
required resources for healthcare services and innovative medicines remains a common 
dilemma in many regions in the world particularly in low-income countries. The challenges in 
medicines’ access are being constantly addressed by global health organisations, governments 
and all other related stakeholders including the pharmaceutical industry in order to improve 
access to healthcare and medicines (EFPIA, 2010). This becomes crucial, especially for life 
threatening diseases, where access to innovative medicines makes an important difference in 
patients’ lives. Access to healthcare in Turkey has undergone dramatic changes in the past 
decade as a positive outcome of the economic growth and the “Health Transformation 
Programme” which was initiated in Turkey in 2002 (Akadagi, 2008). While, the reforms 
resulted in major developments in the pharmaceutical regulatory environment, which 
improved public access to health services, a number of measures were undertaken by the 
government to control the increasing healthcare budget, mainly pharmaceuticals to enable a 
sustainable financing source for a wider healthcare coverage in Turkey. (Tarmur, 2011).  
Furthermore, restricting healthcare expenditures will have a negative impact on patients’ 
access to high quality healthcare and innovative medicines. Thus, there could be a different 
perception of public and patients of the recent developments in the pharmaceutical 
environment and as to whether they are in line with those worldwide. Yet, so far, no available 
data was able to illustrate the impact of such developments on patients’ access to healthcare 
and the quality of available medication treatments. One of the key areas requiring 
investigation is to identify and assess the awareness of Turkish patients to those changes in 
the pharmaceutical regulatory environment and its impact on their access to innovative 
medicines in Turkey.  
 
OBJECTIVES 
The objectives of this study were to:  
• Identify public awareness and knowledge of the regulatory environment in Turkey. 
• Evaluate the impact of the regulatory and reimbursement processes on patients’ access to 
innovative medicines. 
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• Assess the patients’ perspective of their role in the decision-making process for the 
approval and reimbursement of medicines. 
• Identify patients’ views of the barriers to accessing medicines and the possible solutions. 
 
METHODS 
Study Design  
A comprehensive paper-based questionnaire was designed following discussion with patients 
and physicians regarding patients’ knowledge and concerns about the regulatory environment. 
This questionnaire was then piloted by distributing to a group of patients to determine its 
acceptability and its content validation. It was designed to be complementary to the two other 
studies, which were to examine both the pharmaceutical companies’ perspective as well as the 
TITCK perspective in relation to the regulatory environment in Turkey. The study was 
designed as a cross-sectional study, aimed at collecting data during a specific period of one 
month and included a total number of thirty questions to ensure a statistical standardisation 
and facilitate objective analysis and comparison. The questionnaire was designed in three 
parts; 
1. General demographic details; i.e. age, gender, educational background,  
2. Knowledge of the regulatory environment including the review and reimbursement 
processes in Turkey.  
3. Key challenges and possible solutions regarding patients’ access to medicines. 
 
The study timeline was planned to be three months from the time of the first patient enrolment 
to final outcome report. The approximate time for patients to complete the questionnaire was 
estimated to be ten to fifteen minutes. The schematic design of the study is summarised in 
Figure 6.1. Each text box in the diagram represents a key milestone and contains study-
specific information and the required activity for each step.  
 
Development of the Questionnaire 
Pilot study 
A pilot phase of one month for this study was designed with the aim of content validation to 
identify areas of improvements in the questionnaire in terms of wording, terminology, 
deletion and/or addition of questions to ensure that questions were clear and easy to 
understand. The questionnaire was translated from English to Turkish and back translated as 
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well as proof read to ensure quality of the translation. Thus, it was presented to patients in 
Turkish and the time required to complete the questionnaire was individually recorded.  
 
Figure 6.1: Schematic design of the questionnaire study 
 
 
Upon completion of the questionnaire, all participants were asked to provide input on the 
questions stated in Table 6.1. The pilot study was conducted with thirteen patients and five 
doctors as semi structured face-to-face interviews. Patients were selected with similar 
inclusion and exclusion criteria to the main study.  
 
Table 6.1: Pilot phase questions for content validation 
 In general how did you find the questionnaire? 
 How do you evaluate the language of the questionnaire? 
 Are there any questions which you found difficult to answer, and if so, which ones? 
Please state briefly why you think they were difficult? 
 Are there any repetitive questions in the questionnaire? 
 Are there any questions you think are not relevant? 
 Are there any other questions you would like to add? 
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Study Participants 
Main study 
The questionnaire was designed to be distributed to outpatients who were under treatment 
with medicines in the following therapeutic areas: oncology, cardiovascular disease, diabetes, 
rheumatoid arthritis, central nervous system and hormonal disorders. The study took place in 
Istanbul, the largest city in Turkey with a population of approximately 14 million (January 
2015) since it has the most representative demographic population in terms of ethnic groups, 
minorities, religion, cultural and educational background.  Furthermore, the study population 
was targeted to cover equal representation of patients from the different demographic groups 
and the following factors were considered: 
• Equal number of questionnaires to be distributed to both male and female participants. 
• Questionnaires to be distributed to adults from various ages (≥18). 
• Equal number of questionnaires to be distributed to patients with different demographic 
and social groups (employed versus retired), and different educational backgrounds. 
 
Participating in this study was voluntary. Patients were not compensated nor did they receive 
any payment for their participation. Yet, in order to be eligible to participate individuals had 
to meet all of the inclusion criteria (Table 6.2) and were asked first to read the patient 
information sheet (Figure 6.3) and accordingly sign and date an informed consent which 
includes a confidentiality declaration (Niles, 2006) (Figure 6.4). 
 
Table 6.2: Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
• Adults aged 18 years old and above. 
• Both genders, male or female. 
• Currently under chronic disease treatment 
and / or have received treatments in 
Turkey. 
• In good general mental and health status 
and capable to read, understand and 
complete the questionnaire. 
• Provide a signed informed consent form. 
• Those below 18 years old. 
• Those not on medication treatment. 
• Those not covered under the social security or 
any reimbursement system. 
• Those with any medical condition that would 
prevent their participation in the study. 
 
 
Data Collection and Processing 
The study was conducted in accordance with the local research requirements in Turkey. The 
validated paper copies of the questionnaire were distributed to patients’ associations, clinics, 
pharmacies and family medicine clinics and were collected within one month.  
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Figure 6.2: Patient questionnaire 
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Figure 6.3: Patient information sheet 
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Figure 6.4: Informed consent 
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Hypotheses 
The Turkish healthcare system has undergone significant change since the implementation of 
the Health Reform Programme in 2003 to enhance access to healthcare in all aspects. For 
example; through the different social security schemes provided by the government, the health 
insurance coverage of the Turkish population increased to 87% compared to 64% in 2003 
(OECD, 2015). As a result, patients in Turkey have increased access today to the various 
healthcare services including medicines. Furthermore, Turkish patients have a considerable 
amount of interest in general health issues and treatments and it is identified that on average 
each patient visits physicians eight times a year, which is more frequently than in other peer 
countries (OECD, 2014). However, patients’ awareness about the pharmaceutical regulatory 
environment as well as the decision-making processes of the regulatory bodies seems not to 
get the same level of attention in Turkey. Thus, the general perception is that the role of 
patients or patients’ organisations in informing which medicines need to be approved or paid 
for by the government is not as active compared to other countries (Noordman, et al., 2010). 
 
This study examined the following hypotheses, 
1. Patients have considerable interest in their treatment and medicines. 
2. Patients have little knowledge and understanding of the regulatory review and 
reimbursement processes. 
3. The perception of patients is that the Turkish healthcare system is not comparable to 
other developed countries. 
4. Patients in Turkey are not satisfied with their access to innovative medicines. 
5. Patients have little interest in being directly involved in decision-making with respect 
to the regulatory review and reimbursement processes. 
 
RESULTS:  
This study was designed to identify the awareness of Turkish patients in relation to the 
pharmaceutical regulatory environment, the approval, reimbursement and decision-making 
processes regarding new medicines and the impact of such changes on patients’ access to 
medicines.  
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Pilot Study 
The questionnaire was piloted among thirteen patients who were adults under active chronic 
disease treatment for more than five years and four doctors of different specialties (Table 6.3). 
 
Table 6.3: Participants’ demographic and therapeutic area distribution for pilot study 
Demographic Characteristics Doctors (n=4) Patients (n=13) 
Gender 
Male 
Female 
 
50% 
50% 
 
46% 
54% 
Age 
Median 
Mean 
 
44 
45 
 
65 
62 
Education   
Primary School 
High School 
Graduate 
Postgraduate 
 
N/A 
N/A 
N/A 
100% 
 
0% 
46% 
38% 
15% 
Therapeutic Area / Disease 
Endocrinology / Diabetes 
Cardiovascular  
Central Nervous System 
Oncology / Cancer 
Family Medicine 
 
25% 
25% 
N/A 
25% 
25% 
 
38% 
31% 
15% 
15% 
N/A 
 
The inputs and recommendations provided by the patients and physicians in the pilot phase 
were then gathered and analysed collectively. As a result, in general patients found the 
questionnaire relatively easy to read and understand (Figure 6.5) and appreciated their 
enrolment in the content validation of such a questionnaire where they have stated that it 
increased their awareness in relation to the regulatory environment in Turkey. Accordingly, 
some patients suggested adding a specific question to evaluate the role of patients in the 
regulatory review and reimbursement processes of medicines in Turkey. 
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Figure 6.5: Patients’ evaluation of the questionnaires’ language 
 
 
Additionally, 38% (n=5) of the patients stated they had difficulty in understanding some 
words and terminologies used in the questionnaire such as; reimbursement, regulatory review, 
registration approval and suggested that these words to be simplified. Patients were hesitant 
to answer the question related to the improvements in health care system in Turkey since 2012 
and thus suggested that this question should not be limited to a specific period. 
 
The inputs received from the physicians who participated in the pilot phase were very much 
aligned with the patients’ comments and thus emphasised the importance of reviewing the 
questionnaire again to simplify the wording and ensure that it is patient friendly and easy to 
read and understand. In the light of the above, the questionnaire was modified and updated to 
incorporate all the received comments and suggestions, where some questions from the 
questionnaire were deleted, some were merged and others were added and modified as per the 
inputs to ensure the readiness of the questionnaire for the main study (Table 6.4). 
 
 
 
54% 38% 
8% 
Very clear and understandable (I was
able to read and understand all
questions)
Moderate (In general the
questionnaire was clear but I was not
able to read and understand some
questions )
Not clear (I was not able to read and
understand most of the questions)
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Table 6.4: Questionnaire modifications as a result of the pilot study 
Question 
Change 
Pilot Study Main Study 
One page cover letter Two pages ‘Patient Information 
Sheet’ 
Added with more details 
for patients 
N/A 
 
Question 9: Do you always take 
your medicines as directed? 
Question added 
Q.12: …registered by the 
government? 
Q.12: …approved by the 
government? Word simplified 
Q.13: …how government’s 
registration process of medicines 
Q.13: how government approves 
the marketing of medicines 
Sentence simplified 
Q.14: … novel alternative 
medicines Q.14: innovative medicines Word simplified 
Q.16: Are you aware of how 
medicines are reimbursed … N/A 
Question deleted and 
merged with question 17 
Q.23: Five multiple choices Q.23: Seven multiple choices 
Choices added: 
□ Other, please name 
□ I have no information 
N/A 
Q.26 and Q.27 ‘…role of patients 
in informing which medicines 
need to be approved / paid by… 
Question 26 and 27 added 
Q.28: … three most important 
enhancements since 2012 in 
obtaining… 
Q.28: …three most important 
improvements in obtaining.. 
Question modified 
N/A Q.30: Do you have any further 
comments… 
Question added 
 
Main Study 
Characteristics of study participants 
A total number of three hundred and fifty questionnaires were distributed as paper copies to 
outpatients in ten clinics and twelve pharmacies in Istanbul. Additionally, face-to-face 
interviews were conducted with twenty-two patients while asking them to complete the 
questionnaire. Adult patients of both genders, on chronic disease treatment for more than five 
years were selected to participate voluntarily to conduct a face-to-face interview and were 
encouraged to share their inputs and experiences regarding the study. By the end of the study 
period, two hundred and ten patients completed the questionnaire and thus a response rate of 
60% was achieved among which 10% was interviewed face to face. Moreover, the results 
demonstrated a balanced representation of patient population in terms of demographic 
characteristics and background as shown in Table 6.5. Seventy four percent of patients 
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(n=155) were on medication for various chronic diseases from six disease areas namely 
(80%): cardiovascular, diabetes, hormonal disorder, CNS, nephrology and cancer (Figure 
6.6).  
 
Table 6.5: Characteristics of study patients 
Demographic Characteristics (n = 210) Background and Status (n = 210) 
• Gender 
Male 
Female 
• Age 
Median 
Mean 
• Age Range* 
Early Adulthood (18-39) 
Adulthood / Middle Age (40-64) 
Maturity (≥65) 
 
51% 
49% 
 
54 years 
56 years  
 
55 % 
19 % 
26 % 
• Education   
Primary School 
High School 
Graduate 
Postgraduate 
• Working status 
Retired 
Working 
Other, (part time, freelance, 
etc…) 
 
25 % 
31 % 
37 % 
8 % 
 
50 % 
34 % 
16 % 
*Stages of Social-Emotional Development (Erikson, 2015) 
 
Figure 6.6: Percentage of patients relevant to their therapeutic areas treatment 
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Out of the two hundred and ten participants, 77% (n=162) of the patients had a single disease 
while the rest of the patients had multiple diseases for which they were receiving various 
medications. Results showed that 55% (n=115) of patients were on chronic disease treatment 
for three to ten years and 20% (n=42) for more than ten years.  
 
The key results of the main study are presented in four parts: 
1. Patients’ awareness and knowledge of their medicines. 
2. Patients’ perception and knowledge of the regulatory and reimbursement environment 
and access to medicines. 
3. Role of patients in the regulatory review and reimbursement processes. 
4. Challenges and possible solutions to improve access to medicines. 
 
Part 1: Patients’ awareness and knowledge of their medicines. 
This study identified that 98% (n=206) of patients on chronic disease treatment were able to 
define their medical condition in general and knew about their medicines they take. In 
addition, 59% (n=124) of patients indicated that they always attempt to learn about their 
medicines from the various available sources (Figure 6.7) with 70% (n=124) of patients 
believe they get sufficient useful information from these sources about their medicines’ 
benefits and harms.  
 
Figure 6.7: Patients’ attempt to obtain information about their medicines 
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Accordingly, patients generally rely on their doctors to obtain information about their 
medicines. Pharmacists and the summary of the product characteristics (SmPC) are the 
secondary sources. Furthermore, 41% (n=86) of the patients stated that they rely on one 
source to get information about their medicines, while 59% (n=124) stated that they rely on 
several sources to learn more about their medicines, such as the summary of the product 
characteristics (SmPC), internet and pharmacists (Figure 6.8). 
 
While 67% (n=140) of patients declared that they get sufficient information about the benefits 
and harms of their medicines, 62% (n=130) of patients stated that the information they obtain 
about their medicines is very useful. Additionally, 85% (n=179) of patients indicated that they 
do recognise the importance of treatment compliance and therefore expressed that they are 
compliant in taking their treatments as directed.  
 
Figure 6.8: Sources of patients to obtain information about their medicines 
 
Reporting of adverse events 
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related to the reporting of adverse events by patients in Turkey. The culture and awareness of 
patients in reporting adverse events and pharmacovigilance cases was also evaluated in this 
study. Surprisingly, a high proportion of patients (91% (n=191) stated that they are keen to 
report adverse events with 78% (n=164) reporting directly to their physicians (Figure 6.9).  
 
Figure 6.9: Reporting of adverse events by patients 
 
 
Part 2: Patients’ perception and knowledge of the regulatory and reimbursement 
environment and access to medicines.  
This study identified that the majority of patients demonstrated a good knowledge of the 
pharmaceutical regulatory environment and the registration review and reimbursement 
processes. Although 84% (n=177) of patients knew that medicines had to be approved by the 
government, yet 81% (n=170) of patients stated that they are not aware of the details of the 
regulatory review process with the overall majority (73%, n=153) unaware of how long it 
takes the government to approve a new medicine (Figure 6.10). 
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Figure 6.10: Patients’ knowledge of the government’s timelines to approve a new 
medicine
 
 
Twenty-three patients (11%) believed that the government took between up to twelve months 
to approve a new medicine, whereas 16% (n=34) thought that it was more than two years. 
This coincides with the industry experience of between two to three years (Figure 5.13). 
 
Standard of Approval  
The standard of the regulatory approval process and access to medicines is critical for the 
health of a nation. As agreed at the European Council in December 2004, accession 
negotiations for Turkey as a candidate country was launched on October 3, 2005 and therefore 
similar to many other regulated industries in Turkey, the pharmaceutical requirements and 
standards have undergone a number of developments to establish an alignment with those of 
the European Union and enhance the standards of requirements and process (Ministry for EU 
Affairs, 2016).  However, 37% (n=70) of patients believed that the Turkish approval process 
to be of a lower standard compared to United States and Europe, whereas 25% (n=52) thought 
that it was of a similar or a higher standard (Figure 6.11). 
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Figure 6.11: Patients’ perception of government's standards compared to medicines 
approved internationally 
 
 
A significant proportion of patients (60% n=126) thought that new medicines only become 
available in Turkey after other developed countries, whereas, 70% (n=147) were under the 
impression that there are novel alternative medicines for their disease available in other 
developed countries mainly in the USA (49%) and the EU (44%) (Figure 6.12). 
 
Figure 6.12: Availability of novel alternative medicines 
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Reimbursement and Access to Medicines 
Although a key step in patients’ access to medicines is having the product registered and 
licensed by regulatory authorities, nevertheless, with the current economic climate and 
controls on healthcare expenditure, reimbursement is becoming the determining milestone of 
access to medicines.  The results indicate that 39% (n=82) of patients rated their access to 
medicines as excellent or good whereas 34% (n=71) stated that they were satisfied with the 
availability of their medicines, while 27% (n=57) rated their access as poor (Figure 6.13). 
 
Figure 6.13: Patients’ assessment of their access to medicines 
 
 
This study demonstrated that patients in Turkey knew more about the reimbursement system 
compared to the review process, where the majority of patients 75% (n=157) recognised that 
the government is the main payer, even though insufficient information is provided about new 
medicines. Almost half (49%) of the patients involved in this study stated that they were 
satisfied or very satisfied with the reimbursement system with 34% (n=72) describing access 
to new medicines as adequate in Turkey.  However, 28% (n=59) stated that they were not 
satisfied and 22% (n=46) indicated that they were unsure (Figure 6.14). 
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Figure 6.14: Patients’ evaluation of the reimbursement system 
 
 
Part 3: Role of patients in the regulatory review and reimbursement processes. 
Currently the role and responsibility of patients and patients’ advocacy groups in the decision-
making process of approving new medicines is becoming a high priority for all stakeholders 
including the pharmaceutical industry, the regulatory authorities and health technology 
assessment agencies (HTA) as well as payers. However, this study demonstrated that 71% 
(n=149) of patients stated that they do not have any role in the decision-making process for 
approving new medicines while 72% (n=151) stated that they do not have any role in the 
reimbursement process. Therefore, most of them indicated that they needed to be more 
involved in reimbursement 60% (n=126) as well as in the approval process 58% (n=122). 
 
Part 4: Challenges and Possible Solutions to Improve Access to Medicines  
Currently the key issues concerning access to medicines relate either to the challenges facing 
the regulatory authorities or the barriers experienced by patients. As a result of this study the 
following major challenges facing the government were identified by the patients namely; the 
cost of new medicines is high, there is a lack of government resources and scientific expertise 
which were recognised as the top three issues (Table 6.6). 
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Table 6.6: Major challenges facing the government in providing new-marketed 
medicines 
Challenge Percentage (n = 210) 
• Cost of new medicines is high 23% (n=48) 
• Lack of government resources 19% (n=40) 
• Lack of scientific expertise in government  18% (n=38) 
• Pharmaceutical companies pricing policies 14% (n=29) 
• Have no information  17% (n=36) 
• The patients’ needs not taken into account 10% (n=21) 
 
Within this study only sixty patients out of two hundred and ten (29%) were able to list the 
most important barriers they face in obtaining the medicines they need. The top four barriers 
were; the high price of medicines, their access to treatment, the lack of an appropriate 
healthcare system infrastructure and the unavailability of new products (Figure 6.15). 
 
Figure 6.15: Barriers to medicines’ access as identified by patients 
 
Similarly, patients were also able to offer some solutions to address these concerns, which 
were then grouped into four principal categories (Figure 6.16). The majority of the proposed 
solutions reported by patients were related to improving the health and pharmaceutical care 
systems (n=27), implementing better pricing and regulatory policies to enable timely access to 
new marketed medicines (n=18), as well as considering the patients’ needs and supporting 
their roles in the decision making process of approving and reimbursement of new medicines 
(n=7).  
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Figure 6.16: Principal solutions and patients’ statements 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION: 
Turkey with its large population and good educational level is a developed country and 
among first world countries (OECD, 2015). Its economy is developed and ranked as the 
world’s 16th among the G20 countries in 2015. Therefore, it was concluded from this study 
that patients in Turkey are as comparable to other developed countries in the world and they 
increasingly want to be more involved in the registration and reimbursement processes.   
 
The study aimed to evaluate patients’ perspective of the Turkish healthcare system and the 
regulatory review process; and thus assessed how comparable the results are to other medium 
size countries in terms of a scientific review. Additionally, the study aimed to evaluate the 
level of involvement and the role of patients in the decision making process of new medicines 
in Turkey. While it is crucial to evaluate the healthcare system services from the patients’ 
perspective to achieve the optimal outcome of treatments, patients’ active participation in the 
selection and use of their treatments has also been increasingly encouraged recently by all 
health organisations (WHO, 2002). Recent studies have demonstrated that making the patient 
a part of the process will also increase the patient’s compliance to the treatment (Maxwell, 
2009) as well as enhances the strategic development of medicines (Hoos, et al., 2015).  
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The study examined five hypotheses and thus the findings correlating to each hypothesis are 
discussed below. 
 
Hypothesis 1: Patients have considerable interest in their treatment and medicines. 
The results of this study identified patients’ current knowledge of their medicines as well as 
their compliance with their treatment regimens. The study showed a positive correlation 
between the patients’ knowledge and the duration of their medication. This was mainly 
identified among relatively educated (patients with high school or university degree) and 
patients with polypharmacy. Furthermore, their level of interest about their treatments and 
medicines correlates to their keenness to ensure treatment compliance and learn more about 
their medicines such as their use, benefits, harms and adverse events. 
 
The culture of reporting adverse events is an important aspect of modern patient safety and is 
vital to improve the healthcare quality (Verbakel, et al., 2014). Thus, a culture is described as 
the cumulative result of an entire set of common behaviours, experiences, beliefs, and values 
that reflects how things are done in a certain environment and therefore an assessment of the 
current culture to identify the behaviours, practices as well as to identify the areas for 
improvement, is an important step to establish a specific culture in the healthcare system 
(Scott, et al., 2003). The results identified that the culture of patients in Turkey is to rely more 
on their physicians in obtaining relevant information about their medicines and reporting 
adverse events. Therefore, to overcome the under-reporting problem of pharmacovigilance in 
Turkey, it is suggested that it is important to encourage a reporting culture mainly among 
physicians to enhance the reporting of adverse events to the Turkish Pharmacovigilance 
Centre within the TITCK and ensure that all important adverse events reported by patients are 
also reported to the authorities in a timely manner. Furthermore, physicians and pharmacists 
play a crucial role in guiding, consulting and educating patients about their medicines and 
other health related issues and processes. Therefore, these results support the hypothesis. 
 
Hypothesis 2: Patients have little knowledge and understanding of the regulatory review 
and reimbursement processes. 
This study has demonstrated the importance of the patients’ awareness, knowledge and role 
with regards to the decision-making process of registration review and reimbursement 
procedures in Turkey. Most patients in Turkey indicated that they know that the government 
must approve medicines before they are marketed. However, both the process of registration 
review and reimbursement are not familiar to patients and thus they seem to have little interest 
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in understanding these processes. Therefore, the public interest and level of patients’ 
awareness of the pharmaceutical regulatory environment in Turkey can be enhanced if the 
sources of such information and benefits are better explained to patients as well as appropriate 
tools being created to ensure their active involvement. From these results, this hypothesis was 
confirmed and therefore accepted. 
 
Hypothesis 3: The perception of patients is that the Turkish healthcare system is not 
comparable to other developed countries. 
The perception of patients is that there is a correlation between the efficiency of healthcare 
system and their access to innovative medicines in Turkey. As a result, patients in Turkey do 
not believe that they have comparable access to innovative medicines compared to other 1st 
world countries. Most patients in Turkey are under the impression that alternative novel 
treatments are available in other countries and that the regulatory review processes and 
timelines are of a lower standard compared to other developed countries. The study therefore 
identified that patients are unaware about early access and TITCK named patient supply 
programmes. These aim to ensure the timely access of patients who are in critical need of life-
saving medicines, prior to their registration approval in Turkey, which enables access to 
medicines within a similar timeframe to the developed countries. Moreover, early access to 
innovative medicines programmes constituted approximately 7% of the allocated 
pharmaceutical budget (SGK 2015) of the SGK, which is the main reimbursement body in 
Turkey. Therefore, it is suggested that both the TITCK and the SGK need to develop an 
increasing public awareness in relation to regulatory review and access processes in 
comparison with other countries globally. This would educate patients about early access 
programmes, which would ensure the timely access to innovative medicines for patients in 
critical need. This hypothesis was therefore accepted. 
 
Hypothesis 4: Patients in Turkey are not satisfied with their access to innovative 
medicines. 
When patients were asked to describe the three most important recent improvements in 
obtaining the medicines they need, they indicated access to medicines, improved health and 
pharmaceutical care as well as price. This was despite the major challenges they perceived 
facing the government namely; the cost of innovative medicines is still too high as well as 
lack of government resources and scientific expertise. Thus, the “Health Transformation 
Program” which was initiated in Turkey in 2003 has generated a number of developments in 
the healthcare services and was mainly appreciated by patients in several areas including 
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timely access to medicines. Patients indicated that they do recognise the governments’ efforts 
in enhancing the healthcare services and patients’ access to medicines through pharmacies 
and hospitals. Therefore, this hypothesis was not accepted. 
 
Hypothesis 5: Patients have little interest in being directly involved in decision-making 
with respect to the regulatory review and reimbursement processes. 
The role of patients in the decision-making process of approving and reimbursing new 
medicines by the government should be encouraged since currently patients do not have any 
active involvement in Turkey. Patients suggested that to ensure that their needs are met in a 
timely way, that patients’ associations become more involved in decision-making regarding 
new medicines and that there is a considerable public representation in the process. This is in 
line with the many international calls from regulators, pharmaceutical industry representative 
as well as academia to engage patients in in the pharmaceutical research and development, 
regulatory decision-making and healthcare access (Anderson & McCleary, 2015). 
 
Patients’ interest was mainly concerned with decision-making regarding access to medicines 
and reimbursement rather than the registration review process, since the general perception of 
patients was that the registration process of medicines is a technical procedure that requires 
more scientific expertise than the reimbursement. Face-to-face interviews with patients also 
identified that they think that they should be more involved in the reimbursement process 
since it is all about quality of life and thus namely through patient organisations, patients can 
share their own experiences with regards to their access to medicines and their use. Therefore, 
patient organisations have significant potential role to play in the reimbursement process. 
Studies showed that large and professional organisations seem to play an active role in this 
respect; they enable better accessibility of medicines for patients, negotiate to expand the 
coverage of the reimbursement for a larger group of patients as well as they lobby regarding a 
variety of medicines and better reimbursement conditions (Verbakel, et al., 2014). Within this 
study, it is concluded that the use of patient questionnaires online or via physicians, 
pharmacists and/or patients’ organisations together with the use of social media could raise 
the awareness of patients to regulatory changes and reimbursement procedures, which could 
enable more active participation from the public. These results confirmed that this hypothesis 
was not accepted as patients in Turkey have considerable interest in the decision-making 
process of medicines.  
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SUMMARY 
• This study has demonstrated the importance of patients’ awareness, knowledge and 
their role with regard to the regulatory review and reimbursement procedures in 
Turkey.  
 
• When patients were asked to describe the three most important improvements in 
obtaining their medicines, they indicated that it was access to medicines, improved 
health and pharmaceutical care as well as price. This was despite the major challenges 
they perceived facing the government namely, the cost of innovative medicines being 
too high as well as lack of government resources and scientific expertise.  
 
• Patients were willing to offer four principal solutions to address these concerns such as 
more collaboration between academic experts and government to enhance 
pharmaceutical policies and shorten the registration process, encourage involvement 
through patients’ questionnaires and online forms, more effort by the government to 
enhance patients’ timely access to medicines with lower costs and encourage 
healthcare professionals to raise the awareness of patients regarding access to 
medicines. 
 
• The role of patients in the decision-making process of approving and reimbursing new 
medicines by the government should be encouraged. Patients suggested that to ensure 
that their needs are met in a timely way that patients’ associations become more 
involved in decision-making by ensuring a fair representation in the process. It is 
concluded that the use of patient questionnaires online or via doctors and pharmacists 
together with the use of social media could raise the awareness of patients to 
regulatory changes and access procedures. 
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CHAPTER 7 
 
 
 
 
 
 
 
 
 
ASSESSMENT OF STAKEHOLDERS’ 
KEY ISSUES AND A PROPOSED NEW 
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PROCESS 
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INTRODUCTION 
Decision-making for approving a new medicine, from a health authority perspective, is a 
complex scientific process, which requires careful assessment of all the potential benefits and 
harms. Thus the success criteria for a regulatory authority to ensure the timely access of 
patients to new medicines is based on quality, safety and efficacy standards as well as a low 
risk of withdrawals from the market due to therapeutic failures, quality concerns or serious 
adverse events. In broader terms, the mission of a regulatory health authority is to protect and 
promote public health (Salek, et al., 2012). 
 
As a regulatory health authority, the TITCK has a significant role in fulfilling its 
responsibilities to the public, the pharmaceutical industry and other relevant governmental 
authorities as well as to its staff and reviewers. These include the responsibility for 
maintaining an efficient good review system to enable the approval of high quality and safe 
medicines in a timely manner, ensuring patients’ access to their medicines while safeguarding 
the phamacoeconomic impact on the healthcare budget and eliciting adequate transparency 
with the public and industry for the rationale behind the approval or rejection of medicines. 
This is not an easy task mainly because of the increasing number of NAS applications to the 
TITCK and the eagerness of pharmaceutical companies to complete the registration 
requirements to gain access to the market in the shortest possible time. However, the outcome 
from the TITCK and pharmaceutical industry studies demonstrated that the TITCK is facing a 
number of challenges in granting the timely approval of new medicines. Overall, the TITCK 
has a good review system, yet, there are some major barriers, which relate mainly to the 
structure and organisation, insufficient infrastructure, staffing issues, lack of a communication 
policy or a structured approach to decision-making as well as the challenges related to 
requirements and alignment with global standards. Therefore, it was essential to evaluate the 
regulatory review system and the key milestones individually to identify the type and impact 
of these barriers and consequently assess the ability of the TITCK to implement a successful 
standardised and efficient regulatory review system.  
 
The purpose of this research was to evaluate the regulatory environment and its impact on 
patients’ access to medicines in Turkey. The study began with an evaluation of the regulatory 
review process and approval timelines at the TITCK to understand the key milestones, review 
dynamics, internal procedures and quality measures. This was then followed with a 
comparative study between the TITCK and four regulatory agencies in Australia, Canada, 
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Saudi Arabia and Singapore, to explore the similarities and differences in the regulatory 
review process and good review practices between the TITCK and agencies. Similarly, the 
pharmaceutical companies’ experiences of the review process and the trends in new 
medicines approval timelines over the period from 2012 to 2015 were analysed. Finally, since 
the ultimate recipients of medicines are the patients, a study was designed to assess the 
knowledge and role of patients in decision-making for approving and reimbursing new 
medicines. This was a major study conducted for the first time in Turkey, which demonstrated 
that despite patients having little knowledge about the review process of medicines, yet they 
were generally aware of the challenges in medicines’ access and the agency’s capacity issues. 
 
Having identified the areas of concern from all relevant stakeholders, it is now possible to 
explore the opportunities to improve the Turkish review system. Therefore, this chapter 
examines the four studies to identify the common areas of concern between these stakeholders 
and brings together the related outcomes to provide recommendations for a new improved 
model for the TITCK if it aims to become a more efficient and effective regulatory agency in 
line with other mature health authorities and meet public expectations. Improving the 
TITCK’s capacity and ability as an agency will enhance the quality of the review process in 
terms of quality decisions and timelines, whilst streamlining the processes and improving the 
communication policies, which will enable faster access to new medicines with a better 
sustainable environment for the industry for investment and development.  By optimising its 
resources and improving the review process, the TITCK may also enjoy substantial cost 
savings as well as fundamental developments, which could lead the agency to become a 
reference for regulatory excellence in the region. 
 
OBJECTIVES 
The main objectives of this chapter were to: 
• Identify the key issues of concern facing the TITCK as they endeavour to become an 
international recognised authority. 
• Evaluate the main outcomes recognised by relevant stakeholders including the 
pharmaceutical industry and patients with regards to the regulatory review process. 
• Compare similarities and differences among the different stakeholders with a view to 
making new medicines available in an efficient and timely manner.  
• Propose a new improved model for the Turkish regulatory review based on the key 
issues identified by different stakeholders. 
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METHODS 
Stakeholders’ perspectives and suggestions for improving the regulatory review in Turkey 
were assessed from the outcomes of four major studies namely; 
1. An evaluation of the TITCK regulatory review process and timelines,  
2. An assessment of current TITCK regulatory review processes and timelines in 
comparison with other international, mid-sized regulatory health authorities,  
3. An evaluation of the experiences and views of pharmaceutical companies with respect 
to the Turkish registration review process, 
4. Finally an assessment of the awareness of Turkish patients concerning the 
pharmaceutical regulatory environment and its impact on patients’ access to 
innovative medicines. 
 
A comparative analysis between these four studies (Figure 7.1) highlights the challenges 
faced by these stakeholders as a prelude to making the necessary recommendations.  These 
facilitated the proposal of the new model. 
 
Figure 7.1: The contribution of the four studies to enhance patients’ access to medicines 
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RESULTS AND DISCUSSION 
The results of this comparative analysis are presented in three main parts:  
• Part I: Organisational structure of the TITCK and the regulatory environment. 
• Part II: Turkish regulatory review process. 
• Part III: Turkish regulatory review times and access of patients to new medicines. 
 
Part I: TITCK organisational structure and the regulatory environment  
The TITCK was established as a separate agency within the administrative structure of the 
Ministry of Health to regulate the pharmaceutical and medical device industry in Turkey. This 
follows the approach taken by Australia, Canada, Saudi Arabia and Singapore; the local law 
and regulations define the role and responsibilities of the TITCK, which are well known by 
the pharmaceutical industry. In addition, this study identified that the majority of Turkish 
patients were also aware of the government’s responsibility to approve new medicines. 
 
The organisational structure of the TITCK is publicly available on the agency’s official 
website. At present, they have a total staff of over one thousand with more than 25% having a 
medical background as either physicians or pharmacists. This is comparable to other mid-
sized regulatory agencies such as Canada, Saudi Arabia and Singapore. One hundred and 
forty-seven of the TITCK staff members are assigned as reviewers for marketing 
authorisation applications and product licences. In addition, nineteen committees of six 
different types within the TITCK carry out various scientific assessments. For this, external 
experts are selected from a list of one hundred and twenty for the assessment of scientific 
data. An examination of the organisational structure demonstrated that the TITCK considers 
itself scientifically competent and capable to conduct its own full review process (Type 3A 
assessment model) where in general the quality, safety and efficacy assessments are carried 
out in parallel, which is line with other mature agencies. Nevertheless, the resources and 
abilities of TITCK were perceived differently by the pharmaceutical industry with the 
majority of the participating companies indicating that the number of commissions and 
experts involved in the review process was insufficient for the increasing number of NAS 
applications submitted. This was considered a major area, which would have a significant 
impact as the industry think that the TITCK is under resourced. Moreover, the pharmaceutical 
companies believed that the current TITCK reviewers’ scientific competencies and agency’s 
abilities to review biological and biotechnological applications were satisfactory or good. Yet 
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the changeable structure of the TITCK and its staff as well as the insufficient number of 
reviewers and expert committees were the main cause indicated by the industry to delay 
approvals. In addition, patients were under the impression that the lack of government 
resources and scientific expertise were the major challenges facing the regulatory authorities 
in ensuring their timely access to medicines.  
 
According to pharmaceutical regulations in Turkey, a marketing authorisation approval by the 
TITCK is required for any pharmaceutical product prior to marketing in the country. A 
number of regulatory guidelines are issued and made available by the TITCK to guide the 
pharmaceutical industry and support their applications. Therefore, all pharmaceutical 
companies are fully aware of the application and approval requirements for any new 
medicine. This also seemed to be well recognised by the public since most of the patients 
indicated that new medicines had to be approved by the government prior to marketing 
although, not surprisingly, they were unaware of the details of the regulatory review process.  
 
Similar to other countries, the requirements for new drug applications in Turkey are fully 
aligned with the ICH. Thus, the application dossier must be prepared according to the CTD 
with quality, safety and efficacy modules covering both the active drug substance and the 
finished product. Nevertheless, the pharmaceutical industry’s perception is that, in general, 
local requirements for NDA applications are subject to various interpretations although they 
are clearly listed. They believe that these requirements are only partially aligned with 
international standards such as the EU and that sometimes, additional data requested by the 
TITCK are not always aligned with international regulatory requirements especially those 
related to CMC. Furthermore, companies expressed their satisfaction with the improvements 
in the regulatory area especially in relation to prioritisation and accelerated registration 
review, which were recently issued. However, they emphasised that the TITCK still needs to 
focus more on harmonising requirements such as; the Turkish GMP process, the scientific 
evaluation and approval of indications, product quality control and laboratory analysis; post 
marketing variation requirements, orphan drug requirements and the pricing procedure. 
Furthermore, it was a surprising finding that the majority of patients were under the 
impression that the Turkish pharmaceutical approval process and requirements to be of a 
lower standard compared to international and developed countries like the US and the EU 
(Table 7.1). 
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Table 7.1: The TITCK and pharmaceutical regulatory requirements 
Requirement TITCK Industry perception 
Public 
perception 
Other 
agencies 
Agency Structure, Role & Requirements 
Agency’s role in regulating the 
pharmaceutical environment and 
approving new medicines. 
Known Known Known Known 
Alignment of requirements and 
standards with ICH/ EU & 
International standards 
Aligned 
 
Partially 
aligned 
Not aligned Aligned  
Agency reviewers & commissions 
are sufficient 
Sufficient Insufficient Not known Not identified 
Agency’s abilities & capacities are 
adequate 
Adequate Adequate Inadequate * Adequate 
Clear roles and responsibilities for 
reviewers 
Defined Not defined ** Not available Defined  
* Lack of scientific expertise at government” is one of the challenges highlighted by patients in approving new medicines. 
**Majority of companies indicated that the TITCK structure, roles and responsibilities are not stable.  
 
Part II: Turkish Regulatory Review Process 
This study explored the Turkish review and assessment model, where the TITCK conduct a 
full review assessment (Type 3A) for all new active substance applications. While, any new 
marketing authorisation application can be submitted to the TITCK at the same time as any 
submission in the world, evidence of approval in the country of origin, EU or USA must be 
submitted prior to the final approval. This is similar to other regulatory agencies like Canada, 
Australia, Saudi Arabia and Singapore who also perform full review for some applications, 
but do not necessarily require authorisation by another reference agency. Some regulatory 
agencies such as Singapore and Australia utilise a risk stratification approach and conduct an 
abridged review where the product has previously been approved. This enables a faster 
approval and an improved management of limited resources. 
 
The majority of the pharmaceutical companies indicated that the TITCK’s review practices 
were not aligned with global GReP. However, the comparative study with other agencies 
demonstrated that the TITCK do have most of the quality measures of the regulatory review 
process in place, namely an internal quality policy, GReP system, SOPs for assessors, 
assessment templates, a dedicated quality assurance department and a scientific committee. 
However, an official GReP framework for the TITCK is not codified. In addition, 
pharmaceutical companies believed that the review process is not transparent as applications 
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cannot be tracked easily during the review process except through direct communication 
and/or question and answer. They also thought that the review process was not predictable 
and they also did not know whether the TITCK had a structured approach to decision-making 
(Table 7.2). These were among the improvement initiatives that seemed to be missing from 
the TITCK study when compared with other agencies. Finally, the majority of patients 
perceived that the review process is of a lower standard compared to international authorities 
and that the key elements for a high standard review model were inadequate including the 
lack of scientific expertise and standardisation of the decision-making process. 
 
It also appeared that the TITCK does not have a peer review system, which is considered by 
some authorities as beneficial. For example in the EU reports from the rapporteur and co-
rapporteur for a NAS are subsequently peer reviewed by the CHMP committee before the 
final decision is issued. Furthermore, the pricing process in the TITCK is carried out in 
parallel following the clinical and safety assessment while the details of the Risk Management 
Plan (RMP), labelling and technological evaluation are assessed in parallel. This again is a 
positive approach even though in Europe pricing and reimbursement are reviewed separately 
following the regulatory review. However, the pricing process is perceived by the industry as 
a delaying step to timely market medicines, even though it can be reviewed in parallel.  
 
Table 7.2 TITCK review and Decision-Making process 
Process Elements TITCK Industry Perception 
Public 
Perception 
Other 
agencies 
Implementation of a standard review 
model to approve medicines.  Agreed Agreed Agreed Agreed 
Standard processes for review 
procedures; SOPs, assessment 
templates. 
 
Partially 
implemented 
Not 
implemented Not available Implemented 
Agency scientific expertise and 
abilities. 
Accepted Not accepted Not accepted Accepted 
Implementation of Good Review 
Practices (GReP). 
Informally 
Implemented 
Not 
implemented 
Not known Implemented 
Review process transparency. 
Ability to track progress of 
application internally and externally. 
Transparent Generally transparent Not available Transparent 
Predictability of the review process. Predictable Not predicable Not known Predictable 
Utilisation of a structured-decision 
making process. 
Structured 
Not 
structured Not known Structured 
Structured Benefit-Risk approach Not available Not available Not known 
Available 
(except for SA) 
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Part III: Turkish Regulatory Review Time and Patients’ Access to 
Medicines 
The regulatory approval time for a pharmaceutical product is the time calculated from the date 
of submission to the date of approval by the regulatory agency, which includes agency and 
company time (Bujar, et al., 2016). The approval timelines of new medicines differs from 
country to country and from product to product. Nevertheless, many countries define in their 
regulations the target approval times to ensure the completion of the review process within a 
reasonable time frame provided that all required data are available and adequate. For example, 
the overall target approval time for a new medicine in the European centralised review 
procedure is defined as two hundred and ten workings days (two hundred and ninety-four 
calendar days) excluding the clock stops during questions and additional requests to the 
applicant (Wade, 2010).  
 
According to the regulations in Turkey, the overall approval timeline is set to be two hundred 
and ten working days for new drug applications. Furthermore, the prioritised accelerated 
review is defined as one hundred and eighty working days and for highly prioritised products, 
the target approval time is one hundred and fifty working days. In contrast, the TITCK mean 
approval times for the years 2013, 2014 and 2015 exceeded the agency’s overall target time, 
which indicated that there is room for improved timeliness, consistency and process 
predictability in the system. The study demonstrated that the TITCK has longer approval 
timelines compared with other major health authorities such as the EMA and the FDA and the 
PMDA (Bujar, et al., 2016). 
 
 Although the approval times at the SFDA, TGA and HSA from 2011-2013 exceeded agency 
target times, yet it would appear that the approval timelines in Turkey are still longer by two 
to three months compared to these countries. This was in line with the data for NAS approval 
timelines obtained from the pharmaceutical industry as well, where the median time for the 
TITCK approval was identified to be twenty-one months. This highlighted the fact that 
patients have access to new medicines as they become available in the Turkish market 
approximately three and a half years later compared to first approval of the product in the 
world. This also coincides with the general patients’ perception of the government’s timelines 
to approve a new medicine, which was more than two years. Thus, a significant proportion of 
patients thought that new and alternative medicines only become available in Turkey after 
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other developed countries (Table 7.3). Surprisingly, both the industry and patients have a 
common perception that the maximum target approval timeline for the TITCK should be 
twelve months.  
 
Target timelines for key milestones of the review process such as queuing, clinical assessment 
and expert committees’ timelines, are not defined in the regulation or in the agency’s internal 
SOPs. Thus, part of the delay in approval could be attributed to the time taken by the 
company to respond to agency’s questions. As industry experience also shows the question 
and answer phases can take fifteen months with an average of ten to fifteen questions received 
for each NAS application and an average of two to four months to answer each question. 
Therefore, setting deadlines for the question and answer phase should improve approval 
timelines. It is also suggested that the TITCK batch their questions and encourage companies 
to keep a systematic record of the number of questions received and response times.  
 
Table 7.3: Availability of medicines and target timelines of TITCK 
Process Elements TITCK 
Industry 
perception 
Public 
perception 
Other 
agencies 
The agency set target approval timelines for 
the review and approval of an application. 
Available Available Not known Available 
Target approval times are defined for each 
review milestone and scientific assessment 
of committees. 
Not 
available 
Not 
available 
Not known Available 
Question and answer response deadlines 
defined. 
Not defined Not defined Not known Defined* 
Target approval times are met by the 
agency within reasonable limits. 
Not 
achieved 
Not 
achieved 
Not known Achieved 
New medicines become available at the 
same time of other developed countries. 
Not agreed Not agreed Not agreed 
Agreed 
(except SA) 
 
* There is a 90 days’ time limit (clock stop) for sponsors to reply to questions from SFDA. However, until now SFDA still 
accept responses even if it exceeds the time limit 
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TITCK Workshop and Focus Group 
Reviewing the outcomes of the four studies and conducting analyses of all the common areas 
of concern led to a final step by key experts at the TITCK to make recommendations for an 
improved review system. This was achieved by conducting a two-day workshop with focus 
group discussions by the senior management of the TITCK in Ankara. The aim was to review 
the challenges and opportunities for the TITCK to improve their review system and ultimately 
become an international centre of regulatory excellence in the region. The workshop was 
organised in collaboration with the Centre for Innovation in Regulatory science (CIRS) and 
TITCK where the participants included the president, vice president and thirty-three staff 
members from different departments as well as external academic reviewers. Following the 
workshop, a full report was made available (Appendix IV). 
 
The objectives of the workshop were to: 
• Provide an independent assessment of the TITCK in comparison with other medium 
sized international regulatory agencies. 
• Understand the key issues of concern from the pharmaceutical industry and patients 
regarding the pharmaceutical regulatory environment and possible solutions. 
• Explain the importance of quality decision-making and a systematic structured 
approach to the benefit risk assessment of medicines. 
• Determine the challenges and opportunities for TITCK to become a Recognised 
Centre of Regulatory Excellence. 
 
The president of the TITCK, who spoke of the major developments achieved recently in 
Turkey through the Healthcare Transformation Program (HTP) since 2002, opened the 
workshop. During this time, several initiatives took place to examine the healthcare system 
from different perspectives and an international point of view, which helped significantly in 
improving the healthcare system. Therefore, he indicated that a similar approach could be 
valuable for the evaluation of the pharmaceutical regulatory review process in Turkey. He 
concluded that the TITCK is recognising the challenges they face regarding their review 
system and particularly in meeting target approval times for new medicines. Therefore, he 
emphasised that the agency is aiming to implement a number of improvements within the 
process including a systematic approach to monitor individual milestones. This is to fulfil the 
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TITCK’s vision to become a leading reference regulatory agency; this requires commitment, 
high quality work and partnership with national and international stakeholders.  
 
The workshop included five sessions where the objectives, methods and key outcomes of the 
four main studies were presented. Furthermore, there were two sessions explaining the 
structured approach for the benefit risk assessment of medicines and quality decision-making 
in medicines development and the regulatory review. These provided a comprehensive 
background to the structured approach for the Benefit Risk (B-R) assessment of medicines, 
which is key to improving decision-making in drug development and the regulatory review. 
The current B-R Frameworks implemented by other regulatory agencies were evaluated and 
examples of how these contributed to the improvement of the decision making process were 
presented. 
 
 The penultimate session was about Quality Decision Making (QDM) in medicines 
development and the regulatory review. Thus, the importance of QDM and the development 
of a decision making tool as well as the practicality and applicability of QDM practices in the 
regulatory environment, were emphasised. Finally, the last session of the workshop included a 
focus group with round table discussions aimed at identifying the key issues to be addressed 
by the agency. During this session, participants were organised into five separate groups and 
were asked to provide feedback to three questions in the light of the information they had 
been given (Table 7.4). Accordingly, the feedback established the basis for the key 
recommendations for an improved review model. 
 
Table 7.4: The three key questions for the TITCK round table discussion 
 
Q1.  
Please list the most important key issues that you believe as an agency should be 
addressed? 
Q2.  
What is the area you would like the agency to address in order to improve and become 
an “International Centre of Regulatory Excellence”? 
Q3.  
What would you like to change and improve in the regulatory review process of the 
TITCK? 
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Areas to be addressed and recommendations for the TITCK 
In the focus group discussions, the participants identified the most important key issues that 
TITCK should consider in order to become a “Centre of Regulatory Excellence” (Figure 7.2). 
 
Figure 7.2: Key issues for consideration by the TITCK  
 
  
 
TITCK organisation and capacity: it was suggested that the TITCK should increase the 
number of scientifically qualified staff/personnel in the organisation and ensure a stable 
structure as much as possible with clear roles and responsibilities to be made known to 
stakeholders. 
 
Training and staff competencies: participants recommended that TITCK create a formal and 
standard process for training within the agency to ensure a high calibre of reviewers as well as 
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enabling consistency and quality of assessment. Thus, the following should be considered to 
further improve the training process: 
 
• Establish formal induction training for all new employees. 
• Deliver focused training that is specific to the different scientific areas in order to 
increase the expertise of the staff and reviewers within their own areas of 
responsibility. 
• Increase the partnership with the other regulatory agencies, encourage secondments, 
and job shadowing as well as the participation of TITCK staff in international training 
abroad. 
• Ensure a standard process to transfer and share the best practices from those staff 
participating in international training. 
• Follow a structured approach for “on the job” and “in house” training for staff and 
ensure they are also monitored and evaluated in terms of knowledge understanding. 
• Leverage a transparent policy for staff training. 
• Establish a “Regulatory Science Academy” within the TITCK in collaboration with 
universities and/or the pharmaceutical industry where specific regulatory scientific 
topics and Good Regulatory Practice training can be delivered to both internal and 
external reviewers. 
 
Transparency and communication with all stakeholders: The agency should enhance the 
transparency and consistency of its decision-making process and improve its communication 
policy with its stakeholders. Thus, the following recommendations were provided: 
 
• Consider making available summary basis of approval for stakeholders and 
assessment reports for applicants to justify how and why the agency took certain 
decisions. 
• Implement a structured framework for pre-submission scientific advice/consultation 
meetings for the industry in order to minimise rejections, optimise the approval 
process and enhance communication with applicants before and during submission. 
• Increase the number of scientific commissions to meet the increasing number of 
applications. 
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• Establish a formal process for tracking all the review process milestones and target 
timelines. 
• Develop regulations and SOPs for standardisation/ alignment with international 
standards. 
• Increase the cross-functional coordination within the agency and streamline processes.  
• Implement a structured approach for the decision-making process and build quality 
systems to ensure consistency and business continuity. 
• Assign specific staff or departments for external communication to improve 
consultation with applicants. 
 
Agency infrastructure and quality management system:  it was suggested that the TITCK 
should improve its physical and electronic infrastructure including information technology 
and quality management system by: 
 
• Supporting the full adaptation to the (e-CTD) and enhance the review process and 
timelines through electronic tracking systems leading to faster communication with 
applicants.  
• Increasing its quality management systems and ensure a standard policy for quality. 
• Ensuring the efficiency and appropriate training of internal reviewers by preparing 
SOPs for the key tasks and clearly defining roles and responsibilities.  
 
Furthermore, participants identified two main areas where the agency should focus in the near 
future in order to progress its mission to become a recognised reference regulatory agency; 
Good Review Practices (GReP) and the standardisation of the decision-making process. 
Thus, the majority of participants indicated that the TITCK should prioritise the adoption of a 
structured formal approach for GReP and decision-making process and ensure that it is fully 
implemented and monitored. 
 
 For this purpose reviewing and importing the best practices from other regulatory agencies 
could be beneficial. In conclusion, having identified the key issues from the four studies and 
the TITCK focus group, Figure 7.3 summarises the recommendations to be considered in the 
improved review model. 
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Figure 7.3: Recommendations to be considered in the improved review model 
 
 
 
IMPLICATIONS FOR AN IMPROVED REVIEW MODEL 
In the light of the outcomes of the studies, a number of key recommendations were made by 
the pharmaceutical companies, patients and the agency’s senior management to address the 
challenges in the review process and access to medicines. These were mainly in the following 
areas:  
• Strengthening the structure and organisational capacity of the TITCK,  
• Alignment of the regulatory review process and requirements with international standards,  
• Implementation of a structured approach for Good Review Practices and Benefit-Risk 
assessment to become mandatory,  
• Monitoring the review milestones and establishing key performance indicators to achieve 
target approvals, 
• And enhancing transparency of the decision-making process. 
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Structure and organisational capacity of the TITCK 
It is recommended that the TITCK devote some effort to improving its organisational capacity 
and reviewing its capabilities by establishing a clear professional role for reviewers and 
experts and defining the responsibilities of the administrative tasks. This could optimise its 
limited scientific expertise for the assessment of new medicines and establish performance 
criteria for reviewers. By building a more stable structure, it could mitigate the turn over and 
changing roles of staff based on scientific merit as well as addressing the retention of 
expertise. Based on the solution proposed by patients and the recommendations from the 
agency’s focus group; it was suggested to increase the collaboration between the academic 
experts and the regulatory health authorities to enhance pharmaceutical policies and shorten 
registration by increasing the review capacity of the agency through training opportunities. 
The agency staff recommended that a “Regulatory Science Academy” should be established 
and be capable of delivering regulatory affairs training modules and conducting research 
programs in collaboration with universities and industry to continuously improve the 
regulatory review system. 
 
Another recommendation was related to the placements and secondments of the TITCK staff 
in other agencies, which would enhance the quality, and competencies of the staff. As the 
TITCK president stated in his opening presentation, the number of committees as well as 
committee members already has increased and should continue in response to the number of 
applications. Moreover, the number of internal reviewers with Ph.D.s has increased and this 
facilitated their active participation and membership within committees. This was again 
positive, nevertheless, the working principles and timelines of the committees should be 
reviewed by setting clear SOPs to define the roles and enhance collaboration with internal 
assessors. As a result, an optimum working environment for all scientific committees can be 
ensured while providing them with the internal technical support they need. 
 
Review model 
In the last decade, the TITCK had continuously improved the registration procedure and 
increased its staff level of expertise enabling it to conduct a full assessment and accept NAS 
applications in parallel with other mature health authorities such as the EMA and the FDA. 
However, it is suggested that the TITCK adopt different regulatory review pathways such as 
the verification model for products already approved by reference agencies or an abridged 
review model in the case of NAS applications, where the TITCK can conduct its own 
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assessment while placing some reliance on other agencies’ decision and approval thereby 
saving time and resources. Singapore, for example, conducts a verification review for all 
types of medicines, which are previously authorised by at least two reference agencies (EMA, 
US FDA, Health Canada and MHRA) (Hashan, et al., 2016), except for biological and 
biotechnology products and an abridged review if approved by one reference agency. 
 
Moreover, in terms of the assessment and review process, it seems that the TITCK my need to 
invest more effort to enhance the standardisation and predictability of the review process by 
utilising SOPs, detailed assessment templates and feedback forms. In addition, the agency 
would need to formally mandate the full implementation of all the elements of Good Review 
Practices and a structured approach for decision-making using a benefit-risk framework. 
These will contribute to the scientific quality level of the decision-making process as well as 
enhance consistency, efficiency, clarity, and transparency. Furthermore, the TITCK could 
consider publishing the summary basis of approvals (PARs for stakeholders) and assessment 
reports to be provided to the applicants. In addition, the TITCK could explore the possibility 
of conducting shared or joint reviews with other comparable regulatory authorities. 
 
Communication policy 
The outcome of these studies emphasised the importance of an effective open communication 
between the industry and the authority. Several examples were shared of some agencies where 
the key milestones of the assessment process are made available to the industry including key 
agency contacts for each application, which could facilitate dialogue during the review 
process. Moreover, it is recommended that the TITCK should have an official communication 
policy with all its stakeholders whereby all types of communication steps and vehicles are 
officially described and implemented in a structured way. These would include the following: 
• Share periodically the TITCK long-term vision and strategic plans. 
• Establish a structured formal process for consultation with stakeholders prior to the 
issuance of a new regulation or a change in local pharmaceutical requirements. 
• Develop standard procedures for scientific advice and pre-submission meetings with 
applicants before and during the review process. 
• Enhance the use of electronic communication tools to accelerate the exchange of 
information with applicants and the tracking of responses. 
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• Enable applicants to directly communicate with assigned contacts for each application 
and facilitate scientific presentations to committees when required. 
• Publish the summary basis of approvals to be shared with stakeholders while 
communicating assessment reports to applicants to justify the rationale behind the 
decision outcomes. 
 
Approval timelines 
The lack of resources, mainly human expertise in the TITCK contributes as well to the delays 
even though there is an effective collaboration and sharing of information between the TITCK 
and its external academic reviewers. Recruiting external experts can aid the TITCK with the 
shortage of human expertise, but there is a concern that this will influence the review quality. 
Additionally, delays in approval may also be related to the structure and working procedures 
of the committees. Therefore, as mentioned previously the TITCK should consider delegating 
the review and assessment of some variations or extensions to internal assessors in order to 
reduce the number of dossiers assessed by committees and enhance the committees’ scientific 
review thus allowing them to focus on new product applications and major clinical or quality 
variations. Although currently the TITCK has a manual system for tracking applications: they 
are planning to convert this into an electronic internal system, which will enable the 
monitoring of milestone timelines. Therefore, it is recommended that the agency define target 
times for each review milestone in addition to the overall target timeline and this information 
should be available to stakeholders. Thus, establishing an electronic tracking system with 
target timelines would enhance the efficiency and continuity of the review process while 
enabling the TITCK to monitor the timelines between milestones as well as to observe the 
time between first-in-world approval and approval in Turkey. Therefore, the TITCK should 
evaluate the resources required and the expected number of applications reviewed in order to 
meet the target times. This can be achieved by introducing a more collaborative systematic 
approach between the TITCK and the industry. Thus, pharmaceutical companies should notify 
the TITCK in advance of the expected number of major regulatory submissions including 
NAS applications at the time of their annual budget/resource planning. This could facilitate 
both the planning for the review process as well as enhance the transparency and 
communication prior to applications. Additionally, the agency should batch the questions 
raised during the review process and set reasonable deadlines for companies to respond. 
Similarly, this would enable companies to better plan their resources and maximise their 
efforts to reduce the clock stop period during the review. The findings from this study also 
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suggest that the TITCK could consider collaborating with other regulatory health authorities 
as well as increasing the amount of available resources to meet the target timelines. The 
TITCK have continued to put initiatives in place to improve the quality and timeliness of the 
review, which may explain the increase of its review performance in 2015 and the number of 
approvals granted within the same year. One area the agency has been concentrating on was 
the improvement of the electronic infrastructure and use of electronic systems to receive and 
record applications, track products, communicate with companies, handle some question, and 
answer cases.  
 
Aligning requirements and pricing 
The TITCK has been investing and updating guidelines and regulations to support the 
industry and facilitate the standardisation in many regulatory areas such as new drug 
applications, prioritisation, labelling, risk management plans, GMP process and clinical 
research applications. Such activities further improve consistency and predictability of the 
review, but have also influenced the overall approval time either in a positive or negative way 
as seen in the last decade. Therefore, it is important for the TITCK to consider strengthening 
and aligning its national regulatory requirements with global standards and the EU to ensure 
the timely approval and use of medicines. For example, the TITCK is involved in the initial 
pricing process of medicines, which is based on reference pricing and is conducted in parallel 
to the registration review. However, a separate body (SGK) in Turkey determines the final 
reimbursed price. Whereas in Australia and Canada, the pricing mechanism for medicines 
depends on a Health Technology Assessment and is determined by a review body 
independently of the registration review process (Bonner, 2010). This has three main 
advantages, firstly the pricing process is conducted independently of the review process, 
therefore the budget impact is not influencing the scientific assessment of the agency, 
secondly, the product approval is not impacted by pricing delays and thirdly the pricing 
decision is based on cost effectiveness data of the product rather than comparative pricing. 
 
Another important aspect that needs to be highlighted is the local GMP requirement as a pre-
requisite to a new medicine application. This process is found to be acceptable by the majority 
of pharmaceutical companies, only if it could be in parallel to the registration review process. 
However, currently it is not. Therefore, it is critical to consider a thorough analysis of the 
impact of the GMP step with regards to new medicines approval. In response to feedback 
from the pharmaceutical industry, the TITCK has recently carried out work to streamline the 
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GMP process. They focused on this area and the quality has improved significantly over the 
last five-years. The number of GMP inspectors and assessors increased from ten to forty. 
Nevertheless, the main critical challenge remains in having the GMP process as a pre-
requisite for the marketing authorisation applications as well as the fact that the TITCK still 
rely only on local GMP approvals. Therefore, it is crucial to streamline the process to allow 
the conduct and review of the GMP process in parallel to the registration review process so as 
not to impact the approval times and accepting other international recognised GMP approvals 
such as PIC/S to save time and cost both for the agency and the companies and ultimately the 
patients.  
 
As a result, considering these recommendations facilitated the mapping of an improved model 
with individual milestones, defined timelines and key enablers clearly described within the 
review process (Figure 7.4). The new model enables an effective parallel review namely for 
the GMP, pricing and quality control analysis as well as for the scientific assessment by 
committees. Moreover, it illustrates the key enablers and quality elements required to ensure 
that the review process is conducted in a timely, transparent, consistent manner leading to 
approvals of medicines based on their quality, safety and efficacy merit.  
 
Key Steps for the Proposed Review Model 
The key steps for the TITCK improved review model are each given a number and described 
in details in this section. However, some of them may not include a change and the key 
milestones that are changed have been highlighted in the following process flow (Figure 7.4). 
 
GMP Process 
The current GMP steps as demonstrated in this study require a pre-requisite approval, which 
can then enable a marketing authorisation application for a NAS. Therefore the proposed 
model includes firstly conducting the TITCK GMP in parallel to the review process which 
can start by submitting a GMP application at the same time as the new drug application. 
Secondly, the milestones for this process, though remaining the same, will have an overall 
target approval time of two hundred and ten working days so as to ensure that it is completed 
prior to the license issuance. Thirdly, with this model, it should be possible to accept other 
PIC/S countries GMP certificates in view of the fact that Turkey is currently in the process of 
becoming a member of PIC/S. 
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Figure 7.4: Proposed improved review model for TITCK 
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Marketing Authorisation Process 
Step 1 - Marketing authorisation application submitted 
This step in the current process requires the submission of an e-CTD application of the NAS 
uploaded electronically via the agency’s website. This step remains unchanged in the new 
model. 
 
Step 2: Receipt and validation 
This step involves the validation of the application in terms of the content of the file including 
the format and compliance to the required sections of the CTD dossier. The date of 
application is formally recorded and TITCK has to complete the validation review within 
thirty working days and in the case of an incomplete application, the applicant is requested, 
via an electronic mail, to complete the missing data within another thirty days. If the 
application is evaluated in a second validation review and missing documents are not 
submitted, the application will be rejected. This step has not changed. 
 
Step 3: Valid application accepted for review – Day 0 
Following the thirty days validation review, if the application is complete, the file is accepted 
officially and the date of acceptance is recorded formally and notified to the applicant via an 
e-mail, marking the start of the two hundred and ten (working days) registration review 
process. This is a proposed change to the review model. 
 
Step 4: Queue time (Thirty working days / forty-two calendar days) 
On acceptance of the file following the validation step, the application is held in a queue. The 
queue time should be thirty working days (six weeks). However, prioritised products are 
taken out of the queuing system and the time for fast track applications should be 
approximately two – four weeks.  
 
This step is proposed for the project management of the file and applications should be 
allocated to internal project managers to be prepared and presented to the scientific 
committees for further review. Thus, the committees are notified about the application receipt 
in order for them to plan their acceptance for review within the target of thirty days. At this 
step the applicant must pay the assessment fees required for the scientific review process to 
commence. This is a proposed change to the current review model. 
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TITCK project managers: The new model proposes the appointment of project managers, 
who are internal to whom files can be allocated following the validation step depending on the 
type of applications and their area of expertise. They would be responsible for managing the 
application and following it internally within the agency during the review by the different 
committees as well as being the contact point for applicants in case of questions or further 
clarifications. Moreover, internal project managers would also be responsible to consolidate 
the different assessment reports from the scientific committees to be presented to the scientific 
advisory committee for peer review and assessment for final approval. The advantage of 
having a project manager is that it provides applicants with a single point contact that is 
beneficial for communication and avoids the previous concerns of bias, which could occur if 
the contact was the reviewer. It has been shown in previous situations that this improves the 
efficiency, transparency and communication of the process.  
 
Step 5: Start of scientific assessment by committees in parallel (Sixty working days / 
eighty-four calendar days) 
The scientific assessment of the application is conducted in parallel by five scientific 
committees with a target time for the conclusion of their assessment in sixty working days. 
This includes the parallel assessment of clinical, safety, efficacy and technical sections by the 
current committees along with the external reviewers. These committees are the Clinical 
Evaluation Committee, the Technological evaluation committee, the Bioavailability and 
Bioequivalence Committee, the Pharmacological Evaluation Committee and the Risk 
Management and Pharmacovigilance Committee. 
 
Each committee will have to provide its scientific assessment report including the proposed 
questions to the project manager within the target time. These should have been reviewed 
based on a structured decision-making process taking into account the ten quality decision-
making practices and incorporating a framework for benefit risk assessment. 
 
The new model continues to employ the current committees in the TITCK. However, the roles 
and responsibilities of the committees, in particular for the previous clinical commission, will 
change as well as defining a target approval time for this step. Therefore, this is a new 
proposed process to be incorporated into the new review model, as it would save time, be a 
more efficient process and ensure that the committees are working within a consistent 
decision-making process in their areas of expertise. 
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Step 6: Submission of scientific assessment report 
The project manager should consolidate the assessment reports from the five committees as 
well as review the questions to avoid any repetitions to be presented to the scientific advisory 
committee assessment as a peer review. This is another new step proposed for the review 
model. 
 
Step 7: Review of submission by advisory committee (Thirty working days / forty-two 
calendar days) 
The advisory committee would review the consolidated report prepared by the project 
manager and assess whether the suggested questions are valid and are not already answered in 
the submission. The advisory committee may also suggest additional questions. In this way, 
the advisory committee would provide a peer review of the overall submission, which is in 
line with the recommendation made by the TITCK focus group and reflects the current review 
model in EU where the CHMP peer reviews the reports from the rapporteur and co-rapporteur 
regulatory authorities to ensure consistency and validity of the decision. 
 
Step 8: Additional information requests from the applicant  
In case there is any additional information required by the advisory committee from the 
applicant, questions should be batched and sent to the applicant online by the project 
manager. This is a new approach for the TITCK to consider when communicating questions 
to the applicants during the review. 
 
Step 9: Applicants response to additional request (Thirty working days / forty-two 
calendar days) 
Once the additional requests and questions are sent to the applicant, a thirty working-day 
period would start in order for the company to respond. Nevertheless, if required, applicants 
could request an extension to respond while the review clock would stop. Thus batching the 
questions and establishing deadlines would enable companies to anticipate the type of 
questions they might receive in order to be prepared to meet the target times and consequently 
plan the required resources. In addition, this would ultimately encourage applicants to ensure 
that their local regulatory representatives are well trained with the appropriate level of 
expertise required to coordinate the responses. Applicants may also be given the opportunity 
to present to the project manager and committee if further clarification is required. This is a 
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new approach to handle the questions and additional requests from the TITCK by the 
applicants, which is in line with other established authorities such as the EMA. 
 
Step 10: Assessment of response (Thirty working days / forty-two calendar days) 
Once the response is received from the applicant, the project manager would coordinate and 
consolidate the reports, which are to be submitted to the advisory committee for their final 
peer review. 
 
Step 11: Final labelling and SmPC approval (Twenty working days / twenty-eight 
calendar days) 
As soon as the advisory committee provides its positive opinion on the application in view of 
all the additional information submitted by the applicant, the final review of the proposed 
labelling and SmPC would commence. This would be based on the recommendations of the 
pharmacological committee and thus the final review will be made by the administrative and 
licensing department to approve the final SmPC and patient leaflet based on the provision of 
the commercial samples. This step would be completed in twenty working days after which 
the applicant would be notified. This step is currently in place; however, with the new model 
it would have a structured approach with a target approval time. 
 
Step 12: Sponsor notified of decision and provided with an assessment report (Ten 
working days / fourteen calendar days) 
Once all the review steps as well as the GMP and the quality analysis are completed in 
parallel, the overall assessment by the agency should be made available to the applicant where 
the rationale for the decision and a summary basis of approval are provided with a notification 
that the authorisation license would be issued in ten working days. At this stage, the applicant 
must pay the required fees. This is a new step proposed to be included in the review model as 
it would enhance the transparency of the decision-making. 
 
Step 13: Authorisation granted and authority issues License 
The final registration approval and authorisation license is provided to the applicant and the 
approved SmPC will be published on the TITCK website. 
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Pricing Process: 
The new model suggests the separation of pricing from the scientific review process and this 
should be under the jurisdiction of a different department within the TITCK and independent 
of the registration review process. Thus, it should commence at the same time as the scientific 
review to ensure that only accepted applications are assessed in terms of pricing. The current 
reference pricing system can continue based on the five reference countries but the calculation 
should be based on the relevant exchange rate. However, as the existing pricing process 
allows, the Pricing Evaluation Committee (FDK) can still review price negotiations based on 
the pharmacoeconomic evaluation. Therefore, the process remains unchanged, although the 
sequence has been modified. 
 
Quality Control and Laboratory Analysis process 
The quality control and laboratory analysis of the new medicine can start at any time in 
relation to the marketing authorisation review process. Thus in practice this step is initiated as 
soon as the scientific review of the application commences and can be conducted in parallel to 
the registration review process. Therefore, this remains unchanged in the new model, 
however, it is also suggested that only the first commercial batch is subject to laboratory 
analysis. 
 
In conclusion, the new proposed model has a number of advantages in terms of providing an 
optimum use of the TITCK capacity and resources as well as enhancing the approval 
timelines. It suggests setting target approval times for each milestone, which could facilitate 
appropriate planning of the applications to be allocated to each committee and enhance the 
predictability of the process. Furthermore, the TITCK could benefit from the use of project 
managers who are scientifically qualified agency staff and who could both coordinate the 
assessment of applications and participate in review committees to provide the administrative 
support required for each scientific committee. This could create an effective tracking and 
monitoring system of applications and provide overall governance on the review process 
enabling the TITCK to meet its targets and achieve timely approvals. 
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SUMMARY 
• This study focused on assessing the TITCK regulatory review process, evaluating its 
main dynamics and characteristics as well as the quality measures and systems 
implemented by the agency to ensure the timely approval for safe, effective and high 
quality medicines. 
 
• A comparative analysis of the outcomes from the four studies identified the common 
key issues that need to be addressed when developing and improving the review 
model, which is a prelude to making appropriate recommendations. 
 
• The comparative analyses were presented in three parts namely, the organisational 
structure of the TITCK and the regulatory environment, the Turkish regulatory review 
process and the regulatory review times as well as patients’ access to new medicines. 
 
• A final step in the critical assessment of the outcomes was achieved during a two-day 
workshop with a focus group study with TITCK experts who reviewed the challenges 
and opportunities to improve the review system in order become an international 
centre of regulatory excellence. 
 
• A number of recommendations for a new improved system for the TITCK were 
identified namely enhancing the organisational capacity, alignment of the 
requirements with international standards and streamlining the review process and 
timelines. 
 
• It is recommended that the TITCK implement a structured approach for GReP and the 
Benefit-Risk Assessment of medicines to enhance consistency, predictability and 
transparency of the decision-making process. 
 
• The TITCK should work towards streamlining the regulatory review process by 
implementing a systematic approach to measure its regulatory review performance 
based on its capacity the number of applications received, reviewed and approved. 
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CHAPTER 8 
 
 
 
 
 
GENERAL DISCUSSION 
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INTRODUCTION   
The TITCK is a young and dynamic agency with a focus on implementing learning with an 
improving culture at all levels in order to keep pace with the rapid development of medicines. 
Thus, a reforming period has been initiated within the TITCK since 2015 mainly in the review 
and approval system for medicines and medical devices. Accordingly, eight main areas have 
been identified as success factors for an efficient regulatory environment. Each of these 
should be compatible with the other and the TITCK has taken appropriate action to ensure 
certain concrete improvements within each area, which includes:  
 
1. Streamlining the GMP process: The GMP accreditation processes and inspections 
should be conducted in optimum conditions. The TITCK focused on this area and the 
quality has improved significantly over the last five-year period. The number of GMP 
inspectors and assessors increased from ten to forty. There was an important focus on 
enhancing the competency level of inspectors as well as training the TITCK GMP 
experts through different means such as participating in the EMA related meetings, 
conferences and the organisation of in-house high level GMP training. Moreover, the 
TITCK submitted a full membership application to PIC/S in May 2013 and was 
recently inspected to become a full member, which is expected to be finalised shortly. 
2. Laboratory analysis and quality: A significant effort was particularly made to 
improve the physical infrastructure and quality of the laboratories used for the analysis 
of medicines, which included the renovation of the laboratories used as well as 
investing in new modern technological equipment and tools to enhance the reliability 
of the laboratory tests and analysis.   
3. Risk Management within pharmacovigilance: The TITCK introduced a number of 
measures to ensure the safety of medicines by implementing risk management plans. 
Thus, the TITCK has significantly improved the preparation and control of Risk 
Management Plans related to new medicines. 
4. Clinical Research: Several action plans and new regulations were put in place to 
improve the regulatory environment for the conduct of clinical trials and the scientific 
evaluation of medicines in Turkey. 
5. Commissions and expert committees: The number of committees as well as 
committee members has increased over the past few years in response to the 
increasing number of applications for review. The TITCK also increased their working 
time and enhanced the collaboration between their staff and external assessors. They 
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increased the number of qualified TITCK staff with Ph.D. degrees and facilitated their 
active participation within committees. In this way, they ensured an optimum working 
environment for all scientific committees while providing them with the technical 
support they would need. 
6. Administrative reviews: The reviews were pursued under two departments 
previously however, the bureaucratic barriers between these departments were 
decreased to streamline and improve the review processes.  
7. Information Technology (IT) systems: The IT infrastructure of the TITCK has 
improved dramatically over the past few years. Currently e-submissions and e-review 
systems are well established and functioning and there are still more initiatives and 
plans to implement and expand the use of electronic systems. 
8. Communication with the Industry/ applicants: The TITCK is striving to ensure that 
all the requirements are clear for the applicants so that sponsors can make complete 
and precise submissions, which can progress on time. For this purpose, the TITCK is 
continuously organising workshops and meetings with the pharmaceutical industry to 
discuss processes and areas of concern. As a result, such dialogue can also be 
considered as a training opportunity for the industry. 
 
With these in mind, the limitations of the current registration review system of new medicines 
in Turkey are generally related to delayed approval timelines as it was identified that the time 
required for a new medicine to reach Turkish patients is longer in comparison with other 
developed and comparable countries. This is mainly due to the misalignment of local 
requirements with global standards, TITCK capacity and structural issues, ineffectiveness 
monitoring, the disconnection of key review milestones, lack of overall governance of the 
review process, inconsistent concerns about the decision-making process as well as internal 
and external communication challenges. 
 
Thus, the main objective of addressing these limitations was to identify the opportunities for 
the development of a new improved review model, which could enhance the current approval 
process and accelerate the patients’ access to medicines. For this purpose, this research study 
evaluated the Turkish regulatory review process and its impact on patients’ access to 
medicines. Thus, four studies were conducted to evaluate the key issues from the viewpoint of 
the TITCK, other comparable regulatory agencies, pharmaceutical companies and patients. 
Accordingly, data collected from each study were analysed and reviewed individually in order 
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to determine the different areas of concerns and perceptions about the Turkish review process 
and access to new medicines.  
 
The study commenced with a thorough examination of the TITCK review system as well as 
the agency’s dynamics and key milestones influencing the approval process and timelines in 
chapter three. The focus of the second study in chapter four was to evaluate the Turkish 
review process in comparison with other mid-sized regulatory agencies with the aim to gain 
more insight into the key characteristics of the Turkish review system. This included the 
identification of the similarities and differences of the regulatory review process and the 
quality elements employed by each authority to optimise the decision-making process and 
outcomes. Being a critical stakeholder in the pharmaceutical regulatory environment, the 
pharmaceutical companies’ experiences concerning the Turkish review process was also 
examined in chapter five. Similar previous studies were conducted to evaluate the regulatory 
review systems in several emerging countries such as Iran (Mostafavi, 2011), the Gulf region 
(The Gulf Cooperation Council (GCC)) (Al-Essa, 2011), Saudi Arabia (Hashan, et al., 2016) 
and Jordan (Al Haqaish, et al., 2016). Each study included different methods of data 
collection and analysis from different sources of regulatory agencies where the regulatory 
performance of these agencies was evaluated in terms of review/approval times and quality 
measures employed in decision-making.  
 
Moreover, comparative studies with similar data obtained from pharmaceutical companies 
and/or other regulatory agencies were incorporated to evaluate the regulatory environment 
from different perspectives and identify the key areas to be addressed. For example, the Saudi 
Arabia and Jordan studies included similar comparative evaluations with other mid-sized 
regulatory agencies in Australia, Canada and Singapore with the result of developing similar 
proposals to help the agency improve its review process to become an internationally 
recognised reference agency. For example, to optimise agency resources, it was recommended 
that the agencies implement a risk-stratification approach utilising a verification review for 
new medicines that have been approved by two or more reference agencies and conducting an 
abridged review for products that have been assessed by only one reference agency (Al 
Haqaish, et al., 2016).  
 
Furthermore, the findings of these studies demonstrated that although most of the regulatory 
authorities in the emerging markets recognise the importance of transparency and open 
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communication, yet they publish very limited information, which is mainly related to the 
approval dates of the marketing authorisation of new medicines. Therefore, these studies 
recommended the implementation of standard approaches for decision-making and publishing 
summary basis of approvals to enhance transparency as one of the key quality elements of 
GReP (Walker, et al., 2006). In addition, harmonising regulatory requirements with 
international practices and the standardisation of the review process by adopting assessment 
template and SOPs were also proposed in these studies in order to minimise variations in the 
review procedures and approval times (Al-Essa, et al., 2012). 
 
Interestingly, the findings and proposals of this research study were generally in line with 
those of previous studies and mainly related to enhancing transparency, predictability and 
timeliness. Nevertheless, there were special aspects and outcomes for this research project, 
which included a unique study that evaluated patients’ approach and knowledge of the 
regulatory environment in Turkey and the impact of the Turkish review process on their 
access to medicines. This study identified that Turkish patients have a reasonable 
understanding and interest in the pharmaceutical regulatory environment where they were 
able to recognise the positive developments made by the authorities to improve their access to 
new medicines as well as the key challenges for faster approvals. Moreover, in terms of 
requirements, the major concern within the Turkish review process and timely market access 
was identified to be related to the local GMP process and pricing. The quality elements of 
review practices including transparency and communication policies as well as the TITCK 
capacity and organisation were among the key areas of concern compared with other 
regulatory agencies. 
 
The analysis of the outcomes from all the studies in this research project in conjunction with 
review of previous studies, facilitated the development of a proposed improved review model 
for the TITCK. The main outcomes of the four studies were then discussed with senior 
management and experts of the TITCK in a focus group and round table discussions to affirm 
the identified key issues. This assisted in the establishment of a set of recommendations, 
which were considered in the development of a new proposed improved review model for the 
TITCK. 
 
Additionally, the outcomes of this research project underlined the fundamental areas of 
concern and the gaps that needed to be addressed in order to improve the regulatory review 
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system at the TITCK. Thus, the TITCK should follow a strategic plan to enable the 
implementation of the key recommendations from this study and ultimately the proposed 
improved model. This would require a structured change management approach and a good 
planning step to implement successful organisational and procedural changes. For John 
Kotter, change has different aspects both on processes and people and therefore it is essential 
to manage it in a systematic method for which he proposed an eight-step model (Kotter, 
2012). The implementation of the new TITCK improved model can be achieved using 
Kotter’s change management approach as it can be applied in healthcare organisations as well 
(Campbell, 2008) (Figure 8.1). 
 
Figure 8.1: Change management steps for the TITCK to implement the improved 
review model 
 
Based on John Kotter’s Model, Leading Change, 1995 
 
The process should be first initiated by developing the need for the change and ensuring that 
all relevant stakeholders are acknowledging it as evidence-based. Accordingly, clear, relevant 
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and achievable objectives can be set. In this study, the need to improve the TITCK review 
process was recognised by the president and senior management of the TITCK during their 
focus group workshop. The second step of the change management process would include the 
creation of a clear vision for the future TITCK as an agency. Hence, the president of the 
agency indicated that the ultimate vision is for the TITCK to become a centre for regulatory 
excellence in the region. Furthermore, a key principle of change management relates to 
people's response and approach to change. Therefore, it is important to establish robust 
strategic action plans that are clearly communicated to all stakeholders to enable them to 
endorse, implement and monitor the success of progress. Thus, the TITCK should develop 
concrete and measurable action plans and map the key deliverables for the improvement of 
each milestone in the review process. This step would require a structured design and 
planning of individual steps and new procedures to be endorsed as well as the review of 
available resources, capacity, technological infrastructure and additional costs or risks to 
implement the new processes. These include the introduction of a peer review among existing 
committees, the use of project managers and adopting structured approaches for decision-
making including the benefit-risk assessment of medicines.  
 
It is important to identify and involve the relevant departments and staff who could be 
impacted as well as to communicate all changes to key stakeholders in a timely manner.  For 
example, pharmaceutical companies should support or take part in the implementation of 
certain changes such as to follow the strict requirement of responding to questions raised 
during review within a limited period.  The introduction of new processes and practices in the 
review system may also require the need to empower and encourage the agency staff to adapt 
to the change in the behaviour and approach in the new system. For this, breaking the 
objectives down into short-term deliverables could enhance the engagement of the TITCK 
staff and minimise the resistance to adopt new standard approaches. Therefore, for each 
change or new step, it is crucial to ensure that the appropriate education and training, both 
from local and international sources, are delivered in a timely manner. Finally, the TITCK 
should maintain an ongoing monitoring process of the new model and encourage the reporting 
of progress by highlighting the achieved and future milestones as well as identifying the value 
of the successful implementation of the new model. This could be identified through an 
improved review process quality, enhanced transparency and predictability. Thus, the new 
model would bring a number of advantages mainly by enhancing the approval timelines and 
increasing the efficiency of the TITCK in terms of resources and capacity. Additionally, it 
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would enable the TITCK to enjoy a standardised, consistent and efficient review system while 
still employing its current resources, staff and committees. Thus, by adopting an effective 
monitoring system and a standard structured approach for the decision-making process while 
setting target times for each milestone, it would be possible for the TITCK to handle the 
increasing number of new medicine applications and grant timely approvals as well as 
enhance its communication policies and transparency. Furthermore, the new model would 
enable a systematic monitoring of the TITCK performance and accordingly could facilitate its 
comparison with other developed and established regulatory agencies. 
 
This would be immediately reflected in the pharmaceutical regulatory environment where 
pharmaceutical companies would be willing to invest in bringing innovative medicines to the 
Turkish market, which would ultimately be reflected, in an improved patients’ access to 
medicines. 
 
LIMITATIONS OF THE STUDY 
Limitations of the TITCK study: The approval timelines for the TITCK, which are based on 
mean rather than the median approval as well as data related to 2016, were not provided by 
the agency and the TITCK questionnaire did not include any questions to specifically evaluate 
the pricing requirements and process within the agency. Moreover, the opportunity to discuss 
the improved model with the TITCK did not occur due to the time limitations; nevertheless, 
this will be addressed in the near future to ensure that the TITCK reflections and endorsement 
of the model are obtained in order to facilitate its implementation. 
 
Limitations of the pharmaceutical industry study: There were a number of limitations to 
this study and these are as follows: 
• A response rate of 51% was achieved. Nevertheless, as indicated by the Research-
Based Pharmaceutical Companies Association (AIFD) general secretary, this was the 
highest response rate achieved to date for similar questionnaire studies conducted by 
the Association on other topics. Thus, the data collected from the participating 
companies represented the top ten pharmaceutical companies in terms of market share 
and 41% of the total new active substances approved by the TITCK for the years from 
2012 to 2015. Furthermore, only one out of the three identified local companies 
participated in this study. 
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• The question and answer phase during NAS review process was not appropriately 
covered in the questionnaire study so it was not possible to calculate the company time 
in terms of how long does an application or a response reside within a company. 
Therefore, further studies should be conducted to specifically focus on this issue to 
evaluate company time spent in answering questions and the reasons behind any 
response delays to TITCK. Accordingly, it would be possible to determine the 
appropriate changes, which will ultimately improve patients’ access to medicines. 
 
• The questionnaire was mainly focusing on the registration review process and 
therefore the pricing issues and requirements were not addressed since it is a separate 
process and is generally managed by different departments in companies. 
 
Limitations of the patient study: This did not include a focus group discussion following the 
study due to logistic difficulties of bringing the patients together as well as confidentiality 
concerns. This could have been achieved by asking the participants in the questionnaire 
whether they would have been interested in a follow up discussion to this study as this was 
carried out in the pharmaceutical industry and the TITCK studies. Due to some aspects of 
confidentiality and the timing of the TITCK and the industry studies, it has not been possible 
to publish the outcomes in peer-reviewed journals. However, this is planned for the future. 
Whereas data from the patient study were presented at the DIA meeting in June 2016 as the 
data were available in a timely manner (Appendix V). 
 
FUTURE RESEARCH 
The main themes addressed in each of the studies included in this research project are likely 
to remain key issues for the near future. Therefore, if the improved model or some of the 
recommendations were implemented by the TITCK, it would be of value to assess the 
agency’s efficiency and effectiveness in two years’ time and evaluate the impact of the new 
model on the approval timelines and ultimately on patients’ access to medicines. Therefore, it 
is crucial for the TITCK to ensure the availability of the detailed regulatory metrics including 
approval times calculated with respect to mean and median values to facilitate comparison 
with other regulatory agencies and to measure the regulatory performance of the TITCK. 
 
However, should there be no change in the regulatory review of the TITCK; it would still be 
beneficial to continue monitoring the approval trends by collecting, analysing and reviewing 
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approval times for new medicines in coming years as well as mapping the milestones within 
the review process in Turkey. This would provide an updated source of information on any 
new approval timeline trends, or possible changes and improvements in the review system 
over time and consequently on patients’ access to medicines.  
 
In addition, it is suggested to conduct a follow up meeting of the focus group with the TITCK 
to discuss and evaluate the applicability of a benefit-risk assessment framework. This could 
be possible by conducting a retrospective pilot study, which would familiarise the TITCK 
with the UMBRA framework and the related documentation system with a view, if thought 
appropriate, to conducting a prospective study. 
  
Future studies should focus on the evaluation of alternative regulatory review models and 
pathways for the TITCK. It would be of value to examine the possibility of the TITCK 
adopting a risk stratification approach by putting some reliance on selected reference agencies 
that could maximise the use of their resources and expedite their approvals. Furthermore, it 
would be of benefit to examine the decision-making process among the different scientific 
committees (Priority Evaluation Committee, Clinical Evaluation Commission, Technological 
Evaluation Committee, Bioavailability and Bioequivalence Committee, Pharmacological 
Evaluation Committee, Risk Management and Pharmacovigilance Committee). Thus by 
providing them with the same QoDoS (Quality of Decision-making operating Scheme) tool 
and subsequently analysing the assessment outcome, data from each committee in terms of 
the ten quality decision-making practices could be determined (Bujar, et al., 2017). This 
would enable a comparison between the committees in order to make a recommendation as to 
what could be improved in the decision-making and assessment model of these committees so 
that they are consistent and aligned. 
 
Finally, this research project presented for the first time, a comprehensive understanding of 
the regulatory review process for new medicines in Turkey, which also included a unique 
patient study. The initial aims and objectives of this research have been achieved and the 
findings have demonstrated the need to improve the registration review system for new 
medicines in Turkey by streamlining the TITCK review process and therefore enhancing 
patients’ access to medicines. This research project identified the different views of 
stakeholders with regards to the Turkish review process including requirements, structure, 
procedures, quality measures and timelines that highlighted the degree of standardisation that 
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could be achieved. Therefore, it is hoped that the TITCK might recognise the value of the key 
recommendations to their review system, which aim to continually improve the efficiency of 
their processes. Therefore, the outcome of this research would enable the standardisation of 
the TITCK requirements and the enhancement of their regulatory performance, review 
procedures and decision-making, thus leading to a stronger regulatory authority and its 
transformation to become a reference agency and a centre for regulatory excellence in the 
region.  
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The Centre for Innovation  
in Regulatory Science (CIRS) 
 
The Centre for Innovation in Regulatory Science (CIRS) is an independent UK-based subsidiary 
company, forming part of the Intellectual Property and Science business of Thomson Reuters. It is 
governed pursuant to constitutional documents that assure it is operated for the sole support of its 
activities and that CIRS cannot make distributions of any dividends to its parent company or any other 
entity. Any surplus generated from operations can only be applied to support CIRS activities. CIRS 
has its own dedicated management and advisory boards, and its funding is derived from membership 
dues and related activities. 
 
Confidentiality 
CIRS recognises that much of these data may be highly sensitive. CIRS has more than 20 
years of experience in handling similar data provided by agencies regarding individual 
products in regulatory review. All information collected from individual agencies 
will be kept strictly confidential. No data that will identify an individual agency 
will be reported or made available to any third party.  External reports or 
presentations of the data will include only blinded results and any appropriate analytical 
interpretations. 
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REGULATORY REVIEW PROCESS IN TURKEY 
Review of key milestones, target times and quality of decision-making in the  
assessment and registration process 
BACKGROUND 
This questionnaire is designed as part of a PhD project to evaluate the Turkish Regulatory 
environment and its impact on patients’ access to innovative medicines. The aim of the questionnaire 
is to map the regulatory review process of new active substances within the Turkish Medicines and 
Medical Device Agency (TITCK) in terms of structure, relations. This questionnaire is designed in 
association with the Centre of Innovation for Regulatory Sciences (CIRS) and it aims to; 
• Capture the actual registration requirements, review dynamics and practices followed by TITCK. 
• Identify the review process in terms of type, timelines and availability of assessment framework and 
procedures. 
• Identify the interrelations within the agency units and other external reviewers and regulatory 
commissions. 
• Understand the decision making process and transparency of the assessment outcomes and 
review conclusions. 
 
This questionnaire represents the third Phase of the CIRS Emerging Markets Programme which is 
studying the regulation of new medicines in the Emerging Markets Argentina, Brazil, China, Egypt, 
India, Indonesia, Malaysia, Mexico, Saudi Arabia, South Africa, South Korea and Taiwan and 
looking at the regulatory aspirations, barriers, problems and priorities, related to the review of new 
medicines that can have an impact on their availability to patients. The first phase was initiated in 
January 2004 to assess the current regulatory environment in some 30 countries, using comparative 
data, at the country and regional level, in order to identify the key issues for improving review practices 
and making new medicines available in an efficient and timely manner.  
 
OBJECTIVES 
The objectives are to: 
• To identify the key milestones and target times for TITCK and the main activities between 
milestones (for clinical trials applications and registrations). 
• To identify the model(s) of the review which is being undertaken by TITCK. 
• To assess how TITCK is building quality into the assessment and registration processes. 
 
OUTPUT 
By the end of this questionnaire, TITCK will receive a report from which they can compare their 
regulatory procedures with those of peer agencies across the regions. This will include an analysis of 
where time is spent in the review process with the opportunity to identify where time is lost.The 
outcome will allow an analysis of the quality measures that are, or are not, in place for a certain type of 
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review and provide a baseline for subsequent comparative studies across agencies to establish best 
practices. 
 
ABOUT THE QUESTIONNAIRE 
The attached questionnaire is divided into three sections: 
Part I: Key milestones in the registration of medicines, which explores the review and approval 
process for new active substances (NAS) and major line extensions. 
Part II: Building quality into the assessment and registration process which looks at the activities 
that contribute to the quality of the decision-making process and measures adopted to improve 
consistency, transparency, timeliness and competency in the review processes. The Introduction to 
the questionnaire asks the Authority to provide current information on its structure, organisation and 
resources. It also explores review model(s) for the scientific assessment in terms of the extent to 
which data is assessed in detail by the agency rather than relying on the results of assessments and 
reviews carried out elsewhere. The questionnaire is intended to be used as the basis for a face-to-face 
interview between Agency staff and CIRS. 
 
Focus of the Study 
The study is intended, primarily, to document procedures and practices that relate to medicines that 
are the subject of major applications, i.e., new active substances and major line extensions.  
New Active Substance   
A new chemical, biological or pharmaceutical active substance including: 
• a chemical, biological or radiopharmaceutical substance not previously authorised as a 
medicinal product; 
• an isomer, mixture of isomers, a complex or derivative or salt of a chemical substance not 
previously authorised as a medicinal product but differing in properties with regard to safety 
and efficacy from that chemical substance previously authorised; 
• a biological substance previously authorised as a medicinal product, but differing in molecular 
structure, nature of the source material or manufacturing process; 
• a radiopharmaceutical substance which is radionucleotide, or a ligand not previously 
authorised as a medicinal product, or the coupling mechanism to link the molecule and the 
radionucleotide has not been previously authorised 
Major line extension 
A major line extension is a change to an authorised Medicinal Product that is sufficiently great that it 
cannot be considered to be a simple variation to the original product, but requires a new product 
authorisation. Such changes include major new therapeutic indications or new disease states, 
extension to new patient populations (e.g., paediatrics), a new route of administration or a novel drug 
delivery system. 
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PART I: ORGANISATIONA STRUCTURE & TYPE OF REVIEW 
1. Information on the Regulatory Authority 
As background to the discussions about your agency, its practices and procedures it would be helpful 
to have the following basic information on its structure and the way it is established: 
Title of the Agency/Division responsible for the regulation of medicinal products for human use 
 .........................................................................................................................................................  
If this is part of a parent agency with a wider remit (e.g., Food and Drugs) please give the title: 
 .........................................................................................................................................................  
Scope and remit 
1.1 Please indicate the scope of responsibility of the Agency: 
Medicinal products for human use  YES  NO 
Medicinal products for veterinary use  YES  NO 
Medical devices and in vitro diagnostics  YES  NO 
1.2 Indicate the main activities that are covered by the agency 
 Marketing authorisations/Product licences  Clinical trial authorisations 
 Post-marketing surveillance  Regulation of advertising 
 Laboratory analysis of samples  Price regulation 
 Other 
 
Type of agency 
1.3 Indicate which of the following best describes this agency 
 Autonomous agency, independent from the Health Ministry administration 
 Operates within the administrative structure of the Health Ministry 
Date of establishment of the current agency   
 
Size of agency 
Please note that the following questions refer to the regulation of medicinal products for human 
use. 
1.4 Please provide information on staff numbers 
Total staff in the agency   
   
Number of reviewers for applications for marketing authorisations/ 
product licences 
  
 
1.5 Please indicate the professional background and numbers of the technical agency staff 
assigned to the review and assessment of medicinal products 
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 Employed as assessors Number 
Physicians  YES  NO  
Pharmacists  YES  NO  
Other scientists  YES  NO  
Project managers 
Statisticians  
 YES NO 
 YES NO  
 
 
Fee structure 
1.6 Are fees charged to sponsors for the review and assessment of 
applications for medicinal products for human use? 
  
If YES, please provide the following information: 
Marketing Authorisation Application fee for  Local currency  US$ 
                
    
                
    
              
    
              
    
              
    
              
Does the agency charge a fee for Scientific Advice 
 : If Yes please provide 
             
 
Budget  
Please indicate whether the following data     are in the public domain or 
   should be treated as confidential 
1.7 Please provide the following information on the agency budget for the regulation of medicinal 
products for human use 
 Local currency  US$ 
  Total annual budget    
    
 Year for which data are given    
 
 
 
YES NO
New Active substance
Established ingredient - proprietary product
Generic product
Variations
Major line extension
Other (Please specify)
YES NO
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If the budget is sub-divided according to different activities, please specify 
 % of total budget   
  Clinical trial authorisations    
    
  Marketing authorisations    
    
  Pharmacovigilance    
    
  Other post-marketing controls    
    
  Other activities (specify)    
   
 
Sources of funding 
1.8 Please provide the following information in relation to the way the agency is funded 
Funded entirely by the government   YES   NO 
Self funded entirely from fees   YES   NO 
Partially funded from different sources (please give 
proportions of total budget) 
       % Government         % Fees 
       % Other (specify) 
 
To assist CIRS to better understand your organisation please provide copies of any organisation 
charts that show the structure of the agency and its relationship to other regulatory bodies, e.g., 
medical device agency. It would also be very useful to have copies of any background papers that 
describe the functions, remit and mission of the agency. 
 
2. Type of data assessment 
Three basic types of scientific review have been identified as a result of discussions with regulatory 
agencies and presentations at the CMR International Institute Workshop on The Emerging Markets: 
Regulatory issues and the impact on patients’ access to medicines, Geneva, Switzerland, March 
2006. Many agencies apply a different level of data assessment to different applications, according to 
the type of product and/or its regulatory status with other agencies. The data assessment models for 
scientific review are described in section 2.1 below and further questions are set out in 2.2 to analyse 
the types of scientific review in more detail. 
 
2.1 Please indicate by checking the boxes below, which descriptions fit the model(s) used by 
your agency in the assessment of major applications i.e., new active substances (NASs) and 
major line extensions as described on page 2. 
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Data Assessment Type 1  
This model is used to reduce duplication of effort by agreeing that the importing country will allow 
certain products to be marketed locally once they have been authorised by one or more recognised 
reference agencies, elsewhere. The main responsibility of the agency in the importing country is to 
‘verify’ that the product intended for local sale has been duly registered as declared in the application 
and that the product characteristics (formulation, composition) and the prescribing information (use, 
dosage, precautions)  for local marketing conforms to that agreed in the reference authorisation(s)  
TYPE 1  Not used  Used for all major applications 
  Used for selected applications (please specify) 
 
Data Assessment Type 2  
This model also conserves resources by not re-assessing scientific supporting data that has been 
reviewed and accepted elsewhere but includes an ‘abridged’ independent review of the product in 
terms of its use under local conditions. This might include a review of the pharmaceutical (CMC) data 
in relation to climatic conditions and distribution infrastructure and a benefit-risk assessment in relation 
to use in the local ethnic population, medical practice/culture and patterns of disease and nutrition. 
Approval by a recognised agency elsewhere is a pre-requisite before the local authorisation can be 
granted but the initial application need not necessarily be delayed until formal documentation such as 
a Certificate of a Pharmaceutical Product (CPP) is available. 
TYPE 2  Not used  Used for all major applications 
  Used for selected applications (please specify) 
 
 
Data Assessment Type 3 
In this model the agency has suitable resources, including access to appropriate internal and external 
experts, to carry out a ‘full’ review and evaluation of the supporting scientific data (quality, pre-clinical, 
clinical) for a major application. A Type 3 assessment could be carried out on a new application that 
has not been approved elsewhere but, in practice, legal requirements may dictate that the product 
must be authorised by a reference agency before the local authorisation can be finalised.  
TYPE 3  Not used  Used for all major applications 
  Used under the following conditions (please specify) 
 
If your agency has recognised ‘reference agencies’ (as in Types 1 and 2) please provide the list: 
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2.2 Data requirements and assessment 
 
Regulatory Status: 
 
Type I Type II Type III Priority/fast track products 
Evidence of authorisation by other authorities 
Requirements for a CPP as part 
of the review 
 with application 
 before authorisation 
 not essential   
 with application 
 before authorisation 
 not essential   
 before local authorisation 
 not essential   
 with application 
 before authorisation 
 not essential   
Other documentation from the 
authorising agencies accepted 
as evidence of registration 
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
 letter of authorisation 
 copy of full authorisation 
 Internet evidence  
Other evidence accepted  
 
   
Verification of identity between the authorised product and the local application 
The following are checked: Information must be: 
Identical Closely similar 
Information must be: 
Identical Closely similar 
Not applicable 
Information must be: 
Identical Closely similar 
Dosage form           
Strength           
Ingredients           
Indications and dose           
Warnings and precaution           
Product label           
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Regulatory Status: 
 
Type I Type II Type III Priority/fast track products 
Other (specify)     
Scientific data required to support the application (Reference is made below to sections of the ICH Common Technical Document (CTD) as an example of the level of detail but 
does not imply that the CTD in necessarily accepted) 
Pharmaceutical quality/CMC  Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 Summary data (Mod 2.3) 
 Summary + full stability 
 Full data (Mod 3) 
 
 
Scientific data required to support the application (continued) 
Nonclinical data   Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
 Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
 Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
 Written summary (2.4) 
 Tabulated data (2.5) 
 Full data (Module 4) 
Clinical data  Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
 Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
 Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
 Written summary (2.5) 
 Tabulated data (2.6) 
 Full data (Module 5) 
Extent of Scientific Review 
Quality/CMC data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. stability, specification) 
 Only examined if there is a 
query 
 ‘Check list’ review for 
completeness of data 
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Regulatory Status: 
 
Type I Type II Type III Priority/fast track products 
 Selective review in detail 
(e.g. stability, specification) 
 Detailed assessment and 
evaluation report  
 Selective review in detail 
(e.g. stability, specification) 
 Detailed assessment and 
evaluation report  
 Detailed assessment and 
evaluation report  
 Selective review in detail (e.g. 
stability, specification) 
 Detailed assessment and 
evaluation report  
Comment 
 
 
    
Non-clinical data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
 Only examined if there is a 
query 
 ‘Check list’ review for 
completeness of data 
 Detailed assessment and 
evaluation report  
Comment 
 
    
Clinical data  Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 Detailed assessment and 
 Only examined if there is 
a query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 Detailed assessment and 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail 
(e.g. bridging studies) 
 Detailed assessment and 
evaluation report  
 Only examined if there is a 
query 
 ‘Check list’ review for 
completeness of data 
 Selective review in detail (e.g. 
bridging studies) 
 Detailed assessment and 
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Regulatory Status: 
 
Type I Type II Type III Priority/fast track products 
evaluation report  evaluation report  evaluation report  
Comment     
Clinical evaluation: factors included in the risk-benefit assessment 
The clinical opinion takes 
account of: Never sometimes always Never sometimes always Never sometimes always Never sometimes always 
Differences in medical 
culture/practice 
            
Ethnic factors             
National disease patterns             
Unmet medical need             
Additional information, not in the application 
The agency tries to obtain Information is sought: 
Never sometimes always 
Information is sought: 
Never sometimes always 
Information is sought: 
Never sometimes always 
Information is sought: 
Never sometimes always 
Other agencies’ internal 
assessment reports 
 
            
Reports available on the 
Internet (e.g., EPARS) 
 
            
General Internet search 
 
            
Other data (specify 
 
            
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PART II - KEY MILESTONES IN THE REGISTRATION OF MEDICINES 
Review Process Map and Milestones 
This part of the questionnaire is based on the General Model below giving a process map and 
milestones that has been developed from studying procedures followed in ‘established’ and ‘emerging’ 
regulatory agencies. It captures the main steps in the review and approval process and identifies key 
‘milestone’ dates in the process for monitoring and analysing timelines. 
Scientific Assessment 
internal/external cont. 
Notes 
Receipt and validation may include 
administrative registration (reference number) 
and checks on legal requirements, status of 
company, local agent, manufacturer etc. as 
well as a ‘checklist’ validation of the 
application content (e.g., technical sections, 
CPP status).  
Queuing for review: Administrative time 1 is 
a measure of the ‘backlog’ time (if any) while 
valid applications wait for action to begin. 
Scientific Assessment extends from 
milestone C to milestone H and is a measure 
of ‘review time’. In some systems the ‘clock’ 
stops when questions are asked and  
Sponsor time (milestone D to milestone E) 
can be measured and deducted from the 
agency review time. 
Questions to sponsor may be batched and 
sent at one time or asked throughout the 
review process, in which case the Sponsor 
time is not easily measured.  
In some systems, questions may only be sent 
to the sponsor after the end of the ‘first cycle’ 
scientific assessment (at milestone H). 
Committee Procedure: Most review 
procedures for major applications include a 
step where the opinion of an expert advisory 
committee is sought. In this scheme, the 
Committee procedure is ‘nested’ within the 
Scientific Assessment but it may take place 
after the Agency’s scientific assessment is 
complete. 
Second cycle: If the application cannot be 
granted immediately, on technical grounds, it 
enters a second review cycle (new data point 
D: questions to sponsor) and a further 
scientific assessment is made of the 
additional data. The Committee Procedure 
may or may not need to be included in the 
second and subsequent review cycles. 
Approval procedure: The time interval after 
scientific review (Admin time 2) while the 
formal authorisation is issued may be 
extended by pricing negotiations and 
finalisation of analytical and GMP checks. 
Approval time is measured from milestone A 
to milestone.I 
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YES 
Date received A 
Queuing for review  
Reply from sponsor E 
Accepted for review B 
Scientific Assessment starts C 
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Questions to sponsor D 
Questions processed by 
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Review stages and milestones 
This section of the questionnaire is based on the General Model shown on page 6. 
We recognise that not all systems conform to the general model and it would be very helpful if you 
could provide an outline of the model used by your authority. If this differs according to the Type of 
data assessment (see page 5) please provide information on the different models  
When information is given on target or actual times please indicate here whether these are counted in: 
 Calendar days  Working days 
When ‘milestone’ dates are recorded during the review process is the information entered into an 
electronic tracking/recording system? 
 YES, System in current use   NO, System in development (Target date:                     ) 
 NO, A manual system will be used for the foreseeable future 
3. Receipt and Validation 
 
Pre-submission requirements 
3.1. Are there any formal requirements before an 
application is submitted, for example, notification of intent 
to submit, assignment of registration code etc. 
 NO, milestone A is the formal start of the application 
procedure 
 YES (please specify) 
Validation 
3.2 Is the date of receipt (milestone A) formally recorded?  YES  NO 
3.3 Are the following administrative items checked in the pre-review validation process? 
Legal status of applicant/local agent   YES  NO 
GMP status of manufacturer  YES  NO 
Patent/IP status of active ingredient  YES  NO 
Whether company has paid the correct fee  YES  NO 
Other:  
3.4 For those applications where prior authorisation elsewhere is essential (see Section 2) 
please answer the following questions about the Certificate of a Pharmaceutical Product (CPP) 
Is the inclusion of a CPP an absolute requirement before accepting the application as valid? 
 YES  NO  For some applications (please specify) 
If YES must the CPP be legalised by an Embassy or Consulate?  YES  NO 
If NO, please indicate which of the following apply 
A CPP must be provided before the authorisation is issued  YES  NO 
Other evidence of authorisation by other countries is accepted place 
of the CPP (e.g., copy of authorisation, Internet reference) 
 YES  NO 
Comment  
Receipt and validation 
procedureScientific 
t d  
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Date received A 
Accepted for review B 
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Validation (cont.) 
3.5 Is the application also checked for the following items? 
Acceptable format (e.g. ICH CTD or local requirements)  YES  NO 
Correct sections of scientific data (quality, safety, efficacy)  YES  NO 
Other technical items: 
 
Acceptance for review/refusal to file 
3.6 Is the date of acceptance (milestone B) formally recorded?  YES  NO 
3.7 What happens if the application is incomplete? 
 Refusal to file: New application must be made  
 File pending: A request for the missing data is sent to the applicant 
 What is the time limit for the applicant to reply?  
Notes: 
 
Target time for validation 
3.8 Is there a target validation time?  YES (specify)   
 NO 
 
4. Queuing/backlog 
 4.1 Which of the following applies to the queuing 
system for new applications? 
 Held in queue after validation (as in the General 
Model) 
 Held in queue before validation starts (milestone A) 
4.2 What is the current queue time (approximately)? 
 Less than 2 weeks  2-8 weeks 
 2-6 months  6 months-1 year 
 More than 1 year  
4.3 Are priority products taken out of turn in the 
queuing system 
 YES, always 
 YES, sometimes 
 NO, all applications await their turn 
Comment: 
4.4 Does the Agency regard the backlog of applications 
as a problem 
 YES  NO 
If YES, how is this being addressed? 
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Queuing for review  
Accepted for review B 
Scientific Assessment starts C 
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. Scientific Assessment 
5.1 Initiation of scientific review 
 
5.1.1 Is the start of the 
Scientific Assessment 
formally recorded  
(milestone C)? 
 YES  NO 
5.1.2 Is the scientific data 
separated into three sections 
(quality, safety, and efficacy) 
for review? 
 YES  NO 
5.1.3 In what order are the different sections assessed: 
 In parallel  In sequence 
If in sequence, please give order 
 
5.1.4 Who carries out the primary scientific assessment? 
 Agency technical staff   Sent to outside experts 
 Different procedure for different sections 
Please describe the process 
 
5.2 Use of outside experts 
If outside experts are used for the assessment of scientific data (5.1.4 above) please complete the 
following: 
5.2.1 Number of experts on the agency’s list or panel:   
 
5.2.2 Main responsibility:  To provide a detailed assessment report and recommendation 
  To provide a clinical opinion on the product 
  To provide advice to the agency staff on specific technical issues 
  Other (specify 
5.2.3 Is there a contractual agreement on 
working within deadlines set by the agency? 
 YES  NO 
 
5.3 Interaction with the Sponsor 
 
5.3.1 How are questions sent to the Sponsor 
 as they arise during the 
assessment 
 Collected into a 
single batch 
5.3.2 When are batched questions sent to the Sponsor 
 After the initial assessment but before reporting to 
the Scientific Committee (as in the General model) 
 Not until the Scientific Committee has given its 
advice 
 Before and after reference to the Scientific 
Committee 
 
Reply from sponsor E 
Questions to sponsor D 
Questions processed by 
sponsor 
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Sp
on
so
r t
im
e 
Scientific Assessment 
internal/external cont. 
Start of Committee procedure F 
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5.3.3 Does the scientific review cease while questions are being 
processed by the Sponsor (‘clock stop’) 
 YES  NO 
5.3.4 Can the sponsor time be calculated, i.e., are milestones D and E 
recorded? 
 YES  NO 
5.3.5 Is the sponsor given a time limit to reply  YES  NO 
  
If Yes, what time is allowed?   
 
Meetings 
5.3.6 Can the Sponsor hold meetings with the agency staff to discuss 
questions and queries that arise during the assessment 
 YES  NO 
If Yes, what conditions and restrictions (if any) are applied? 
 
5.4 Review by Scientific Committee 
 
5.4.1 Is a Committee of Experts 
(internal and/or external) used in 
the review process 
 YES NO 
5.4.2 If Yes, at which stage in the review? 
 Responsible for the whole assessment of the 
dossier from the start of the review  
 Integrated into the agency’s own internal/external 
scientific review procedure 
 Consulted after the agency has reviewed and 
reported on the scientific data 
 Other (specify) 
5.4.3 Are the dates at the start and end of the Committee Review 
recorded (milestones F and G)? 
 
 YES  NO 
5.4.4 Is the agency mandated to follow the Committee recommendation?  YES  NO 
5.4.5 Is there a time limit for the Committee Procedure?  YES  NO 
If YES, please give the target 
If NO, what is the time range (e.g., 1-3 months)   
   
5.4.6 Is there an additional step in the scientific review process, after 
the Committee has given its opinion? 
 YES  NO 
If YES, please describe briefly the work carried out at this stage (e.g., final report and agency opinion) 
If NO, the milestone G will mark the end of the scientific review for the purpose of calculating the 
review time 
 
 
Start of Committee procedure F 
Committee Procedure 
Opinion received G 
Final report 
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Target for scientific review 
5.4.7 Is a target time set for the scientific review (milestones C to H)  YES  NO 
If YES please give target   
 
 
6. Decision on the Application 
 
At the end of the Scientific Review (see General Model, 
page 6) there is normally recommendation that either: 
The product meets the scientific criteria for authorisation 
(proceed to approval procedure) or 
Further data is required before the scientific criteria are 
met (application enters a second cycle at milestone D 
(questions to Sponsor) or 
The application should be refused (not shown in the 
General Model) 
6.1 Responsibility for the authorisation decision 
6.1.1 Who makes the decision that a marketing authorisation can be granted? 
 The Scientific Committee  The Head of the Agency 
 The Minister of Health  
 Other (please specify) 
 
6.2 Other Criteria to be met 
6.2.1 Is the issue of the authorisation dependent on a pricing agreement  YES  NO 
If YES, when are the pricing negotiations started?  
 At the start of the scientific review  After the end of the scientific review 
 After the start but before the end of the scientific review 
6.2.2 Is the issue of the authorisation dependent on sample analysis  YES  NO 
If YES, when is the analytical work started?  
 In parallel with the scientific review  At the end of the scientific review 
 After the start but before the end of the scientific review 
6.2.3 Is there a separate negotiation of the product labelling/ product 
information after the scientific opinion is given but before the approval is 
issued? 
 YES  NO 
Comments: 
 
6.2.4 Please specify any other legal/administrative matters that must be finalised before the approval 
can be issued 
 
 
Scientific assessment ends H 
Approval procedure 
Approval granted I 
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6.3 Approval procedure 
6.3.1 Is the Sponsor informed of a positive scientific opinion at 
milestone G, i.e., before the authorisation is issued? 
 YES  NO 
6.3.2 Approximately how long does it take from receiving a positive scientific opinion (at milestone H) 
to issuing an approval (milestone I) 
 Less than a month  1-3 months  3-6 months  Over 6 months 
Comment: 
 
 
7. Metrics on the Approval Process for NAS 
It would be very helpful to have the following information on processing times for marketing 
authorisations that have been received and/or determined in the three years 2004, 2005, 2006.  
7.1 Applications received 
Type 
Number of applications received in each year 
Current backlog 2011 2012 2013 
New Active Substance     
Major line extension     
 
7.2 Applications determined 
Type 
Number of applications determined in each year 
2011 2012 2013 
New Active Substances approved    
New Active Substances refused    
Major line extensions approved    
Major line extension refused    
7.3 Average approval times 
Type 
Time from receipt of application to issue of approval 
2010 2011 2013 
New Active Substances     
Major line extensions     
 
7.4 Target for approval times 
Is a target time set for the overall approval process (milestones A to I)  YES  NO 
If YES please give target   
Please comment on the actual review times in relation to the authority’s target time 
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PART III: GOOD REVIEW PRACTICE (GREVP) 
BUILDING QUALITY INTO THE ASSESSMENT  
AND REGISTRATION PROCESS 
Quality in the assessment and registration process is important to regulatory authorities as it ensures 
consistency, transparency, timeliness and competency in the review processes. Regulatory authorities 
are continuously developing and implementing a variety of measures to improve and achieve higher 
quality standards and to meet the expectations of industry and the general public. 
The purpose of this section of the questionnaire is to obtain an insight into the strategies, measures 
and resources that agencies have in place to develop and maintain quality in their review processes.  
 
8. General Measures used to achieve quality 
Please indicate the quality measures currently in place and, where none, plans to introduce such 
measures in the foreseeable future. 
Good Review Practice (GRevP): A code about the process and the documentation of review 
procedures that aims to standardise and improve the overall documentation and ensure timeliness, 
predictability, consistency and high quality of reviews and review reports 
 
8.1 How does your agency define GRevP?: 
Is it different from the Glossary?            
 
If different, please define in here:       
      
Please Outline the key elements that make up GRevP in your agency: 
      
 
Has the Agency formally or informally implemented GRevP?  
  
If YES please give the title and date of formal implementation: 
      
 
How has this been implemented: (Please tick the appropriate Box(s)) 
               
      
YES NO
YES(Formally)
YES(Informally) NO
Guidelines Standard Operating Procedures GRevP Training Program
Other: Please specify:
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Are these documents open and available to the Public?              
If Yes please describe:       
 
Was the establishment of your GRevP based on other agencies or 
International standards? 
 
     
If Yes: please state the name of the agency(ies)/ or Internationals standards  on which your GRevP 
has been based:       
 
Are you satisfied with your existing GRevP framework? 
  
 
 
If could be improved or Unsatisfied, please select reason(s) that best describes your situation. 
  
 
 
  
       
 
If you do not have a formal GRevP system in place are there plans to 
establish this within the next two years? 
 
     
Quality Policy: Overall intentions and direction of an organisation related to quality as formally 
expressed by top management. 
8.2 Does the Agency have an internal Quality Policy?      
If NO are there plans to establish this within the next two years?      
SOPs (Standard Operating Procedures) are written documents that describe in detail the routine 
procedures to be followed for a specific operation. 
8.3 Are there SOPs for the guidance of scientific assessors      
If NO are there plans to establish SOPs within the next two years?      
8.4 Are there SOPs for the advisory committee consulted during 
the review process  
     
 
If NO are there plans to establish SOPs within the next two years?      
YES NO
YES NO
Satisfied Could be improved Unsatisfied
System still evolving 
Requires additional training to understand and learn about Good Review Practice 
Poor acceptance/utilisation by staff 
Benefits of implementing GRevP are not apparent so far
 Other (please provide details) 
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
No committee
YES NO
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8.5 Are SOPs used for any other procedures in the regulatory 
review process (e.g., validation)? 
     
Please specify:       
Assessment Templates set out the content and format of written reports on scientific reviews. 
8.6 Are there Assessment Templates for reports on the scientific 
review of a NAS? 
     
If NO are there plans to establish this within the next two years?      
If Yes are these based on another agencies assessment template      
If Yes, which agency was the assessment template based? Please specify: 
      
Is there an SOP for completing an assessment template      
Can you tick what elements from the list below are included in your agency assessment template? 
    
    
    
     
    
     
  
       
Would the agency be open to sharing their assessment template or 
points to consider with CIRS? 
      
Do you produce an assessment report (AR) following the review?      
If Yes : 
 
Is there an SOP for completing the AR: 
 
What language is the AR prepared in: 
 
Do you share your AR with other regulatory authorities 
 
Do you put your full AR on the webside  
 
 
Do you put your abridged AR on the website 
 
 
       
  
       
 
       
 
       
 
YES NO
YES NO
YES NO
YES NO
YES NO
Drug substance GCP aspects
Drug product Clinical Pharmacology (PK and PD)
Comments on label Clinical Efficacy
Non clinical GLP Aspects Clinical Safety
Non clinical Pharmacokinetics List of questions for sponsors
Toxicology  Benefit risk discussion
Regulatory background (worldwide status on 
regulatory agencies)
Ethnic factors (eg consideration of bridging 
studies)
Other (please specify):  
YES NO
YES NO
YES NO
Local language English
YES NO
Sometimes
YES NO
Sometimes
YES NO
Sometimes
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Do sponsors get a copy of the full assessment report? 
 
Do Sponsors have any involvement in the following in relation to 
AR: 
 
Preparation of assessment reports 
 
Comments on the assessment reports 
 
Translation of assessment reports 
 
Distribution of Assessment reports 
       
 
 
       
       
       
       
 
Peer Review is an additional evaluation of an original assessment that is carried out by an 
independent person or committee. Peer review can occur either during assessment of a dossier or at 
the time of sign-off. 
8.7 Are external peer reviews carried out when a NAS is 
assessed?         
If NO are there plans to introduce these within the next two years?        
8.8 Are internal peer reviews carried out when a NAS is 
assessed?         
If NO are there plans to introduce these within the next two years?        
Do you have target times for following activities and if so can you 
provide your target times? 
 
Overall approval times 
 
Validation of dossier 
 
Scientific assessment 
 
Company (clock stop), time 
 
Other: Please specify:       
If Target times given are they in working days? 
Yes       No     Target Time 
            
              
              
              
            
    
8.9 Are there other general procedures in place to monitor the quality of the review process? 
What other tools does your agency use to build quality into the assessment process?  
(eg  Internal procedure could include; Quality assurance and quality control meeting; Stakeholder 
meeting;  Channel for grievance; Survey of performance from sponsors) Please specify: 
      
 
 
 
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
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9 Quality Management 
Reasons for introducing quality measures in the authority 
9.1 Please select, from the following list,  the three most important reasons for the introduction of  
quality measures 
    
    
    
   
  
 
Monitoring to improve quality 
9.2 Which of the following activities are undertaken by the authority to bring about continuous 
improvement in the assessment and registration process? 
Reviewing assessors’ feedback and taking necessary action    
Reviewing stakeholders’ feedback (e.g. through complaints, meetings 
or workshops) and taking necessary action 
   
Using an internal tracking system to monitor (e.g. consistency, 
timeliness, efficiency and accuracy) 
   
Carrying out internal quality audits (e.g. self-assessments) and using 
findings to improve the system 
   
Having external quality audits by an accredited certification body to 
improve the system 
   
Having a ‘post approval’ discussion  with the sponsor to provide 
feedback on the quality of the dossier and obtain the company’s 
comments  
   
 
Management responsibility 
9.3 Does the authority have a dedicated department for assessing 
and/or ensuring quality in the assessment and registration process? 
   
If YES, how many staff are involved?       
How often do you assess and/or ensure quality in assessment and registration process? 
            
To whom does this section report (e.g. the Chief Executive Officer of the authority)? 
      
If NO, is the Authority thinking of setting up such a department?    
To be more efficient To minimise errors
To ensure consistency To reduce costs
To achieve stakeholder satisfaction To increase transparency
To improve process predictability To improve communications in the authority
Other (please specify) To allocate the regulatory resources 
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
Annually Semi-Annually Adhoc Other (please specify)
YES NO
  
256 
 
10. Quality in the Review and Assessment Process 
Improving the quality of applications 
10.1 Does the authority have official guidelines to assist industry in the 
registration of medicinal products?    
If YES, how are these guidelines made available? (Please indicate all that apply) 
    
   
       
What language are the guidelines available in: 
       
Improving quality through interaction with applicants 
10.2 Does the authority provide pre-submission scientific advice to 
applicants    
If YES how is the quality of that advice monitored?       
10.3 Is the applicant given details of technical staff that can be 
contacted to discuss an application during review?  
   
10.4 Please indicate which of the following best describes the level of contact that companies have 
with agency staff or outside experts during development and during the agency’s assessment. 
 Development Assessment 
Extensive formal contact (including scheduled meetings)   
Extensive informal contact (frequent telephone or email contact)   
Some formal contact (possibility of meetings)   
Some informal contact (possibility of telephone or email contact)   
None, or minimal formal contact (rare occurrences of contact, via 
letter or fax)   
None, or minimal informal contact (rare telephone or email 
contact)   
Please comment on general policy for contact with applicants:       
Committee Procedure 
10.5 If your review procedure includes obtaining the advice of a scientific committee of internal 
and/or external experts (as in Section 5.4) please complete the following:  
Name of the Committee       
Number of Committee Members       
How frequently does the Committee meet? 
       
For NAS applications and major line extensions does the Committee review? 
        
Does the Committee review? 
  
YES NO
Through the authority's website Through official publications
On request Through Industry Associations
Other, please specify:
Local language only   English Other, please specify:
YES NO
YES NO
Once a week Once a month Other, please specify:
All applications Selected dossiers (specify)
The complete dossier Assessment reports from the reviewers
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Shared and Joint reviews with other Regulatory Agencies outside of your country 
A shared review is one where each participating authority takes responsibility for reviewing a 
separate part of the dossier. A joint review is one where the whole dossier is reviewed by each 
authority and the outcome is discussed before a decision is taken. 
Are bilateral-multilateral information sharing agreements in place with other jurisdictions? 
   
If Yes, What is the general nature of those agreements?  
      
10.6 Does your authority conduct shared or joint reviews with other regulatory authorities? 
 
      
 
      
 
If YES do you have formal measures in place to ensure consistent 
quality during the review? 
If Yes, please specify 
   
If NO, do you anticipate undertaking such reviews within the next two 
years? 
   
10.7 Have these joint reviews influenced the way in which your 
authority conducts reviews in general? If so, please comment 
   
11. Training and continuing education as an element of quality 
The following questions relate to training and continuing education of assessors working within the 
authority, including those employed on a full-time basis and those contracted for specific assessments 
were necessary. 
11.1 Do you have a formal training programme for assessors?    
11.2 Which of the following methods are used for training assessors? 
  
  
   
 
 
  
 
      
 
YES NO
YES regularly. Please state which 
authorities
YES occasionally. Please state which 
authorities
NO this has never been undertaken
YES NO
YES NO
YES NO
YES NO
Induction training External courses
On-the-job training Sponsoring of Post-graduate degrees
Placements and secondments in other 
regulatory authorities
Participation in international workshops/ 
conferences
External speakers invited to the authority In-house courses
Training in advanced DRA
Other, please specify:
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Does your authority seek direct assistance of more experienced 
agencies for development of SOPs and Guidelines? 
If Yes please give details:       
   
Does your authority mainly develop SOP, Guidelines etc based on 
information published by more experienced agencies: 
   
11.3 Does your authority collaborate with other agencies in the 
training of assessors? 
   
If Yes, please give details:       
11.4 Is training tested in examination situations once completed?    
 
11.5 Is completion of training courses required for professional 
advancement?    
 
12. Transparency of the review procedure 
This section examines ‘transparency’ in terms of the ability and willingness of the agency to assign 
time and resources to providing information on its activities to both the informed public (which includes 
health professionals) and industry. 
12.1 What priority does your agency assign to being open and transparent in relationships with the 
public, professions and industry? 
   
Please comment:       
12.2 What are the main drivers for establishing transparency? Please indicate the top three 
incentives for assigning resources to activities that enhance the openness of the regulatory system 
    
    
  
  
      
Transparency to the public 
The following questions explore the availability of information to the general public on the performance 
of regulatory authorities 
12.3 Please indicate which of the following information items about the assessment and registration 
of marketing applications is available to the public. 
  
 
  
 
      
12.4 How is this information made available 
    
       
 
YES NO
YES NO
YES NO
YES NO
Partly
YES NO
Partly
High priority Medium priority Low priority
Political will Press and media attention
Press and media attention Need to increase confidence in the system
Need to provide assurances on safety 
safeguards
Better staff morale and performance
Other, please specify:
Approval of products
Approval times
Summary of the grounds on which the approval was granted 
Advisory Committee meeting dates
Other, please specify:
Official Journal/periodical publication From an official Internet website
On request Other, please specify:
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Transparency to companies on application progress 
12.5 Are companies able to follow the progress of their own applications?  
If YES please indicate the mechanisms available to industry 
  
       
12.6 Are companies given detailed reasons for rejecting an application for 
registration? 
 
 
Facilities for providing information 
12.7 Is there an electronic system for registering and tracking applications  
If YES please indicate whether it has the following capabilities 
Tracing applications that are under review and identifying the stage in the 
process 
 
Signalling that target review dates have been exceeded  
Recording the terms of the authorisation once granted  
Archiving information on applications in a way that can be searched  
If NO are there plans to introduce such a system?  
If so, please give target date for implementation:        
 
 
13. Concluding Observations 
The purpose of the following two questions is to try to identify the Agency’s own perception of its 
unique positive qualities and the major impediments it faces in carrying out the review of new 
medicines and making them available to meet patients’ needs.  
13.1 List three factors that make a major contribution to the effectiveness and efficiency of your 
agency’s review procedures and decision-making processes for NAS applications 
1. 
 
2. 
 
3. 
 
13.2 List three factors that act as barriers to making new medicines available in a timely manner 
through the regulatory process 
YES NO
Electronic access to the status of applications E-mail contact
E-mail contact Other, please specify:
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
YES NO
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1. 
 
2. 
 
3. 
 
 
13.3 Any important documents related to GRevP that you would like to share with CIRS? 
 
If yes please list and provide directly to CIRS 
 
14. Sharing Assessment reports: Agency perceptions 
It has been suggested thorugh various platforms that in the future the sharing of assessment 
reports for pharmaceutical assessment between member Economies would be of value.  Please 
read the following statements and mark one of the given options: Strongly agree / Agree / 
Indifferent / Disagree / Strongly disagree.  
 
 
S
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ly
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A
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In
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D
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e 
S
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 d
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re
e 
Sharing of assessment reports for pharmaceuticals  
between economies would be of value to 
streamlining the review process by my agency 
     
In order for Agencies to share assessment reports, assessment 
templates should contain the same key elements      
Sharing of assessment reports will enable agencies to utilise 
their resources more effectively and efficiently      
Sharing assessment reports will reduce the review time for a 
dossier by my agency      
 
S
tro
ng
ly
 A
gr
ee
 
A
gr
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D
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e 
S
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ag
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e 
YES NO
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Sharing activities of assessing a new drug with other agencies 
for simultaneously submitted products will reduce the review 
time for the dossier 
     
ARs should be region-specific rather than global in their content 
if they are to be of value in meeting the agencies’ needs?      
A single aligned standard operating procedure can be developed 
to guide agencies to the use of an assessment template and 
provide consistency in the completion process. 
     
Sharing AR will improve the quality of review by providing my 
agency insight and understanding of differences and regulatory 
controversies encountered by other agencies 
     
Sharing AR will ensure that the industry submit similar dossiers 
across DRAs       
Sharing AR will facilitate regulatory interactions among 
reviewers of DRAs      
 
14.1: Please List three benefits you envision to sharing assessment reports 
1)       
2)       
3)       
 
14.2: Please list three hurdles you envision to sharing assessment reports 
1)       
2)       
3)       
Thank you for completing this questionnaire 
Please sign and date: 
 
Signature 
 
 
Position 
Name 
 
 
Date Email address 
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GLOSSARY AND ABBREVIATIONS  
Additional 
information 
Additional data or additional analyses of existing data requested from 
the sponsor by the regulatory authority during the review process. 
Advisory 
Committee 
An expert committee that advises the regulatory authority of the 
safety, quality and efficacy of new medicines for human use. 
Approval 
 
The approval of a drug product by a regulatory authority, signified by 
the granting of a marketing authorisation, or the issue of a technical 
approval letter. However the product may still not be marketable until 
negotiations for pricing and reimbursement are concluded. 
Clinical summary 
 
Summary of clinical study data that typically includes 
biopharmaceutic studies and associated analytical methods, clinical 
pharmacology studies, clinical efficacy, clinical safety, literature 
references, and synopses of individual studies. Refers to Module 2.7 
in CTD format. 
Common technical 
document (CTD) 
format 
Common technical document (CTD) as outlined in the ICH guideline 
M4 (Organisation of the common technical document for the 
registration of pharmaceuticals for human use; M4). 
CMC Chemistry, manufacturing and controls. All activities conducted to 
optimize, scale-up and validate the processes and technologies for 
transfer to manufacture and all QA, QC and CMC support activities 
(e.g. CMC project management including CMC contribution to project 
teams).  This includes all drug substance R&D i.e. process research 
and process development, all drug product R&D i.e. formulation 
development and process development, all analytical work for drug 
substance R&D and drug product R&D, clinical supplies and CMC’s 
involvement in the compilation of regulatory documentation. 
GCP Good Clinical Practice. 
Good Review 
Practice (GRevP) 
 
A code about the process and the documentation of review 
procedures that aims to standardise and improve the overall 
documentation and ensure timeliness, predictability, consistency and 
high quality of reviews and review reports. 
ICH  International Conference on Harmonisation. 
Internal reviewers  Internal reviewers are employees of the Authority. 
Joint review The whole dossier is reviewed by each authority and the outcome is 
discussed before a decision is taken. 
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Marketing 
Authorisation 
Authorisation issued by a regulatory to launch a drug product on the 
market. 
Marketing 
Authorisation 
Application (MAA) 
Authorisation application submitted to a regulatory authority to launch 
a drug product on the market to which the application has been 
submitted. 
Milestone 
 
A milestone must involve some form of dated written document to 
which the regulatory authority can refer. In addition, a milestone must 
be considered by the regulatory authority to be the point at which one 
event stops and the next one begins so that the times for events are 
interdependent. 
Major Line 
Extension 
A major line extension is a modification to an authorised Medicinal 
Product that is sufficiently great that it cannot be considered to be a 
simple variation to the original product, but requires a new product 
authorisation. Such modifications include major new therapeutic 
indications or new disease states, extension to new patient 
populations (e.g., paediatrics), a new route of administration or a 
novel drug deliver system. 
NAS (New Active 
Substance) 
 
A new chemical, biological or pharmaceutical active substance 
includes: 
a chemical, biological or radiopharmaceutical substance not 
previously authorised as a medicinal product; 
an isomer, mixture of isomers, a complex or derivative or salt of a 
chemical substance not previously authorised as a medicinal product 
but differing in properties with regard to safety and efficacy from that 
chemical substance previously authorised; 
a biological substance previously authorised as a medicinal product, 
but differing in molecular structure, nature of the source material or 
manufacturing process; 
a radiopharmaceutical substance which is radionucleotide, or a ligand 
not previously authorised as a medicinal product, or the coupling 
mechanism to link the molecule and the radionucleotide has not been 
previously authorised. 
Non-clinical 
summary 
 
Summary of non-clinical data including: pharmacology, 
pharmacokinetics and toxicology. Refers to Module 2.6 in CTD 
format. 
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Peer review 
 
Peer review means an additional evaluation of an original 
assessment carried out by an independent person or committee. 
Peer review can occur either during assessment of a dossier, or at 
sign-off. 
Quality control 
 
Quality control is operational techniques and activities that are used 
to fulfil requirements for quality. It involves techniques that monitor a 
process and eliminate causes of unsatisfactory performance at all 
stages of the quality cycle. 
Quality policy 
 
Overall intentions and direction of an organisation related to quality 
as formally expressed by top management. 
Questions to 
sponsor 
The process of asking the sponsor for additional data or additional 
analyses of existing data. The requests are made by the regulatory 
authority during the review process. 
Scientific 
assessment 
Review of the dossier in terms of safety, quality and efficacy of data 
submitted. 
Shared review 
 
Each authority takes responsibility for assessing a separate part of a 
dossier.  
Sponsor 
 
A company, person, organisation or institution that takes 
responsibility for initiating, managing or financing a clinical study. 
Standard 
Operating 
Procedures (SOPs) 
 
Detailed, written instructions to achieve uniformity of the performance 
of a specific function. 
Validation of a 
dossier 
The process whereby the authority verifies that all parts of the 
submitted dossier are present and complete and suitable to be 
assessed as part of the assessment and registration process. 
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 Confidentiality Agreement 
This Agreement, dated as of ____________, is between the Centre for Innovation in Regulatory Science Ltd, 
(hereafter, “CIRS”) The Johnson Building, 77 Hatton Garden, London, EC1N 8JS, UK  and 
______________, doing business at ___________________________________. 
 
Each party intends to disclose certain confidential information to the other party so that the parties may develop 
proposals for possible services by CIRS or for CIRS to conduct any actual work using any such Confidential 
Information. In consideration of each party making such confidential information available to the other party, 
the parties hereby agree as follows: 
1. As used in this Agreement, the term "Confidential Information" means any technical or business information 
provided by one party (the "Disclosing Party") to the other party (the "Receiving Party") pursuant to this 
Agreement.  Such Confidential Information include, without limitation, trade secrets, know-how, inventions, 
technical data, business or financial information, research and development activities, product and marketing 
plans, and customer and supplier information. 
2. The Receiving Party agrees that it shall: 
a. maintain all Confidential Information in strict confidence, except that the Receiving Party may disclose or 
permit the disclosure of any Confidential Information to its employees and advisors who are obligated to 
maintain the confidentiality of such Confidential Information  
b. use all Confidential Information solely for the purposes of this Agreement; and 
c. allow its employees and advisors to use or reproduce the Confidential Information only to the extent and 
purposes of this Agreement. With all reproductions being considered Confidential. 
3. The obligations of the Receiving Party under Section 2 above shall not apply to the extent that the Receiving 
Party can demonstrate that certain Confidential Information: 
a. was in the public domain prior to the time of its disclosure under this Agreement; 
b. entered the public domain after the time of its disclosure under this Agreement through means other than the 
Receiving Party; 
c. was independently developed or discovered by the Receiving Party without use of the Confidential 
Information 
d. is or was disclosed to the Receiving Party at any time, whether prior to or after the time of its disclosure 
under this Agreement, by a third party having no fiduciary relationship with the Disclosing Party and having 
no obligation of confidentiality with respect to such Confidential Information; or 
e. is required to be disclosed to comply with applicable laws or regulations, or with a court or administrative 
order, provided that the Disclosing Party receives prior notice of such disclosure and that the Receiving 
Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure. 
 
Acknowledged and agreed: 
 
CIRS               Company:________________ 
SIGNATURE:                  SIGNATURE:      
NAME:              NAME:      
TITLE:               TITLE:      
DATE:               DATE:       
 
MUTUAL CONFIDENTIAL 
DISCLOSURE AGREEMENT 
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INDUSTRY QUESTIONNAIRE STUDY 
QUESTION AND ANSWER DOCUMENT
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Organised by: 
Professor Stuart Walker PhD. MFPM. FRSC. FIBiol. FRCPath. 
Founder of the Centre for Innovation in Regulatory Science  
Professor at the School of Pharmacy & Pharmaceutical Sciences 
University of Cardiff, Wales, UK 
& 
Ms Emel Mashaki, Pharm. Msc. MBA 
PhD Student with the 
School of Pharmacy & Pharmaceutical Sciences 
University of Cardiff, Wale, UK 
 
 
 
 
CIRS - The Centre for Innovation in Regulatory Science - is a neutral, independent UK-based subsidiary 
company, forming part of the Intellectual Property and Science business of Thomson Reuters. The mission of 
CIRS is to maintain a leadership role in identifying and applying scientific principles for the purpose of 
advancing regulatory and HTA policies and processes. CIRS provides an international forum for industry, 
regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and 
reimbursement policy through the innovative application of regulatory science. It is governed and operated for 
the sole support of its members’ activities. The organisation has its own dedicated management and advisory 
boards and its funding is derived from membership dues, related activities and grants. 
 
 
 
 
Centre for Innovation in Regulatory Science (CIRS) 
The Johnson Building, 77 Hatton Garden, London, EC1N8JS, UK 
Email: cirs@cirsci.org 
Website: www.cirsci.org 
 
Report date:  March 2017
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Section 1: Executive Summary 
 
Background to the Workshop 
Determining the benefit-risk balance of a medicine is one of the most important steps in its 
development, review and post-approval reassessment. There is a general agreement amongst 
agencies and companies that there is a need for both to be utilizing a structured, standardized, 
systematic approach for the benefit-risk assessment of medicines using a framework that should 
ideally be feasible and practical within the regulatory review process.  
 
The advantage of a systematic standardised approach for the benefit-risk assessment of medicines is 
that the review would be more transparent, predictable and consistent.  This would be in line with the 
WHO Good Review Practices for regulatory authorities released in 2015.  In addition, the systematic 
standardisation of the benefit-risk assessment of medicines could be of considerable value to 
agencies as a cornerstone with respect to building quality into their decision making process as well as 
in communicating their views and decisions. Such a system would be of further value to agencies 
conducting both abridged and verification reviews where there is reliance to some degree on the 
assessment by reference or comparable agencies. 
 
CIRS has been involved in this area for over a decade, including the development of the Universal 
Methodology for Benefit-Risk Assessment (UMBRA) framework and its documentation system, both 
within drug development and during the regulatory review. Furthermore, CIRS has undertaken a 
collaborative initiative with agencies in Australia, Canada, Switzerland & Singapore & more recently 
agencies in Southeast Asia have been assessing the UMBRA framework and the associate summary 
documentation together with the user manual. In addition, CIRS have also engaged with the US FDA 
& the European Medicine Agency to discuss this and other issues relating to the Review of Medicines. 
 
Workshop objectives  
The objectives of this workshop for the TITCK were to: 
 
• Provide an independent assessment of the TITCK in comparison with other medium sized 
international Regulatory agencies. 
• Understand the key issues of concern from the pharmaceutical industry and patients regarding 
the pharmaceutical regulatory environment and possible solutions. 
• Explain the importance of quality decision-making and a systematic structured approach for 
the benefit risk assessment of medicines. 
• Determine the challenges and opportunities for TITCK to become a International Centre of 
Regulatory Excellence. 
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Agenda of the Meeting 
Day 1: 23rd February 2017 
SESSION ONE 
10:30 Welcome and Introduction - Overview of the TITCK organisation and its approach to clinical 
assessment of new medicines 
Dr. Hakkı Gürsöz, TITCK 
11:15 Introduction and overview of the Centre for Innovation for Regulatory Science (CIRS) 
Prof Stuart Walker, CIRS 
11:45 Evaluation of the regulatory review process and timelines of the TITCK 
Emel Mashaki 
12:30 Discussion 
SESSION TWO 
14:00 An evaluation of the TITCK review process in comparison with the regulatory agencies in 
Australia, Canada, Saudi Arabia and Singapore 
Prof Stuart Walker, CIRS 
14:45 Discussion 
15:00 An Evaluation of the attitude and experiences of pharmaceutical companies towards the 
Regulatory review process 
Emel Mashaki 
SESSION THREE 
16:15 A structured approach to the benefit risk assessment of medicines: the key to improving 
decision-making in drug development and to the Regulatory review 
Prof Stuart Walker, CIRS 
17:00 Discussion 
 
Day 2: 24th February 2017 
SESSION FOUR 
08:30 Introduction and summary of day one  
Prof Stuart Walker, CIRS 
08:40 Public awareness of the Regulatory environment in Turkey and its impact on patients’ 
Access to medicines  
Emel Mashaki 
09:20 Discussion 
09:30 Quality decision-making in medicines development and the Regulatory review: the key to 
patients’ Access to medicines  
Prof Stuart Walker, CIRS 
SESSION FIVE 
10:30 Key issues to be addressed by an agency to become a Centre of Regulatory Excellence 
Emel Mashaki and Prof Stuart Walker 
11:15 Round table discussion 
Participants will be in groups to review the key issues and provide feedback to the plenary 
11:45 Summary and way forward for the TITCK 
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Key points from presentations 
SESSION 1, PRESENTATION 1: INTRODUCTION & OVERVIEW OF THE TITCK ORGANISATION 
AND ITS APPROACH TO CLINICAL ASSESSMENT OF NEW MEDICINES, PRESIDENT HAKKI 
GURSOZ (HEAD OF TITCK) 
Dr. Hakkı Gürsöz, (head of the Turkish Medicines and Medical Devices Agency (TITCK)), opened the 
meeting by giving a brief historical background to the idea behind having the meeting with the CIRS as 
well as the aims he was hoping to achieve from such meetings. He spoke of the major developments 
achieved recently in Turkey through the Healthcare Transformation Program (HTP) in which he was 
personally involved and which was initiated first by the preparation of a comprehensive report 
examining the Turkish healthcare system from different perspectives and an international point of view 
would help significantly in improving the regulatory system. The TITCK is a young and dynamic 
agency with a focus on implementing learning with an improvement of culture at all levels in order to 
keep pace with the rapid development of medicines. Thus a reforming period has been initiated within 
the TITCK since 2015 mainly in the review and approval system for medicines and medical devices. 
Accordingly eight main areas have been identified as success factors for an efficient regulatory 
environment. Each of these should be compatible with the other and the TITCK has taken appropriate 
action to ensure certain concrete improvements within each area including: 
 
1. Streamlining the GMP process: GMP accreditation processes and inspections should be 
conducted in optimum conditions. The TITCK focused on this area and the quality has 
improved significantly over the last five-year period. The number of GMP inspectors and 
assessors increased from ten to forty. There was an important focus on enhancing the 
competency level of inspectors as well as training the TITCK GMP experts through different 
means such as participating in the EMA related meetings, conferences and the organisation of 
in house high level GMP training. Moreover, the TITCK was recently inspected to become a 
full member of the PIC/S and this is expected to be finalised shortly. 
2. Laboratory analysis and quality: A significant effort was particularly made to improve the 
physical infrastructure and quality of the laboratories used for the analysis of medicines which 
included the renovation of the labs used and investing in new modern technological equipment 
and tools to enhance the reliability of the laboratory tests and analysis.   
3. Risk Management within pharmacovigilance: The TITCK introduced a number of measures 
to ensure the safety of medicines by implementing risk management plans. Thus the TITCK 
has significantly improved the preparation and control of Risk Management Plans related to 
new medicines. 
4. Clinical Research: Several action plans and new regulations were put in place to improve the 
regulatory environment for the conduct of clinical trials and the scientific evaluation of 
medicines in Turkey. 
5. Commissions and expert committees: The number of committees as well as committee 
members has increased over the past few years in response to the increasing number of 
applications for review. The TITCK also increased their working time and enhanced their 
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collaboration between the TITCK staff and external assessors. They increased the number of 
TITCK staff with PhDs and facilitated their active participation within committees. In this way 
they ensured an optimum working environment for all scientific committees while providing 
them with the technical support they would need. 
6. Administrative reviews: The reviews were pursued under two departments previously 
however, the bureaucratic barriers between these departments were decreased to streamline 
and improve the review processes.  
7. IT systems: The IT infrastructure of the TITCK was improved dramatically over the past few 
years. Currently e-submissions and e-review systems are well established and functioning and 
there are still more initiatives and plans to implement and expand the use of electronic 
systems. 
8. Communication with the Industry/ applicants: The TITCK is striving to ensure that all the 
requirements are clear for the applicants so that sponsors can make complete and precise 
submissions which can progress on time. For this purpose, the TITCK is constantly organising 
workshops and meetings with the pharmaceutical industry to discuss areas of concerns and 
processes; thus such dialogue can also be considered as a training opportunity for the 
industry. 
 
Finally, Dr. Gürsöz, highlighted that five years ago the TITCK had established its vision to become a 
leading and reference regulatory agency worldwide. Thus to become an international centre of 
regulatory excellence is a journey which requires commitment and high quality work and partnership 
with all national and international stakeholders. Dr. Gürsöz believed that this workshop would be the 
first step for a long-term partnership with CIRS in this journey to excellence. 
 
SESSION 1, PRESENTATION 2: INTRODUCTION & OVERVIEW OF CIRS, PROF.STUART 
WALKER (CIRS) 
Professor Walker, (Founder of the 
Centre for Innovation in Regulatory 
Science (CIRS)), gave workshop 
participants an overview about of the 
CIRS organisation in terms of structure 
and membership including the 
scientific advisory council, partner 
agencies and member companies. He 
also summarised the current initiatives 
of CIRS in the four major focus areas; 
Global Drug Development, Regulatory 
Review Workshops, Health 
Technology Assessment and Frameworks for Benefit Risk Assessment & Decision-Making.  
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He also informed the participants that the CIRS benchmarked regulatory agencies using agency-
supplied data since 1995 which was used to identify where time is spent in the review process, 
increase internal transparency, and establish programmes of internal benchmarking and to monitor the 
effects of change initiatives. Examples of the different CIRS services, workshops and meetings in the 
areas of regulatory review and decision-making processes were shared with the audience.              
          
Finally, Professor Walker, set the 
scene for the meeting and reviewed 
the agenda and clarified the 
academic background of the study 
within the workshop with the TITCK.  
 
 
 
 
 
 
 
SESSION 1, PRESENTATION 3: EVALUATION OF THE REGULATORY PROCESS AND 
TIMELINES OF THE TITCK, MS. EMEL MASHAKI 
Emel Mashaki, (PhD Student at Cardiff University), reported on the main outcomes of the study 
conducted with the TITCK which aimed to evaluate the TITCK review process, timelines and 
implementation of Good Review Practices for the period from 2012 to 2015.  
 
The findings identified that the TITCK performs a full review (Type 3A) as its assessment model for all 
new active substance (NAS) applications. Therefore, a new marketing authorisation application for an 
NAS can be submitted in Turkey prior to any approval in the world. However, evidence for approval in 
the country of origin, European Union (EU) or United States (US) must be submitted prior to the final 
approval by the TITCK. Marketing authorisation applications must be submitted to TITCK in 
compliance with the common technical document (CTD) with quality, safety and efficacy modules 
covering both the active drug substance and the finished product and it is therefore fully aligned with 
the ICH content requirements and international standards.  However,  local GMP accreditation of all 
manufacturing sites of the product is a pre-requisite to the marketing authorisation application. The 
results indicated that there is an official procedure for priority/fast track products to accelerate the 
marketing authorisation process for critical applications for certain products such as orphan drugs and 
life-saving medicines and products meeting medical needs which are given priority in the queuing line 
and assessment process. The study identified that the TITCK has a number of quality measures and 
policies in place to ensure consistency and standard performance including SOPs, review templates 
and an electronic submission tracking system. However, Good Review Practice (GReP) guidelines 
have still to be fully developed and implemented. 
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In addition, the results identified that the TITCK review performance was improving over the past few 
years. There was an indication that, while the number of approved applications by TITCK was 
increasing, there was a decreasing trend in the approval timelines which is a positive development 
even though the target timeline of two hundred and ten working days is still to be achieved.  
  
Finally, Ms. Mashaki indicated that the study provided for the first time a comprehensive overview of 
the TITCK registration review with all the milestones based on accurate data directly obtained from the 
TITCK since it was established as an agency and took over the responsibility for pharmaceutical 
regulations from the Ministry of Health in 2011. Thus, this facilitates the in depth analysis and 
understanding of the Turkish review system’s strengths and areas for improvement. Therefore this 
enabled the establishment of the required action plans by all stakeholders be it the agency or the 
industry in order to enhance the ultimate target of enhancing patients’ access to medicines. 
 
DISCUSSION: 
There was a question as to whether detailed information about the assessors and assessment 
process should be shared with the industry about the processes, and an example was requested from 
other agencies. Professor Walker, emphasized the importance of effective open communication 
between the industry and the authority on the quality of the review process and shared the example of 
some agencies where the key milestones of the assessment process are well informed to the industry 
including key contacts for each application within the regulatory agency which could facilitate the 
dialogue during the review process. 
 
Furthermore, Ms. Eda Cindoğlu: (TITCK International Relations Department Head), commented that 
placements and secondments of the TITCK staff in other agencies do not effectively occur within the 
TITCK and thus perhaps the TITCK could consider implementing these as one of the training tools to 
enhance the quality and competencies of the agency staff. 
 
Dr. Ali Alkan, (TITCK Vice President), commented on the different aspects of the presentation 
mentioning both the current challenges of meeting target approval timelines as well as a number of 
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actions implemented by the TITCK to ensure the timely access of patients to new medicines such as 
parallel submissions and review of GMP and marketing authorisations of orphan drugs, the early 
access of medicines via the named patient supply, the pricing system which is based on the lowest 
reference price which makes Turkey one of the countries with lowest medicines’ price and finally the 
introduction of compulsory licencing application which would enable the availability of all medicines 
needed regardless of the price and patent. 
 
He also highlighted that the TITCK is already working on streamlining the regulatory review process 
and timelines by implementing a systematic approach to measure the regulatory review performance 
of the TITCK based on the number of applications received, reviewed and approved versus the 
capacity of the TITCK. By providing several examples on the number of applications under review and 
number of approvals granted versus approval timelines, he emphasized that the TITCK is taking 
serious actions to systematically calculate the time both spent within the agency and from submission 
to approval for each application following the pre-assessment evaluation of 30 days. Thus the TITCK 
aims to measure individual performance within their systems by implementing key indicators for each 
milestone and evaluate the target approval timeline of 210 working days excluding the pre-assessment 
review. He added that the agency will be able to implement this system by the beginning of 2018 as 
soon as they can deal with all pending applications towards the end of this year (by November 2017). 
Accordingly, TITCK will be announcing to the industry the new process and the expected capacity of 
the TITCK to receive and review new drug applications (expected to be 60 to 70 regulatory 
applications/ month).  
 
Dr. Alkan, also mentioned that as a second action to manage applications and review backlog, the 
TITCK will start to impose “application suspension fee” (20.000TL/year) for all companies who 
continue to hold their medicine applications as suspended and that will be only for a maximum period 
of 2 years. This way, they may allow companies either to withdraw their applications or de-register 
products which they no longer market or ensure the transfer of the suspended applications and 
licenses to other local companies to manufacture or register. Finally, he indicated that they are 
currently looking at improving the pricing process and are therefore considering separating the pricing 
approval from final approval of the marketing authorisation so as not to impact the total approval 
timeline as generally companies obtain the price approval for their applications before regulatory 
approval.The conclusion was that the TITCK is recognising the challenges they face regarding 
meeting target approval timelines and therefore they are implementing a number of improvements 
within the process including a systematic approach to monitor the individual timelines. Professor 
Walker, commented that Turkey is similar to other countries in terms of the challenges of the number 
of approved products, however, this study focused on New Active Substances (NASs) only. In 
addition, he recommended that the TITCK track their approval timelines calculated from the date of 
submission to the date of approval including documenting the median and mean so as to enable 
scientific comparisons with industry data and approval timelines from other authorities. 
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SESSION 2, PRESENTATION 1: AN EVALUATION OF THE TITCK REVIEW PROCESS IN 
COMPARISON WITH THE REGULATORY AGENCIES IN AUSTRALIA, CANADA, SAUDI ARABIA 
AND SINGAPORE, PROF.STUART WALKER (CIRS) 
Professor Walker, compared the TITCK‘s review process with other mid-sized regulatory agencies 
like Australia, Canada, Saudi Arabia and Singapore which enables the development of several 
proposals to assist the agency in its efforts to become an internationally recognised reference agency. 
He also shared brief overviews and comparisons of the different quality elements these agencies 
implement within their overall quality management system. He shared the outcomes of the 
comparative study which identified that the TITCK review model and the marketing authorisation 
requirements are in general similar to other regulatory agencies’.  
 
 
Furthermore, the study identified that Good Review Practices (GReP) are implemented informally to a 
certain extent within the TITCK. The comparative study also indicated that the TITCK is currently 
lacking some elements that could contribute to transparency and the communication of a regulatory 
agency. These would include publicly available summaries of the basis for approval, developing 
standards for scientific and advisory meetings for applicants prior to submission as well as developing 
relationships with other reference agencies to encourage training through secondments and job 
shadowing. 
 
DISCUSSION AND KEY RECOMMENDATIONS: 
In response to participants’ questions, Professor Walker provided some examples of improving 
transparency of decision-making among different regulatory authorities such as EMA who publish the 
summary basis of approvals (EPARs for stakeholders) and assessment reports to be shared with the 
applicants. Furthermore, the audience discussed whether Turkey as a country should be following and 
fully aligned with the decision-making process of other developed regulatory authorities such as FDA 
and EMA or not. Professor İsmail Balık, (Academic Member and Head of the Clinical Evaluation 
Commission at the TITC), shared previous experiences of the TITCK independent decisions regarding 
product safety assessment which were not aligned with other authorities, but proven afterwards to be 
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timely and correct. Similarly, he gave examples where the TITCK did follow the regulatory decision of 
major authorities which were constantly questioned during the post-approval phase. 
 
Accordingly, the key recommendations that were made in this session were mainly in the following 
areas; alignment of regulatory review process and requirements while still maintaining the local 
decision-making and review models, implementation of a structured approach for Good Review 
Practices (GReP) and Benefit-Risk Assessment to become mandatory and carefully monitored as well 
as enhancing transparency of the decision-making process. Furthermore, it was suggested that the 
TITCK could conserve resources and reduce the time in the review process, by exploring the 
possibility of introducing shared or joint reviews with other similar regulatory authorities. It was 
recommended that the TITCK define target times for each review milestone in addition to the 
predefined overall authorisation procedure approval timing as well as improving internal tracking 
systems to monitor these milestones and thus enable this information to be available to all 
stakeholders as Dr. Ali Alkan, (TITCK VP), stated that such an electronic tracking system is planned 
to be in place by the end of 2017. 
 
SESSION 2, PRESENTATION 2: AN EVALUATION OF THE ATTITUDE AND EXPERIENCES OF 
PHARMACEUTICAL COMPANIES TOWARDS THE REGULATORY REVIEW PROCESS, MS. EMEL 
MASHAKI 
Emel Mashaki, presented the background, aims and methods of the study which focused on 
evaluating the attitudes and experiences of companies towards the regulatory review process in 
Turkey. It aimed to evaluate the changes in the regulatory approval timelines and processes between 
2012 and 2015 and identified the key issues companies are facing in the Turkish regulatory 
environment with regards to the review process as well as possible solutions and improvements to 
ensure that the drug approval process is effective and efficient in order to enhance patients’ access to 
innovative medicines. The results of 
the survey conducted among twenty-
one pharmaceutical companies 
indicated that the majority of 
companies experience significant 
delays in obtaining marketing 
authorisation approval for their 
products and therefore access of 
patients to their products is 
prolonged compared with other 
developed countries. The median 
time of NASs from the first approval 
anywhere in the world to TITCK 
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approval time was identified to be 1217 calendar days which is approximately 41 months (3.4 years) 
despite the industry’s eagerness of parallel submissions with major authorities such as FDA and EMA 
as indicated in the regulation.  
 
This is mainly due to several factors such as long GMP processes; increased number of questions 
asked by the TITCK thought to be outside of global requirements, constant changes in the TITCK 
organisational structure and commission members, pricing procedure and long laboratory analysis 
steps. Furthermore, 62% of companies agreed that the maximum time for the TITCK to complete the 
review process for a NAS application should be 12 months which is approximately 257 working days 
compared with the 210 working days for target approval stated in the regulation. With regards to the 
TITCK transparency (in terms of ability to track applications), findings indicated that the majority of 
companies evaluated the TITCK to be generally transparent. Furthermore, most of the companies 
were supportive of the TITCK utilising a structured Benefit-Risk Framework for the decision making 
process.  
 
KEY RECOMMENDATIONS: 
The key issues, which were identified by the industry regarding review process, as well as the 
industry’s proposed possible were as follows: 
1. GMP Process. The key recommendations from the industry to improve this process includes: 
o Increase in the use of a risk-based inspection approach,  
o Transition from line based inspection into pharmaceutical form inspection,  
o Expansion of the content of the parallel GMP and NDA submission to category 2 
(priority 2). 
o Recognision of internationally accredited GMP approvals following PIC/S 
membership. 
 
2. Early Access to New Innovative medicines. The industry suggested the following; 
o Adopt flexible regulatory pathways to ensure faster approvals for the different varieties 
of applications including biological products and orphan drugs. 
o Alignment of guideline and regulations with international standards. 
o Determine the prioritisation criteria based on scientific, clinical and unmet medical 
need basis. 
 
3. Communication and Transparency. The key recommendations of the industry were as 
follows: 
o Enhance the dialogue with the pharmaceutical industry at all levels. 
o Build a structured framework for the agency communication policy. 
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SESSION 3: A STRUCTURED APPROACH FOR THE BENEFIT RISK ASSESSMENT OF 
MEDICINES: THE KEY TO IMPROVING DECISION-MAKING IN DRUG DEVELOPMENT AND FOR 
THE REGULATORY REVIEW, PROFESSOR  STUART WALKER (CIRS) 
Professor Walker gave a comprehensive background to the structured approach of the Benefit Risk 
(B-R) assessment of medicines and mentioned why such a structured framework is crucial for benefit 
risk (Harm) assessment of new medicines as well as the added value it could provide to the regulatory 
agency decision-making process in terms of consistency, transparency and predictability. He also 
reviewed the current B-R Frameworks implemented by other regulatory agencies and shared 
examples of how these contributed to the improvement of the decision making process. 
 
SESSION 4, PRESENTATON 1: PUBLIC AWARENESS OF THE REGULATORY ENVIRONMENT IN 
TURKEY AND ITS IMPACT ON PATIENTS’ ACCESS TO MEDICINES, MS. EMEL MASHAKI 
Emel Mashaki shared the objective, methodology and conclusions of the patient study which 
demonstrated the importance of patients’ awareness, knowledge and their role with regard to the 
regulatory review and reimbursement procedures in Turkey. 
 
In summary, the three most important 
improvements that patients identified 
in obtaining their medicines were; 
access to medicines, improved health 
and pharmaceutical care as well as 
price. The major challenges patients 
perceive as facing the government to 
provide new medicines were; the cost 
of innovative medicines being too high 
as well as the lack of government 
resources and scientific expertise.  
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The patients provided four principle solutions to address the access issues which included; 
 1. Collaboration between academic experts and government to enhance pharmaceutical 
policies and shorten the registration process, 
 2. Encourage involvement through patients’ questionnaires and online forms,  
 3. Government to enhance patients’ timely access to medicines with lower costs, 
 4. Encourage healthcare professionals to raise the awareness of patients regarding access to 
medicines. 
 
The role of patients in the decision-
making process for the approval and 
reimbursement of new medicines 
should be encouraged. Patients 
suggested that to ensure that their 
needs are met in a timely way that 
patients’ associations become more 
involved in decision-making by 
ensuring a fair representation in the 
process. The use of patient 
questionnaires online or via doctors 
& pharmacists together with the use 
of social media could raise the 
awareness of patients to regulatory changes and access procedures.    
 
DISCUSSION: 
Dr. Ali Alkan raised the concern of the active role and willingness of the pharmaceutical companies to 
increase the awareness of the patients through establishing patient’s organisation regarding possible 
treatments and access to medicines, which in general is supported due to commercial objectives. He 
highlighted the importance of supporting the establishment of patient’s organisations on their own 
initiative to address the public unmet needs. Professor Walker, added that there are similar concerns 
in different countries such as the UK, however, he emphasized the importance of the public and 
patients associations’ role in the decision-making process of medicines access particularly in the 
reimbursement process. Furthermore, Emel Mashaki, responded to the audience by stating that 
patients’ involvement in the decision-making process may not necessarily shorten the approval 
timelines, but rather ensures a high quality decision that would have a better impact on patients’ 
access to treatment. She also added that some regulatory agencies facilitate public awareness about 
new approvals by publishing summaries for the public such as the EPAR in the EU and organise the 
involvement of patients in reimbursement. It is believed that it is the responsibility of the HCPs and 
regulatory authorities to ensure a transparent communication and briefing to the public regarding 
medicines approvals and accessibility. Finally, Dr. Ali Alkan, concluded that in such studies the 
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opinion of the non-governmental organisations like TEB (Turkish Pharmacist Association) who take an 
active role in ensuring patients’ access to medicines in Turkey, should be included in similar studies in 
the future since their opinion could be very important while the TITCK is aiming to become a centre of 
excellence.  
 
SESSION 4, PRESENTATION 2: QUALITY DECISION-MAKING IN MEDICINES DEVELOPMENT 
AND THE REGULATORY REVIEW: THE KEY TO PATIENTS’ ACCESS TO MEDICINES, 
PROFESSOR STUART WALKER 
Professor Walker emphasized the importance of Quality Decision Making (QDM), the development of 
a Decision Making tool, the practicality and the practicality of applicability of QDM Practices in the 
Regulatory Environment. A summary of this work was presented in the (CIRS R&D Briefing no. 61). 
 
                    
 
SESSION 5, PRESENTATION 2: KEY ISSUES TO BE ADDRESSED BY AN AGENCY TO BECOME 
A CENTRE OF REGULATORY EXCELLENCE - ROUND TABLE DISCUSSION. 
PARTICIPANTS WERE GIVEN THE OPPORTUNITY TO REVIEW THE KEY ISSUES AND PROVIDE FEEDBACK TO THE 
PLENARY 
Recommendations from Roundtable Discussions  
Q1. Please list the three most important key issues that you believe, as an agency should be 
addressed?  
 
 TITCK organisation and capacity: The Agency should increase the number of qualified 
staff/personnel in the organization and ensure a stable structure as much as possible. 
 Training and staff competencies: There should be a formal and a standard process for 
training within the agency to ensure a high calibre of reviewers as well as the consistency and 
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quality of assessment. Thus the following should be considered to further improve the TITCK 
training process: 
o Establish a formal induction training programme for all new employees of the TITCK. 
o Deliver focused training that is specific to the different scientific areas in order to 
increase the expertise of the staff and reviewers within their own areas of 
responsibility. 
o Increase the partnership with the other regulatory agencies and encourage 
secondments and job shadowing as well as participation of TITCK staff in international 
training abroad. 
o Ensure the transfer and sharing of best practices from those staff who participated in 
international training. 
o Follow a structured approach for “on the job” and in-house training for staff and 
ensure they are also monitored and evaluated. 
o Transparent policy for staff training (who should be trained within the TITCK). 
o Establish a Regulatory Science Academy within the TITCK in collaboration with the 
universities and/or pharmaceutical industry where specific regulatory science and 
Good Regulatory Practice training can be delivered mainly to reviewers whether 
internal or external. 
 
 Transparency and communication with all stakeholders: 
o The TITCK should enhance the transparency and consistency of its decision-making 
process. Accordingly, the agency could consider publishing the summary basis of 
approvals for stakeholders and assessment for applicants to justify how and why the 
agency took certain decisions. 
o TITCK should consider the implementation of a structured framework for pre-
submission scientific advice/consultation meetings for the industry in order to minimize 
rejections, optimise the approval process and enhance communication with applicants 
before and during submission. 
o Increase the number of scientific commissions to meet the increasing number of 
applications. 
o Establish a formal process for tracking all the review process milestones and target 
timelines. 
o Develop regulations and SOPs for standardisation/ alignment with international 
standards 
o Increase the cross-functional coordination within the agency and streamline the 
review process.  
o Implement a structured approach for the decision-making process and build quality 
systems to ensure consistency and business continuity. 
o Assignment of specific staff or departments for external communication to improve the 
consultancy process with applicants. 
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  Improve the IT Infrastructure of the agency. 
o Full adaptation to electronic system (e-CTD). 
  Increase the focus on the TITCK quality management systems and ensure a standard 
policy for quality. 
o Ensure the efficiency and appropriate training of internal reviewers within the TITCK 
by preparing the required standard operations procedures (SOPs) for the key tasks 
and define roles and responsibilities clearly.  
 
Q2. What is the area you would like the agency to address in order to improve and become 
an International Centre of Regulatory Excellence? 
The following were identified by all the participants to be areas to be focused on in the future; 
 
1. Good Review Practices (GReP): This area was identified by the majority of participants 
to be a priority on which the TITCK should focus if it wants to improve and become a 
recognised centre of excellence. They highlighted that the TITCK would need to review 
the best practices from other regulatory agencies. 
2. Standard approach for Decision- Making process.  
 
 
Q3. What would you like to change and improve in the regulatory review process of the 
TITCK? 
• Increase focus on specialization, experience and expertise during regulatory processes 
and acceleration of review timelines. 
• Develop local regulations, SOPs and assessment templates. 
• Improve the quality of the regulatory process. 
• Establishing the TITCK Regulatory Science Academy which would be capable of 
delivering various regulatory affairs training modules and conduct research programmes in 
collaboration with the universities and industry to continuously improve the regulatory 
review process, the TITCK competencies and the overall regulatory environment in 
Turkey. 
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APPENDIX: WORKSHOP ATTENDEES 
Regulatory agencies 
Participant Role/Position Institute 
Dr. Hakkı Gürsöz TITCK President TITCK 
Dr. Ali Alkan TITCK Vice President TITCK 
Prof. Dr. Akın Kaya TITCK academic commission member Ankara University 
Dr. Bahar Kayserilioğlu International Relations Department TITCK 
Dr. Banu Bayar Economical Evaluation & Drug Supply Department Head TITCK 
Assoc. Prof. Dr. Berrin Erdağ TITCK academic commission member TÜBİTAK 
Çisem Budak Drug Regulatory Department TITCK 
Dr. Demet Aydınkarahaliloğlu Pharmacovigilance Department Head TITCK 
Ecem Bulut Licensed Medicines Department TITCK 
Eda Cindoğlu International Relations Department Head TITCK 
Elif İnci Somuncuoğlu Clinical Research Department – Unit supervisor TITCK 
Emel Aykaç Pharmacovigilance Unit Head TITCK 
Prof. Dr. Filiz Öner TITCK academic commission member Hacettepe University 
Gökçe Yıldırım Drug Regulatory Department TITCK 
Handan Çelikel Technological Evaluation Unit  TITCK 
Hülya Karahasanoğlu Clinical Review Department TITCK 
Prof. Dr. İsmail Balık TİTCK Head of Clinical Evaluation Commission. Ankara University 
Prof. Dr. İsmail Tuncer Değim TITCK academic commission member Gazi University 
Manolya Kıvılcım Clinical Review Department TITCK 
Prof. Dr. Müzeyyen Demirel TİTCK academic commission member  Anadolu University 
Nihan Burul Bozkurt Clinical Research Department Head TITCK 
Nihal Saat Yerlikaya Technological Evaluation Unit Head TITCK 
Oğuzhan Koyuncu CTD Department TITCK 
Pelin Aksungur International Relations Department TITCK 
Dr. Sabiha Alper Hayta Managerial Regulatory Department TITCK 
Senem Sevtap Ölmez  International Relations Department TITCK 
Serkan Yener Drug Regulatory Department TITCK 
Prof. Dr. Sevda Şenel TITCK academic commission member Hacettepe University 
Süheyla Taş Clinical Research Department TITCK 
Şule Gülşen CTD Department TITCK 
Tuncay Paşaoğlu Drug Regulatory Department TITCK 
Yasemin Akyürek International Relations Department TITCK 
Dr. Yasemin Karabey Drug Regulatory Department TITCK 
Yelda Çakıcı Pharmacovigilance Risk Management Unit Head  TITCK 
Züleyha Yavuz Medicines and Pharmacy Department TITCK 
Centre for Innovation in Regulatory Science 
Emel Mashaki Ceyhan PhD Student – Cardiff University – UK 
Professor Stuart Walker Founder of the Centre for Innovation in Regulatory Science – UK 
Şebnem Uslu Şenoldu External Consultant and rapporteur 
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PARTICIPANTS’ EVALUATION OF THE MEETING 
• 88% of the participants rated the overall quality of the presentations as “Excellent” or “Very 
Good”. 
• 76% of the participants rated the workshop as “Excellent” or “Very Good”  
• 94% of the participants agreed that such studies described should be encouraged in Turkey. 
• 52% of the participants believed that the outcome of these studies can contribute to the   
 
COMMENTS FROM PARTICIPANTS 
“The meeting was very useful, especially in that it provided us, as an agency, the opportunity to 
compare the TITCK with other regulatory agencies’ practices which will definitely help us improve our 
regulation process in terms of improving our review timelines as well as consistent decision making”. 
 
“It gave us the guidance on how to implement Good Review Practices (GReP) and Quality 
Decision-Making which is crucial for an effective & efficient regulatory agency”.  
 
“The studies provided us with a comprehensive perspective with regards to the regulatory review 
perception in Turkey, particularly the public awareness study which was innovative and a topic that we 
need to consider significantly in the future”. 
SUGGESTIONS FROM PARTICIPANTS 
 “It is crucial to identify the areas of concerns in such meetings, however, it is equally important to 
decide on concrete action plans as well and share a structured set of recommendations for the 
improvement of the TITCK in the future” 
 
 “In the future, it would be very useful to see concrete examples of regulatory review models and 
practices from other countries and discuss these in detail”. 
 
“I suggest that we ensure that there will be a follow up process for the action plans from this CIRS 
workshop and evaluate the progress of the TITCK over time following such meetings.” 
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PATIENT STUDY DIA POSTER 
(June 2016) 
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